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Definitions and abbreviations 
(TrxS)2 Oxidised thioredoxin 
+ve CTRL Positive control 
°C Degrees Celsius  
µL Microliter 
µM Micromolar concentration 
µmol Micromole concentration 
13C NMR Carbon-13 nuclear magnetic resonance 
1H NMR Proton nuclear magnetic resonance 
3D7 Chloroquine sensitive strain (whole cell parasite) of Plasmodium 
falciparum 
Å Angstrom 
Å3 Cubic Angstrom 
ABPP Activity based protein profiling 
ACN Acetonitrile 
ACT Artemisinin based combination therapy 
ADRs Adverse drug reactions 
AMP Adenosine monophosphate 
Amu Atomic mass units 
Aq Aqueous 
ARE Antioxidant response element 
ARP3 Actin-related protein 3 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BF3.OEt2 Boron trifluoride diethyl etherate 
BL21 Escherichia coli 
BPs Biotinylated probes 
BSA Bovine serum albumin 
BzCl Benzoyl chloride 
C18 Octadecyl carbon chain 
CD36 Cluster of Differentiation 36 
CDDO 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid 
CDDO-Epoxide 2β-Cyano-3,12-dioxo-1,2-epoxyolean-9(11)-en-28-oate 
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CDDO-Im 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide 
CDDO-Me Methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate 
CI Chemical ionisation 
CKD Chronic kidney disease 
Conc. Concentrated 
C-radical Carbon radical 
c-Rel Proto-oncogene c-Rel 
CRM1 Exportin-1 
Cys Cysteine 
d Doublet 
DCM Dichloromethane 
dd Doublet of doublets 
ddd Doublet of doublet of doublets 
DDO-Epoxide Methyl 3,12-dioxo-1,2-epoxyolean-9(11)-en-28-oate 
DDO-Me Methyl 3,12-dioxooleana-1,9(11)-dien-28-oate 
DDQ 2,3-Dichloro-5,6-dicyano-p-benzoquinone 
ddq Doublet of doublet of quartets 
ddt Doublet of doublet of triplets 
DEPT135 Distortionless enhancement by polarization transfer 135° 
Dex-mes Radiolabelled dexamethasone 21-mesylate 
DHA Dihydroartemisinin 
DMAP 4-Dimethylaminopyridine 
DMEM Dulbecco's modified eagle medium  
DMF Dimethylformamide 
DMPK Drug metabolism and pharmacokinetics 
DMSO Dimethyl sulfoxide 
DMSO-d6 Deuterated dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dt Doublet of triplets 
EC200 Effective concentration to double response 
ECL Enhanced chemiluminescence 
EDCl 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA Ethylenediaminetetraacetic acid 
EI Electron ionisation 
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emPAI Exponentially modified protein abundance index 
EPI Enhanced product ion 
equiv Equivalent 
ErbB2 Receptor tyrosine-protein kinase erbB-2 
ESI / ES Electron spray ionisation 
FA Formic acid 
FAD Flavin adenine dinucleotide 
FADH2 Reduced flavin adenine dinucleotide 
FBS Fetal bovine serum 
Fe2+ Ferrous iron / iron(II) 
FeO3+ Iron (II) oxide 
G6PD Glucose-6-phosphate dehydrogenase 
GR Glutathione reductase 
GSH Glutathione 
GSSH Oxidised glutathione 
GSTP1 Glutathione-S-transferase pi 
H4IIE Rat hepatoma cell line 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid  
His Histidine 
HMQC Heteronuclear multiple-quantum correlation 
HPLC High-performance liquid chromatography 
HPLC-UV Ultraviolet detection by high-performance liquid chromatography 
hr Hour(s) 
HRMS High resolution mass spectrometry 
HRP Horseradish peroxidase  
Hz Hertz 
IC50 The half maximal inhibitory concentration 
IFN-γ Interferon gamma 
IKK IκB kinase 
IKKβ Inhibitor of nuclear factor kappa-B kinase subunit beta 
IL-1 Interleukin 1  
iNOS Inducible nitric oxide synthase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IR Infrared spectroscopy 
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IκB Inhibitor of nuclear factor kappa B 
J Coupling constant (hertz) 
JAK Janus kinase 
kD Kilodaltons 
Keap1 Kelch-like ECH-associated protein 1 
LB Lysogeny broth 
LCMS Liquid chromatography mass spectrometry 
LDA Lithium diisopropylamide 
lit Literature 
LMB Leucomethylene blue 
M Molar concentration 
m Multiplet 
m/z Mass to charge ratio 
mA Milliamps 
Mafs Transcription factor Maf 
MB Methylene blue 
mCPBA meta-Chloro-peroxybenzoic acid 
MG132 Proteasome inhibitor 
MHz Megahertz 
mins Minutes 
mL Millilitre 
mM Millimolar concentration 
mm Millimetre 
mm3 Cubic millimetre 
mmol Millimole 
MMP Matrix metalloproteinase 
MOPS 3-(N-Morpholino)propanesulfonic acid  
mp Melting point 
mRNA Messenger ribonucleic acid 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
MudPIT Multidimensional protein identification technology 
n= Number of repeats 
NAC N-acetyl cysteine 
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NADPH Nicotinamide adenine dinucleotide phosphate 
NF-κB Nuclear factor kappa B 
nL Nanolitre 
nM Nanomolar concentration 
nm Nanometre 
NMR Nuclear magnetic resonance 
nOe Nuclear Overhauser effect 
NQO1 NAD(P)H:quinone oxidoreductase 1 
Nrf2 Nuclear factor erythroid 2-related factor 2 
OAT Ornithine δ-aminotransferase 
OD600 Optical density reading measured at 600 nm 
P. falciparum Plasmodium falciparum 
p50/p105 (NF-κB1) Nuclear factor NF-kappa-B p105 subunit 
p52/p100 (NF-κB2) Nuclear factor NF-kappa-B p100 subunit 
PAH Pulmonary arterial hypertension 
PAL Photoaffinity labelling 
PBS Phosphate buffered saline  
PC Phosphatidylcholine 
PfATP6 Sarco/endoplasmic reticulum calcium ATPase of P. falciparum 
pH log10 hydrogen ion concentration 
Ph3P=CHCO2Et Ethyl (triphenylphosphoranylidene) acetate 
pKa Acid dissociation constant 
PPARγ Peroxisome proliferator-activated receptor gamma 
ppm Parts per million 
PTFE Polytetrafluoroethylene 
p-TsCN p-Toluenesulfonyl cyanide 
Pyr Pyridine 
r.t. Room temperature 
RelA (p65) Nuclear factor NF-kappa-B p65 subunit / transcription factor p65 
RelB Transcription factor RelB 
Rf Retention factor 
RIPA Radioimmunoprecipitation assay  
ROS Reactive oxygen species 
rpm Revolutions per minute 
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s Singlet 
S.D. Standard deviation 
SAR Structure activity relationship 
sec Second(s) 
STAT Signal transducer and activator of transcription 
t Triplet 
TBS Tris buffered saline 
td Triplet of doublets 
TEA Triethylamine 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMS Trimethylsilyl 
TNF-α Tumour necrosis factor alpha 
TrxSH Reduced thioredoxin 
UV / U.V. Ultra violet 
V Volt(s) 
v/v Volume to volume 
-ve CTRL Negative control 
vs. Versus  
VT-NMR Variable temperature Nuclear magnetic resonance 
w/v Weight to volume 
w/w Weight to weight 
XIC Extracted ion count 
X-ray X radiation 
β-ME β-Mercaptoethanol 
δ Chemical shift (parts per million) 
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Abstract 
Adverse drug reactions (ADR) are a major concern for the pharmaceutical industry and 
health practitioners as they can cause morbidity and in severe cases mortality. ADRs are 
one of the major reasons why drugs fail during clinical trials so research directed at 
predicting ADRs to minimise failure is essential. The CDDO (2-cyano-3,12-dioxo-oleana-1,
9(11)-dien-28-oate) and the synthetic endoperoxide series are two promising classes that 
have potential for the treatment of cancers and malaria and may revolutionise treatment, 
within their fields, if approved for clinical use. The two main aims that are presented in this 
thesis are to; (i) design and synthesise novel analogues and chemical probes to identify 
potential molecular targets for both the CDDO and endoperoxide series (ii) develop 
appropriate in vitro test systems to help define the molecular mechanism of each class of 
drug. 
CDDO-Me (methyl 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oate) is one of the most 
potent inducers of Nrf2, a transcription factor that regulates the expression of numerous 
cell defence genes in mammalian cells. Nrf2 is sequestered in the cytosol by Keap1, which 
‘senses’ chemical and oxidative stress via its 27 cysteine residues. Although CDDO-Me is 
one of the most potent inducers of Nrf2, the molecular target and chemical mechanism is 
still not defined. Current literature suggests that a reversible 1,4 conjugate addition to 
specific cysteine residue(s) located on the Keap1 protein results in an increase in Nrf2 
levels. In order for SAR work to be performed a synthetic route to CDDO and analogues was 
developed which involved nine steps using oleanolic acid as starting material.  Highlights of 
the chemistry included addition of the ketone using mCPBA and incorporation of the cyano 
group in steps 3 and 7 of the synthesis.  In addition to preparing the target molecule CDDO 
a number of additional molecules were prepared to define the importance of functional 
groups in the A and C rings of CDDO. 
Genetically modified H4IIE rat hepatoma cells transiently transfected with the an Nrf2-
sensitive luciferase reporter gene were used to screen the CDDO-Me analogues, including 
DDO-Me which lacks a cyano group on the A ring, for their ability to induce Nrf2. NMR 
studies with model thiols were performed to determine the ability of these compounds to 
form reversible or non-reversible adducts. Mass spectrometry (MS) was used to confirm 
the NMR data and interpretations. In total, four probes were identified that reacted in a 
non-reversible fashion: DDO-Me, DDO-Al and DDO-Az (click probe versions of the parent 
DDO-Me that can be used to facilitate proteomic studies) and CDDO-Epox (a probe with 
similar overall structure to CDDO-Me but can react at the β-carbon in a non-reversible 
fashion; this feature should aid proteomic approaches to reactive cysteine residue 
identification). To further investigate if these compounds were reactive to cysteine 
residues within a model protein, recombinant human GSTP1 was used as a model protein 
for chemically reactive molecules. Cys-47 located on GSTP1 has been shown to react with 
other electrophones and during our studies LCMS has confirmed that all four of the 
synthesised active probes were capable of attaching covalently to Cys-47 of GSTP1. 
The emergence of malaria parasite resistance to most available drugs, including the semi-
synthetic artemisinin derivatives artemether and artesunate, has led to efforts to create 
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new synthetic peroxides as potential antimalarial agents. Leading examples of synthetic 
endoperoxides include OZ277 (arterolane), a molecule in phase III clinical trials in 
combination with piperaquine, and OZ439, a second generation derivative with improved 
pharmacokinetics and enhanced in vivo antimalarial activity. 1,2,4,5-Tetraoxanes are 
another class of endoperoxide with proven excellent antimalarial profiles against both 
chloroquine-resistant and chloroquine-sensitive strains of Plasmodium falciparum and oral 
activity in murine models of the disease. It is currently widely accepted that endoperoxides 
have a similar antimalarial mechanism to artemisinin, whereby Fe2+ medicated generation 
of cytotoxic carbon-centred radicals, results in death of the parasite. It is presumed that C-
radicals can react with important key proteins; however, the specific molecular target(s) 
that leads to eventual parasite death are still unknown.  
A chemical synthesis of tetraoxane probes that contain a UV chromophore was performed 
and analogues were subsequently screened for antimalarial activity. The most active 
tetraoxane identified was exposed to a range of Fe2+ salts and conditions developed to 
mimic the biological environment. Primary, secondary and novel carbon-centred radical 
derived products (surrogate markers of bioactivation) were purified using UV-HPLC, 
characterised and submitted as chemical probes and standards for biological studies. 
In order for proteomic studies to be initiated, an allyl or azide group was incorporated into 
a semi-synthetic artemisinin skeleton. The azide (and alkyne) functional group within these 
probes provides a handle for protein pull down via click chemistry. Azide and acetylenes 
were chosen over direct linkage to the biotin group to reduce steric hindrance in the semi-
synthetic probe. The synthesised click probes were tested for antimalarial activity and were 
submitted for protein pull down and identification of potential molecular targets. Similarly 
DDO allyl and azide were synthesised and were tested for Nrf2 induction and further 
confirmed as viable probes via NMR experiments with simple thiols and GSTP1. 
In summary, novel CDDO non reversible probes were synthesised and have shown 
potential as chemical tools to identify the molecular targets/mechanisms by which these 
compounds activate Nrf2. Tetraoxanes also have been prepared along with artemisinin 
click probes and the latter have been submitted for click chemistry pull down experiments, 
within Plasmodium falciparum parasites, to identify potential molecular targets. 
 
12 
 
   
 
 
 
 
 
 
 
CHAPTER 1 
General introduction 
 
Chapter 1 – General introduction 
 
13 
 
Chapter 1 
1.1. Basic principles of pharmacology 14 
1.2. Drug interactions 15 
1.2.1. Reversible drug interactions (non-covalent) 16 
1.2.2. Non-reversible drug interactions (Covalent) 16 
1.2.3. Drug target identification and validation 20 
1.3. Malaria - Antimalarials 23 
1.3.1. Artemisinin 23 
1.3.1.1. Model studies 25 
1.3.2. Next-generation synthetic antimalarial drugs 26 
1.3.2.1. Trioxolanes and tetraoxanes 27 
1.4. CDDO and derivatives 29 
1.4.1. Pharmacology of CDDO 29 
1.5. Cellular protection against stress 31 
1.5.1. Nuclear factor kappa B (NF-κB) 31 
1.5.2. Nuclear factor erythroid 2-related factor 2 (Nrf2) 33 
1.5.3. CDDO derivatives - potent inducers of Nrf2 33 
1.6. Toxicity issues 36 
1.7. Aims of this thesis 36 
1.8. References 38 
 
  
Chapter 1 – General introduction 
 
14 
 
1.1. Basic principles of pharmacology 
Pharmacology is the study of a chemical substance (drug) that exhibits a biological 
effect upon exposure/administration to a living organism.1 Pharmacology has two 
major sub-disciplines; pharmacokinetics (the study of the fate of a chemical 
substance once administered to a living organism), and pharmacodynamics (the 
study of the biological effects provoked by a chemical compound).1 For a biological 
effect to occur, the administered drug must reach its site of action. However, there 
are many factors that will influence the bioavailability of a drug. These include 
phase I metabolism, drug absorption and influx and efflux proteins.1 Many 
pharmacologically active compounds that are administered as therapeutic drugs 
overcome these factors and initiate a biological effect by binding to a specific 
protein target, such as a receptor, enzyme or ion channel. This binding can be 
covalent (generally non-reversible) or non-covalent (reversible) in nature, and often 
induces a change in protein structure and/or function, thus triggering a biological 
response.2 Table 1.1 lists a selection of drugs that are known to have a reversible or 
irreversible mechanism of action. 
Drug Target and activity Treatment Reversibility 
Salbutamol β2-receptor agonist Asthma reversible 
Propranolol β1-receptor antagonist 
Hypertension, anxiety and 
panic 
reversible 
Warfarin Vitamin K reductase Anti-coagulant reversible 
Floxuridine Thymidylate synthase 
Anti-cancer (anti-
metabolite) 
Irreversible 
Penicillins DD-transpeptidase Bacterial infections Irreversible 
Omeprazole 
Hydrogen–potassium 
adenosinetriphosphatase 
Peptic ulcer disease Irreversible 
Table 1.1: List of reversible and non-reversible drugs.2-4 
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The mechanism of action for these drugs can be defined due to their known target. 
However, this is not true for all therapeutic compounds that are currently available.  
A perfect example of this is paracetamol (acetaminophen). Paracetamol was first 
discovered in 1877 and introduced as a mild analgesic in 1893, which is still use 
today.5 However, toxicity still remains a problem and has a clinical burden on 
hospitals and the health care system.6 The exact mechanism of paracetamol’s 
pharmacological and toxicological action remains unclear. The ability to dissociate 
beneficial pharmacological activity from its harmful toxicological effect is vital for 
the design and development of safe new medicines. In order to achieve this, the 
mechanism of action including the molecular target must be understood. However, 
this is not always straight forward and will be discussed in more detail below. 
1.2. Drug interactions 
In modern day drug discovery, drugs must be designed to achieve a number of 
goals. This includes maintaining or improving potency, reducing or potentially 
eliminating adverse drug reactions (ADRs) and improving bioavailability.7 these are 
generally achieved through chemical structure alterations and structure activity 
relationship (SAR) studies. These modifications are primarily driven by medicinal 
chemists but guided by pharmacology and clinical studies.8 
For the majority of drugs, non-covalent target interaction is the main binding 
involved in a drug target interaction. Studies dating back to the 1970s and 80s have 
identified that reactive metabolites resulting from covalent interactions can 
potentially form off-target interactions. Therefore, avoiding incorporation of such 
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groups during the drug discovery stage was understood to reduce ADRs.9-11 ADRs 
are one of the major contributors to drug failure or withdrawal from the market 
and clinical use.12,13 
1.2.1. Reversible drug interactions (non-covalent) 
Reversible binding interactions between drug and target generally involves weaker 
interactions such as hydrogen bonding, van der Waals interactions, π-π stacking, 
ionic bonding and others.7,14,15 These interactions can be disrupted and broken, and 
are thus considered reversible. This is a major advantage over covalent interactions 
as this provides a reversible function that can associate, allowing a drug compound 
to enforce its pharmacological effect, but also the ability to dissociate. This enables 
vital functional proteins such as enzymes to be reused as the de novo synthesis of 
certain vital proteins may be difficult. Therefore non-covalent interactions are 
favoured over covalent interactions during the drug discovery stage.16 
 The most common interaction between a drug and target is hydrogen bonding. 
This interaction occurs between a hydrogen atom bound to an electronegative 
atom such as oxygen, nitrogen and sulphur forming a weak non-covalent 
interaction.15 Although hydrogen bonding is a non-covalent interaction and can 
normally be disrupted, a collection of hydrogen bonds can form stable aggregates. 
An example of this is the complementary strands within DNA.7,17 
1.2.2. Non-reversible drug interactions (Covalent) 
As described above, many drugs are designed to be non-covalent, however, nearly 
30% of drugs on the market act via a covalent interaction.10 
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During covalent interaction between a drug and its molecular target, initial non-
covalent interactions occur between drug and target. This is similar to reversible 
binding. Once this interaction has been established, subsequent covalent bond 
formation occurs between the drug compound and its molecular target.10 This is 
shown in the equation below which is rendered irreversible in nature. 
 
Equation 1.1: The rate equation for covalent binding where k is the rate coefficient 
of the reaction, D is the drug and T is the molecular target. 
Modern medical chemistry has evolved to identify specific groups of atoms also 
known as functional groups that will potentially form direct covalent interactions or 
through activation of specific groups.1,7,12 This is shown in Table 1.2 and includes 
functional groups that are metabolised during phase I metabolism.  
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Alkenes 
 
Epoxides 
 
Ketones 
  
Alcohols 
 
α-halo 
carbonyls 
 
Michael 
acceptors 
 
Thiols 
 
Disulphides 
 
Aldehydes 
 
Halo alkanes 
 
Vinyl sulfones 
Table 1.2: Some functional groups that are capable of forming covalent 
interactions.1,7,12 
Covalent interactions can occur between a drug and cellular proteins or lipids. This 
can occur between cysteine residues, glutathione (GSH) incorporation or radical 
alkylation with proteins or lipids.10 This can result in a number of responses, such as, 
cell death or immune stimulated response hence ADRs occur. However, not all such 
covalent interactions form detectable thiol adducts.10 It is understood that the 
micro-environment within protein structures appears to be crucial in determining 
specific binding.13 The micro-environment is influenced by factors such as acid 
dissociation constant (pKa), hydrophobicity, pH and others.
13 
Although there are risks with covalent interactions such as the ones mentioned 
above, there are also many advantages, that include:- 
- Sustained duration where the pharmacological effect for covalent 
interactions depends on the de novo re-synthesis rate of the functional 
protein. The longer the re-synthesis the longer the pharmacological 
effect.11,18  
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- Less frequent dosing which is due to the sustained duration. Less drug is 
required to maintain a pharmacological effect and the therapeutic window, 
therefore, resulting in a lower systemic drug exposure.11,18 
- Preventing emergence of drug resistance due to consistent target 
suppression.11,18  
In addition, unlike non-covalent interactions, covalent interactions allow potential 
identification of their molecular target by employing a wide range of techniques 
including mass spectroscopy, peptide mapping and protein immunoblotting.10 This 
will be discussed further. 
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1.2.3. Drug target identification and validation 
Identifying and validating molecular targets can be achieved by analysing the drug 
compound bound to its molecular target(s). The drugs ability to bind is also known 
as affinity.7 Specific chemical interactions between the drug and the molecular 
target will determine its affinity.19 The affinity of a covalent compound allows for 
the identification and verification of molecular targets to be a simple process. 
However, for non-covalent drugs the specific chemical interactions are reversible 
and therefore detection of the molecular target can prove difficult. 
In the laboratory, protein validation can comprise of a number of techniques. 
Competition experiments between compounds with similar chemical structure, 
chemical functionality, or activity towards a known target can be utilised as a tool 
to validate a specific target protein.20  Genetics can be used during in vivo and in 
vitro studies to produce transgenic or knockout models. These can then be utilised 
as pharmacological validation techniques, where knockout or point mutations can 
be introduced and tested for the viability of a target.21 However, this only provides 
further evidence of the pharmacological effects and does not give direct evidence 
of the molecular targets and the exact chemical mechanism. A direct approach in 
identifying protein targets involves the isolation of the drug directly bound to its 
target. This generally involves labelling of potential proteins with the drug of 
interest. Labelling or pull-down methods can be optimised to allow incubation with 
the protein or cell lysate followed by purification and analysis of potential targets 
by techniques such as liquid chromatography coupled with mass spectroscopy 
(LCMS) and protein immunoblotting.22,23 Examples of such techniques include 
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affinity tagged proteins such as biotin tagged drugs.22 Although this is the most 
direct approach in identifying protein targets, there are still disadvantages 
especially when dealing with non-covalent drugs. Direct techniques rely upon non-
covalent drugs to have a high affinity towards the protein target.22,23 Large amounts 
of extracts are generally required followed by stringent washing when using direct 
approach methods.23 Pharmacological and toxicological effects can be missed 
through stringent washing. Therefore, stringent washing introduces bias towards 
higher affinity binding drugs.24 
Covalent non-reversible drugs provide a potential solution to the disadvantages 
that non-covalent reversible drugs currently possess. Typically, this involves the use 
of medicinal chemists and the strategic manipulation of functional groups to create 
a bespoke irreversible drug probe.18 The irreversible probe must still be 
pharmacologically or toxicologically relevant compared with the original compound. 
An example of an irreversible probe has been achieved with sulforaphane. 
Sulforaphane is a naturally occurring compound found in vegetables and is well 
known for its anti-inflammatory and antioxidant properties.25 The chemical 
mechanism of sulforaphane is reversible (shown in Figure 1.1A) and therefore poses 
as an obstacle during the purification process as this disrupts the binding of 
sulforaphane, yielding very little data about its targets. The use of chemical 
manipulation has resulted in an irreversible version of sulforaphane allowing 
validation of its target molecule (Figure 1.1B).25 The bias views towards non-
covalent interactions within drug discovery are now beginning to change due to the 
potential advantages that covalent interactions offer. 
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Figure 1.1: (A) Reversible chemical mechanism of sulforaphane and a thiol on a 
protein. (B) Template analogue of irreversible sulforaphane where R1 and R2 are 
chemically modifiable points. Irreversible chemical mechanism of the template 
analogue towards a thiol on a protein. Figure adapted from Ahn et al 2010.25 
ADRs and toxic events can be lessened through optimisation, careful design of 
strategically placed electrophiles (that lead to the selective covalent modifications 
of the target protein) and reducing off target interactions.10 Two classes of 
promising drug compounds are the antimalarial endoperoxides and anticancer 
compounds from the CDDO series and endoperoxide seires. These two classes of 
compounds have demonstrated extraordinary pharmacological activity within their 
potential fields of treatment. However, there are also concerns over their safety 
and use in practise as potential ADRs could occur during clinical use. The 
endoperoxides such as the artemisinins are the front line drug for the treatment of 
malaria. The CDDO series are a promising class of drugs that can be used for the 
treatment of inflammation and cancers. These two classes of drugs are therefore 
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important but their mechanisms of action and biological targets are still poorly 
understood. These classes of compounds will be discussed further below. 
1.3. Malaria - Antimalarials  
Malaria is a preventable and curable disease caused by various species of parasite 
from the genus Plasmodium. It is transmitted to humans through the bite of an 
infected female Anopheles mosquito.26,27 Although there are many different types 
of Plasmodia, only four types are known to cause malaria in humans; Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale. Of 
these, Plasmodium falciparum results in the highest number of deaths.26 An 
estimated 207 million cases of malaria and 0.6 million associated deaths were 
reported in 2012, with the majority being among African children.28 Drug resistance 
to traditional antimalarial treatments have now become prevalent in disease 
endemic areas, fuelling the search for new antimalarial drugs that are active against 
drug-insensitive parasites.29 Endoperoxides such as artemisinin are currently the 
first line treatment for drug resistant malaria and therefore an important class of 
drugs. 
1.3.1. Artemisinin 
Artemisinin is a naturally occurring compound that is also known as qinghaosu.30 
The chemical structure was elucidated in 1972 and was used by the Chinese as a 
herbal infusion.31 Artemisinin-based combination therapy (ACT) is currently the first 
line treatment for drug resistant malaria. The mechanism of action of artemisinin 
has yet to be fully defined, although one widely accepted concept involves the 
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formation of toxic carbon-centred radicals within the parasite (Figure 1.2).32 This 
requires a ferrous iron source that can cleave the endoperoxide bridge of the 
parent compound.32,33 The food vacuole within the parasite contains a high 
concentration of heme due to hemoglobin degradation. It is proposed that free 
heme in oxidation state two (Fe2+)  can catalyse the formation of oxy radicals via 
reductive activation of the endoperoxide bridge.34 The oxy radical products undergo 
rearrangement to form a primary carbon-centred radical or secondary carbon-
centred radical species.34 The carbon-centred radicals are thought to react with 
proteins, lipids and amino acids by alkylation reactions or peroxidation forming 
non-reversible covalent adducts which ultimately leads to parasite death.35,36  
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Figure 1.2: Suggested chemical mechanism underlying the antimalarial action of 
artemisinin, based on the formation of the primary and secondary carbon-centred 
radicals.33 
1.3.1.1. Model studies 
As described above, the formation of primary and secondary carbon centred 
radicals is thought to be involved in artemisinin’s mode of action. Although it is 
postulated that radical alkylation or peroxidation of essential molecular target(s) is 
key to parasitic cell death, the exact molecular target is yet to be defined. A couple 
of decades ago, biomedical scientists were unfamiliar with the chemical processes 
that artemisinins undergo.37 Hence, collaboration with chemists resulted in the 
generation of different theories about artemisinins mechanism of action.38 
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Potential mechanisms of action include: 
- Heme which is a suggested molecular target since the malaria life cycle 
involves the degradation of hemoglobin and the formation of free heme. 
The heme is located in the food vacuole and it has been shown that 
alkylated heme cannot crystallise therefore resulting in toxic levels of heme 
and inhibition of hemozoin formation.39 
- Alkylation of cysteine residues in proteins. Functional proteins/ enzymes 
containing ferric iron can also catalyse the cleavage of the endoperoxide 
bridge resulting in bioactivation and formation of C-radical intermediates. 
These radicals can be quenched by GSH or alkylated within or in close 
proximity to important cysteine residues resulting in inhibition of important 
functional proteins/ enzymes.40 
In recent years, artemisinin resistant parasites have emerged in Southeast Asia, 
further inhibiting efforts to halt the spread of malaria in this region.26,30,41 The 
validity of the present theories are yet to be proved and therefore understanding 
and identifying the main targets will help develop more effective and safer 
antimalarial drugs. 
1.3.2. Next-generation synthetic antimalarial drugs 
Due to the emergence of drug–resistant malaria parasite, great efforts are being 
made to design and develop novel antimalarial drugs with improved efficacy, 
bioavailability and potency. The active pharmacophore within artemisinin is 
understood to be the endoperoxide bridge.42 Using this knowledge, new synthetic 
derivatives have been produced that are cheaper, less reliant on the availability of 
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natural precursors, and pharmacologically more active than current antimalarial 
drugs. Examples include the trioxolane OZ277 (arterolane), OZ439 and the 
tetraoxane RKA182 (Figure 1.3).30,32 
 
Figure 1.3: Artemisinin with the active pharmacophore endoperoxide bridge 
highlighted, trioxolane OZ277, OZ439 and tetraoxane RKA182.32 
1.3.2.1. Trioxolanes and tetraoxanes 
OZ277 was approved in 2012 for use on the Indian market as a combination drug 
with piperaquine phosphate for the treatment of malaria. OZ277 is a 1,2,4-
trioxolane that was first discovered by the Vennerstrom group.43 Since then, 
hundreds of peroxide derivatives have been synthesised including 1,2-dioxolane, 
1,2,4-trioxane and 1,2,4,5-tetraoxanes (Figure 1.4).35   
Chapter 1 – General introduction 
 
28 
 
 
Figure 1.4: General template structure for 1,2-dioxane, 1,2,4-trioxolane, 1,2,4-
trioxane and 1,2,4,5-tetraoxanes.35 
In a phase II clinical trial, OZ277 was found to be unstable in the plasma of malaria 
patients, causing the compound to have an unacceptably short half-life.30 OZ439, is 
a second generation derivative with improved pharmacokinetics and enhanced in 
vivo antimalarial activity.44 Tetraoxanes, such as the 1,2,4,5-tetraoxane RKA182 
discovered by the O’Neill group,30 have shown greater stability in plasma compared 
to the trioxolanes. They are cheap to produce as the tetraoxanes are achiral and are 
easily synthesised using inexpensive materials.45 RKA182 is the first water soluble 
tetraoxane that has antimalarial activity and is currently undergoing preclinical 
trials.30 Although both trioxolanes and tetraoxanes have impressive antimalarial 
activities, the mechanism of action of these compound classes is still under debate. 
However, it is suggested that they have a similar mechanism to that of artemisinin, 
with ferrous iron catalysing the formation of toxic carbon-centered radicals and 
alkylation of important parasitic proteins.33 Understanding the chemical and 
molecular mechanisms of action of these natural and synthetic series of 
antimalarial drugs will ultimately aid their on-going chemical optimisation, minimise 
toxic liabilities, and thus enhance their clinical utility. 
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1.4. CDDO and derivatives 
2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO), 2-cyano-3,12-
dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) and methyl 2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oate (CDDO-Me, bardoxolone methyl) are all semi-
synthetic derivatives of oleanolic acid synthesised by the Sporn group (Figure 
1.5).46,47 These compounds exhibit a wide range of properties including anti-
inflammatory and anticancer activity. These compounds have generated great 
interest due to their multi-functionality and therapeutic potential.  
 
Figure 1.5: Chemical structure of CDDO, CDDO-Me and CDDO-Im with the α,β 
unsaturated carbonyl motifs highlighted. 
1.4.1. Pharmacology of CDDO 
It has often been documented that there is a strong correlation between 
inflammation and cancer.48 Inflammation, oxidative stress and cell proliferation are 
said to promote the onset of cancers.48 Oxidative stress is due to an imbalance 
between production of free radicals also known as reactive oxygen species (ROS) 
and antioxidant responses. This imbalance results in DNA damage and vital 
functional proteins.49 Oxidative stress can result in the activation of a variety of 
transcription factors as a means of cell defence. This includes nuclear factor kappa 
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B (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2) and many more.49 
Molecules that activate this cell defence mechanism without the cause of oxidative 
stress are known as antioxidants.49 
CDDO and its analogues have substantial biological responses at nanomolar and 
micromolar concentrations in cell-based in vitro experiments (Figure 1.6). At low 
nanomolar concentrations, these compounds are antioxidants where they can 
suppress NF-κB, via the direct inhibition of the inhibitor of nuclear factor kappa-B 
kinase subunit beta (IKKβ),14,50 and activate cytoprotective Nrf2 signalling.15,51 In the 
micromolar range, the targets shift more towards actin-related protein 3 (ARP3) 
and other parts of the cytoskeleton, resulting in an inhibition of cell proliferation, 
and ultimately the induction of apoptotic cell death.52  
 
Figure 1.6: Dose-dependent biological responses of synthetic oleanolic 
triterpenoids. Adapted from Liby et al 2012.52  
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Given that the CDDO series demonstrate impressive anti-inflammatory and 
anticancer properties, understanding how these novel naturally derived compounds 
exhibit their pharmacological and chemical activity are therefore important for 
future drug development. 
1.5. Cellular protection against stress 
Cells are constantly stressed by xenobiotics such as drugs, ROS, viral and other 
biological infections and environmental factors such as ultraviolet light.53 
Inflammation serves as a key mechanism of defence against such stresses, although 
prolonged/aberrant inflammation can be deleterious to health. In addition, 
mammalian cells have evolved means of detecting such cell stresses that result in 
the upregulation and increased expression of antioxidant and other cytoprotective 
genes in the presence of hazardous chemical and biological entities. Knowledge of 
the molecular mechanisms that regulate these processes has offered medicinal 
chemists opportunities to design compounds capable of manipulating their 
activities for therapeutic benefit. 
1.5.1. Nuclear factor kappa B (NF-κB) 
NF-κB is a transcription factor that can induce or repress the expression of 
inflammatory genes. There are five NF-κB family members, transcription factor p65 
(RelA or p65), transcription factor RelB (RelB), proto-oncogene c-Rel (c-Rel), nuclear 
factor NF-kappa-B p105 subunit (p50/p105 or NF-κB1) and the nuclear factor NF-
kappa-B p100 subunit (p52/p100 or NF-κB2).31 NF-κB exists as homo- or hetero- 
dimer of these subunits and is sequestered in the cytoplasm by isoforms of 
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inhibitors of nuclear factor kappa B (IκB).40 Activation of NF-κB involves 
phosphorylation of IκB by IκB kinase (IKK), resulting in the dissociation of IκB from 
NF-κB, and enabling NF-κB to translocate to the nucleus and manipulate the 
expression of inflammatory and other genes.10,40 The IKK complex is typically 
activated by pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) 
and interleukin-1 (IL-1), or by ROS (Figure 1.7). 
 
 
Figure 1.7: TNF-α or IL-1 activates IKK, which phosphorylates IκB (IκBα used in this 
example), resulting in the dissociation and nuclear translocation of NF-κB (p50-
RelA). Within the nucleus, NF-κB induces the expression of pro-inflammatory genes. 
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1.5.2. Nuclear factor erythroid 2-related factor 2 (Nrf2) 
Nrf2 is a transcription factor that regulates the basal and inducible expression of a 
large number of genes encoding detoxification enzymes, antioxidant protein and 
other stress response mediators.54 Kelch-like ECH-associated protein 1 (Keap1) 
serves as the cytosolic repressor of Nrf2 by facilitating its ubiquination and 
proteasomal degradation.55,56 Keap1 contains many cysteine residues that act as 
sensors of chemical and oxidative stress.57 Modification of specific cysteine(s) by 
Nrf2 inducers is thought to cause a conformational change in Keap1, rendering it 
incapable of efficiently targeting Nrf2 for ubiquitation and protesomal 
degradation.58 This results in the saturation of Keap1 with Nrf2 and an 
accumulation of the transcription factor in the nucleus of stressed cells.57,59 Here, 
Nrf2 heterodimerises with cofactors such as small Mafs and binds to the 
antioxidant response element (ARE) in the promoter region of target genes, 
resulting in their transcriptional up-regulation.59,60 The net effect of this adaptive 
response is an increased capacity to detoxify chemical and oxidative stresses and 
limit their harmful cellular effects (Figure 1.8). 
1.5.3. CDDO derivatives - potent inducers of Nrf2 
CDDO and derivatives are well known inducers of Nrf2 at nanomolar 
concentrations.61 However, the chemical and molecular features that underlie the 
extraordinary potencies of CDDO derivatives as inducers of Nrf2 are unclear. The 
active pharamcophores of the CDDO derivative are the α,β unsaturated ketones 
located on the A and C ring (Figure 1.5). Ultraviolet (UV) and nuclear magnetic 
resonance (NMR) studies by Sporn et al have demonstrated that these compounds 
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have the potential to form covalent adducts to simple thiols via 1,4 conjugate 
addition.62 It has been proposed that CDDO derivatives interact with cysteine 
residues, particularly Cys-151, on Keap1.55 However, confirmation is problematic 
due to the reversible nature of the conjugate addition reaction of CDDO. CDDO and 
their derivatives are less able to induce Nrf2 in cells expressing a Keap1 protein in 
which Cys-151 has been mutated.63,64 However, the ability of CDDO and derivatives 
to induce Nrf2 is unaltered in embryonic fibroblast derived from transgenic mice 
expressing a Keap1-Cys-151 mutant.56 Therefore, the precise nature of the 
interaction between CDDO and derivatives and the Keap1-Nrf2 pathway requires 
clarification in order to support the ongoing optimisation of these compounds as 
therapeutic agents. 
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Figure 1.8: (1) Normal – Nrf2 is bound to Keap1 ready to be ubiquitinated within 
the cytosol; (2) Nrf2 relocates to the proteasome for degradation; (3) Under 
oxidative stress, cysteine residues act as sensors on Keap1. Changes to specific 
cysteine residues alters the structure of Keap1 such that it can no longer efficiently 
target Nrf2 for ubiquitination; (4) Nrf2 is no longer degraded and so Keap1 becomes 
saturated and newly-synthesised Nrf2 accumulates within the cell; (5) Nrf2 
accumulates within the nucleus and heterodimerizes with other cofactors which 
binds to the ARE located in the promoter regions of target genes. This promotes 
transcription of cytoprotective genes, thereby reducing oxidative stress and 
inflammation. 
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1.6. Toxicity issues 
In 2012, CDDO-Me, also known as bardoxolone methyl, was in phase III clinical trials 
for the treatment of advanced chronic kidney disease.65 However, Reata 
Pharmaceuticals terminated this trial upon recommendation of the independent 
data monitoring committee, due to serious adverse reactions and mortality in 
patients.66 The precise nature of these adverse events suggests cardiovascular 
causes were responsible for the ADRs and mortality of the patients.67 However, the 
underlying chemical and molecular mechanism is unclear, yet such knowledge is 
vital if this class of compound is to have clinical utility. 
1.7. Aims of this thesis 
Given the uncertain chemical and molecular mechanisms of antimalarial 
endoperoxides and anti-inflammatory CDDO derivatives, this thesis aims to provide 
chemical tools to enable characterisation and in depth understanding of such 
mechanisms. As mentioned earlier direct techniques are the most advantageous. 
Such analysis to identify proteins utilising LCMS or protein immunoblotting analysis 
allows confidence and accuracy. Bespoke probes can be designed to explore the 
chemical mechanism and potential use of pull down experiments, resulting in the 
identification and verification of target proteins. 
The identification of the molecular targets for these compounds will allow for the 
design of safer and more efficacious derivatives, along with the potential to 
influence current clinical practice. In order to achieve these aims, both CDDO and 
endoperoxide antimalarials will be synthesised to: 
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I. Enabling identification of important pharmacophores and potential 
functionalization of certain groups will involve the development of a SAR 
profile. This will allow the development of strategies for medicinal chemistry 
optimisation of potency and drug metabolism and pharmacokinetics (DMPK) 
properties 
II. Create novel chemical probes which can be used to define the molecular 
targets of these compounds in biologically-relevant contexts. In the case of 
CDDO specifically, chemical probes are urgently required to test the 
hypothesis that Keap1 is indeed the molecular target responsible for the 
induction of Nrf2 by this compound. 
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2.1. Introduction 
CDDO and its methyl ester CDDO-Me (bardoxolone methyl) are well known potent 
inducers of Nrf2 (Figure 2.1). Both compounds were originally synthesised from 
oleanolic acid by the Sporn group.1-5  
 
Figure 2.1: Chemical structure of Oleanolic acid, CDDO and CDDO-Me including the 
carbon numbering sequence. 
As described in chapter 1, CDDO-Me is one of the most potent inducers of Nrf2 
currently known. Unfortunately, the molecular mechanisms that underlie its 
potency are not completely understood. CDDO-Me was withdrawn from phase III 
clinical trials for the treatment of advanced chronic kidney disease due to 
cardiovascular adverse events and mortality. Therefore, a better understanding of 
the pharmacological and toxicological targets of CDDO-Me is required to prevent 
toxicity from occurring.6 The interaction of CDDO-Me with protein targets is 
hypothesised to be through reversible conjugation to thiols via a 1,4 conjugate 
addition process. The reversibility of CDDO-Me makes it more difficult to detect 
conjugate adducts yet most chemical biological techniques for detecting drug 
protein adducts deal with reversible acting drugs. Based on the chemical structure, 
there are two possible thiol reactive groups in the A ring and the C ring. It has been 
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suggested that the presence of the cyano group facilitates the reversible addition 
through increased acidity of the enolate intermediate. 
The cyano group is a highly electron withdrawing group. The electron withdrawing 
effect pulls electrons from the double bond within the α,β unsaturated ketone. This 
enables weaker nucleophiles to attack at the α,β unsaturated ketone via a 1,4 
conjugate addition. The cyano group can also stabilise a negative charge more 
effectively therefore enabling reversibility. Without the cyano group an 
intermediate enol is formed that can readily tautomerise into a ketone.7 The 
mechanism is shown in Figure 2.2. 
 
Figure 2.2: Reversible and irreversible nucleophilic attack and the effect of a 
withdrawing group. 
  
Chapter 2 – The synthesis and biological profiling of CDDO derivatives 
 
49 
 
2.1.1. Aims 
By understanding the chemistry of these compounds, it will be possible to design a 
compound capable of a non-reversible thiol reaction whilst maintaining biological 
activity. Such a compound would represent a novel tool with which to explore the 
critical targets of CDDO and its derivatives in relevant biological contexts. The aim 
of this section is to enable the production of such a compound by synthesising 
CDDO derivatives. 
In addition, biological tests will involve screening for the induction of Nrf2 using 
western blotting and a high throughput screening assay based on H4IIE cells stably 
expressing the ARE8L-reporter. These will be conducted to ensure that the 
compounds are pharmacologically active. 
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2.2. Results and discussion 
2.2.1. Chemical synthesis of CDDO and derivatives 
Synthesis of CDDO (8) from commercially available oleanolic acid (1) involves an 
eleven step process established by Sporn et al.1-5 (Scheme 2.1) The initial reactions 
involve the protection of the carboxylic acid group at C-28 by methylation followed 
by the protection of the alcohol group at the C-3 position by acetylation with acetic 
anhydride to form an acetoxy group. The literature procedure employed 
diazomethane for the methylation of the carboxylic acid group. Due to the 
explosive properties of diazomethane and the need for a large scale reaction to 
protect the carboxylic acid, the less reactive trimethylsilyldiazomethane (TMS 
diazomethane) was used as an alternative.8 This reaction gave a 51% yield of 9 
(Scheme 2.2). Although TMS diazomethane is safer to handle than diazomethane, 
scaling up the reaction can prove expensive due to the cost of TMS diazomethane. 
The TMS diazomethane route was used to provide authentic methyl ester protected 
material for subsequent spectral analysis.  
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Scheme 2.1: Reagents and conditions: (i) CH2N2, Et2O, THF; (ii) Ac2O, Pyr; (iii) 30% 
H2O2, AcOH; (iv) Br2, HBr, AcOH; (v) KOH (aq) MeOH; (vi) 0°C, CrO3 (2.5M) in 
H2SO4:H2O (1:4); (vii) HCO2Et, MeONa, PhH; (viii) NH2OH.HCl, EtOH; (ix) MeONa, 
MeOH, Et2O; (x) DDQ, PhH; (xi) LiI, DMF. 
 
Scheme 2.2: Reagents and conditions: (i) THF, MeOH, N2 (g), TMS diazomethane 
(2.0M) (1.1 equiv) 51%. 
Alternative routes were explored for the protection of the carboxylic acid group as 
well as the alcohol group. Protection of the alcohol group was achieved by 
acetylation of oleanolic acid. Triethylamine, acetic anhydride and 4-(dimethylamino) 
pyridine were the reagents used to obtain 10 in 95% yield (Scheme 2.3). 
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Methylation of 10 to protect the carboxylic acid using iodomethane and potassium 
carbonate9 gave a 97% yield of 11 (Scheme 2.3). By changing the initial reagents 
and sequence of protection, an alternative synthetic route was produced. This 
provided a safer solution during scale up unlike diazomethane which is toxic, 
expensive and potentially explosive in nature.  
 
Scheme 2.3: Reagents and conditions: (i) DCM, NEt3 (2 equiv), acetic anhydride (2.5 
equiv), 4-(dimethylamino)pyridine (0.01 equiv), N2 (g), 12 hours, 95%; (ii) MeI (4 
equiv) K2CO3 (4 equiv), acetone, r.t., 24 hours, 97%. 
Formation of 2 (Scheme 2.4) involves the epoxidation of 11 to 12 using meta-
chloro-peroxybenzoic acid (mCPBA).10 The intermediate epoxide 12 was not 
isolated during the purification procedure. The reaction proceeded to give methyl 
3-acetoxy-12-oxo-13-oleanolate (2) directly in 99% yield. This was confirmed by 
comparison with the 13C NMR reported in the literature and mass spectrometry. 
The epoxide (12) is prone to ring opening to form a highly stabilised tertiary 
carbocation and upon loss of a proton, leads to the formation of the ketone 
(Scheme 2.5). During subsequent scale up of this step, the epoxide (12) was isolated 
and full analysis later matched published literature.11 However, during purification 
by column chromatography, the epoxide was no longer observed. One explanation 
is that the acidic nature of the silica used for chromatographic purification, could 
have caused the epoxide to rearrange to form 2. The literature preparation 
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required the use of BF3.OEt2 to cause the rearrangement of the epoxide, but this 
step was not required as the epoxide also proceeded to form 2 during the 
purification via flash column chromatography. 
 
Scheme 2.4: Reagents and conditions: (i) mCPBA (1.2 equiv), DCM, 0°C to r.t. 
overnight; (ii) BF3.OEt2, benzene. 
 
Scheme 2.5: Rearrangement of the epoxide to the target ketone. 
The dehydrogenation of 2 to obtain 3 (Scheme 2.1) was initially unsuccessful 
leading to an unknown compound. Mass spectroscopy and NMR indicated 
hydrolysis of the methyl ester to a carboxylic acid had occurred. (Singlet peak 
located at δ3.62 in the 1H NMR was no longer present). As well as dehydrogenation, 
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addition of hydrogen bromine was also observed. The exact structure could not be 
determined due to the overlapping of proton signals. However, mass spectrometry 
indicated the presence of bromine due to the bromine isotope peaks. 
The most likely explanation for ester hydrolysis is the nature of the harsh reaction 
conditions used. The acetic acid was replaced with acetonitrile as the solvent, 
resolving the issue and producing the desired product in excellent yield.12 
Purification by recrystallisation from methanol gave compound 3 in 99% yield. 
 
Scheme 2.6: Reagents and conditions: (i) HBr 48% (0.38 equiv), Br2 [1.0M in MeCN] 
(1.08 equiv), MeCN, 35°C, 16 hr; (ii) Br2 [1.0M in MeCN] over 5 mins, 1 hour, 99%. 
The stereochemistry at C-18 was difficult to determine by NMR spectroscopy due to 
overlapping of proton signals in the 1H NMR. The C-18 can have two configurations 
and the stereochemistry of this position has been shown to have an effect on anti-
inflammatory activity.13 The cis isomer 1a is the naturally occurring isomer for 
oleanolic acid. During the synthesis of CDDO derivatives, there is a possibility that 
the C-18 proton may change in configuration giving the trans isomer 1b. 
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Figure 2.3: Stereochemistry of the C-18 proton from oleanolic acid. 
An X-ray crystal structure of 3 was obtained (Figure 2.4) and confirmed that the 
configuration of the proton located on C-18 was as depicted (3a) i.e. cis and the 
stereochemistry from oleanolic acid was maintained (1a). 
 
Figure 2.4: Chemical structures of two possible diastereoisomers and the X-ray 
crystal of intermediate 3. 
Deprotection of 3 to obtain the alcohol by refluxing with potassium hydroxide in 
methanol gave 13 in 99% yield.3 Oxidation of the alcohol at the C-3 position using 
the Jones reagent gave 4 in 99% yield. (Scheme 2.7) 
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Scheme 2.7: Reagents and conditions: (i) KOH, MeOH, reflux, 30 mins, 99%; (ii) 
acetone, Jones reagent, 0°C stir, r.t. 10 mins, 99%. 
Synthesis of 5 involved the use of sodium methoxide, ethyl formate and toluene 
under anhydrous conditions. The literature procedure used benzene as the 
solvent,2 however, since toluene is less toxic and has similar properties to benzene, 
we utilised toluene for this reaction. Initially this reaction failed and the starting 
material 4 was obtained (confirmed by NMR). Utilising a fresh batch of sodium 
methoxide proved successful and yielded 5 in 98% yield (Scheme 2.8). The seven 
steps from oleanolic acid to 5 were also performed on a larger scale (4 g scale). 
During the scale up, the reactions were higher yielding than on a smaller scale. 
Cyclization of 5 involved refluxing in 9:1 ethanol:water with NH2OH·HCl to obtain 6 
in 86% yield.3 In order to prepare 14, compound 6 was allowed to react with 
sodium methoxide in methanol and diethyl ether. The reaction was initially at 0°C 
then room temperature for 45 minutes to give 14 in 70% yield.3 (Scheme 2.8) The 
chemical mechanism to convert compound 4 to 14 is shown in Scheme 2.9. 
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Scheme 2.8: Reagents and conditions: (i) MeONa (6.05 equiv), toluene, ethyl 
formate (4.5 equiv), r.t., 2 hours, 98%; (ii) EtOH:H2O (9:1), NH2OH·HCl (10 equiv), 
reflux, 1 hour, 86%; (iii) MeOH, Et2O, NaOMe (34 equiv), 0°C to r.t. 45 mins, 70%. 
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Scheme 2.9: Synthesis of 4 to 14 and their chemical mechanism of action. 
Compound 14 could be obtained from compound 4 using an alternative reaction 
shown in Scheme 2.10. The synthetic step involved an addition reaction. Here a 
nitrile functional group was added onto C-2 and reduced the synthetic pathway to 
nine steps. Compound 4 was treated with LDA at -78°C to form an intermediate 
enolate anion which was treated with p-TsCN to obtain 14 in 88% yield. 
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Scheme 2.10: Reagents and conditions: (i) LDA (1.5 equiv) [2.0M heptane/THF/ethyl 
benzene], THF, N2 (g), -78°C to r.t., 20 mins; (ii) p-TsCN (2 equiv), -78°C, 5 mins; (iii) 
DDQ (1.72 equiv), anhydrous benzene, reflux, 15 mins, 87%; (iv) LiI (19 equiv), 
anhydrous DMF, N2 (g), reflux, overnight. 
Dehydrogenation of 14 required refluxing with 2,3-dichloro-5,6-dicyano-p-
benzoquinone (DDQ) in anhydrous benzene for 1 hour gave 7 in 87% yield. Initially 
anhydrous toluene was also utilised as an alternative for benzene for this step, 
however, only starting material was obtained.  The final step involved the hydrolysis 
of the methyl ester on C-28 to obtain the carboxylic acid functional group. 
Formation of CDDO (8) involved the use of lithium iodide in anhydrous DMF at 
reflux overnight to give CDDO in 44% yield. The mechanism is shown in Scheme 
2.11. A side product was also obtained during this reaction (15) where NMR and 
mass spectra confirmed the side product. This could have been caused by a small 
amount of 14 being present during this reaction. This compound is useful for the 
SAR studies to compare the importance of CDDO (8) and CDDO without the double 
bond (15) located on the A ring. 
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Scheme 2.11: Chemical mechanism of lithium iodide hydrolysis 
 
Figure 2.5: Side product obtained when using LiI in DMF. 
2.2.2. Biological analysis 
Following the chemical synthesis of CDDO and derivatives, SAR studies were 
performed to ensure the compounds that were synthesised were biologically active. 
As reported in the literature, CDDO derivatives provoke the accumulation of Nrf2 
which induces the expression of phase II enzymes containing the ARE motifs in their 
promoter region.14  
In order to determine the potency of CDDO and its derivatives, H4IIE rat hepatoma 
cells, stabily transfected with a Nrf2-sensitive luciferase reporter transgene,15 were 
exposed to the compounds for 24 hours. Binding of Nrf2 to the ARE motifs located 
within the reporter transgene causes an increase in the expression of luciferase, 
which catalyses the conversion of luciferin to oxyluciferin with visible light 
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produced as a by-product. (Figure 2.6). H4IIE cell are known to express functional 
Nrf2 and down-stream regulated enzymes.15-17 Therefore, the amount of light 
produced is proportional to the amount of Nrf2 present.  
 
Figure 2.6: Schematic overview of the principle of the luciferase reporter assay for 
determination of Nrf2 activity in H4IIE-ARE cells. Oxidative stress modifies key 
cysteine residues located on Keap1. Nrf2 is no longer regulated by keap1 and Nrf2 
enters the nucleus. Binding of Nrf2 to the ARE motifs located within the reporter 
transgene causes an increase in the expression of luciferase, which catalyses the 
conversion of luciferin to oxyluciferin with visible light produced as a by-product. 
This light can be measured and directly correlates to the amount of Nrf2 present. 
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In order to confirm that CDDO-Me (7) was capable of inducing the accumulation of 
Nrf2 per se, H4IIE-ARE cells were exposed to increasing concentrations of CDDO-Me 
for 1 hour, and Nrf2 levels were determined by western blot. The data 
demonstrates that CDDO-Me provoked a concentration dependant accumulation of 
Nrf2 (Figure 2.7). CDDO-Me was also screened using the Luciferase reporter assay 
and compared to the western blot data. (Graph 2.2) 
 
Figure 2.7: Western blot for Nrf2 and actin. CDDO-Me exposed to H4IIE-ARE cells 
for 1 hour over a range of concentrations. 
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Graph 2.1: Densitometry data from western blot. CDDO-Me was exposed to H4IIE-
ARE cells for 1 hour. Data shown is the average of n=3 where Nrf2 values are 
normalised against actin. 
The luciferase reporter assay was compared with the Nrf2 western blot data. The 
concentrations that were required to provoke a concentration dependant 
accumulation of Nrf2 also provoked an increase in luciferase activity. 
Altogether fifteen intermediates were prepared during the synthesis of CDDO, of 
which seven were selected for screening using the luciferase reporter assay. The 
concentration range that was selected for the screening of these compounds is 
explained as followed. The highest concentration with no observable effect in 
luciferase activity was 0.001 nM during the screening of CDDO-Me, therefore this is 
kept as the lowest concentration range. Above 20 mM, most of these compounds 
are insoluble in DMSO, and maintaining a 0.5% DMSO content in each well will give 
a final concentration of 100 µM. The 0.5% DMSO content in each well will ensure 
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that no toxicity is observed from DMSO. Therefore, the range selected for the 
luciferase reporter assay is between 0.001 nM – 100 µM. The intermediates were 
measured based on their effective concentration to double luciferase activity 
(EC200). 
This screening of the seven compounds is used to provide data that will help to 
further understand the SAR (Graph 2.2 and Figure 2.8). 
In this assay, luciferase activity was not observed when exposed to oleanolic acid at 
the concentration range set.  
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytoplasmic 2-electron reductase 
that is involved in chemoprotection. NQO1 is mediated by the ARE-promoter region 
within DNA. Activation of Nrf2 induces phase 2 genes via induction of ARE-
dependent genes. NQO1 is a phase 2 gene and therefore an increase in NQO1 
results in cell defence mechanism.18 Dinkova-Kostova et al, has demonstrated that 
there is a clear correlation between potencies of compounds that are able to induce 
the phase 2 enzyme NQO1 and the suppression of interferon gamma (IFN-γ) 
dependent transcriptional activation of inducible nitric oxide synthase (iNOS).19 
Therefore, the induction of Nrf2 is also highly linked to the activation of iNOS.  
Oleanolic acid has been shown to inhibit iNOS production induced by IFN-γ in 
mouse macrophages.3 However, it was inactive when tested for its ability to induce 
NQO1.19 Oleanolic acid has also demonstrated its ability to induce Nrf2 in vivo.20 
This suggests that the concentration range used within our assay may not be within 
the range where Nrf2 is accumulated. 
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Figure 2.8: Seven compounds that were tested using the luciferase activity assay. 
Their EC200 values were calculated based on their ability to increase luciferase 
activity. They were grouped based on their EC200 values being in micromolar or 
nanomolar concentrations. 
Compound 2, 3 and 4 are the intermediate products from steps 3, 4 and 6 for the 
synthesis of CDDO respectively. Their ability to induce Nrf2 was increased 
compared to oleanolic acid ranging in the micromolar range. However, these three 
compounds lack the pharmacophore located in the A ring (Figure 2.8). This is the 
α,β unsaturated ketone along with the incorporation of an electron withdrawing 
cyano group in the C-2 position within the A ring. Compound 2 was more active 
than compounds 3 and 4. SAR studies by Sporn et al suggested that the α,β 
unsaturated ketone located on the A and C rings are vital for nanomolar activity and 
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the lack of this functional group decreases activity.2,3 Surprisingly, introduction of a 
double bond in the C ring (compound 2 vs. compound 3) which converts the ketone 
to the α,β unsaturated ketone decreased activity. This suggests that the Michael 
acceptor in the C ring is not of great importance. Converting the acetate group to a 
ketone within the A ring (compound 3 vs. compound 4) resulted in an increase in 
EC200 but only to similar levels to compound 2.  
Compound 7 is CDDO-Me, the most active compound within the series giving an 
EC200 at 0.62 nM. This was followed by compound 8 (CDDO) with an EC200 at 16.26 
nM. Compound 15 also gave nanomolar activity, however, unlike CDDO and CDDO-
Me this was at 740 nM. Compound 15 lacked the double bond in the A ring which 
suggests that this is an important pharmacophore in order to obtain low nanomolar 
activity.  
Structural comparison of CDDO with CDDO-Me showed that the difference in SAR 
was the conversion from methyl ester of CDDO-Me to carboxylic acid CDDO. This 
renders CDDO-Me more lipophilic in nature than CDDO and therefore may 
contribute to the increase in potency. Keap1 is a known cytoplasmic Nrf2 repressor. 
The increase in lipophilicity of CDDO-Me might enable the drug to enter cells more 
readily and therefore results in an increase in drug concentration within cells. If 
Keap1 is indeed the target protein for CDDO derivatives then the increase in 
concentrations within the cells will result in more drug being available for drug 
target interactions and therefore will result in an increase in potency. Other 
literature examples that adopt similar structural conversions from a carboxylic acid 
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group to an ester group to increase lipophilicity and hence potency are shown in 
Table 2.1. 
Name, conversion from 
(therapeutic area) 
Chemical structure and 
highlighted functional group 
Detail of potency 
Latanoprost from 
Lantaoprost acid 
(Glaucoma) 
 
Improved lipophilicity 
resulting in increase 
absorption and safety 
Tazarotene from 
Tazarotene acid 
(psoriasis, acne and 
tropical skin disorders) 
 
Improved lipophilicity 
but maintains adequate 
aqueous solubility 
resulting in improved 
skin permeation 
Dipivefrin from 
adrenaline 
(Glaucoma) 
 
600 fold increase in 
lipophilicity compared 
to dipivefrin enabling 
dipivefrin to permeate 
the human cornea 17 
times faster than 
adrenaline 
 
Table 2.1: Table contains examples of drugs resulting in improved potency by 
converting the carboxylic acid groups to esters (highlighted in red). Adapted from 
Rautio et al.21 
CDDO-Me and CDDO have also been tested for the inhibition of INF-γ dependent 
transcriptional activation of iNO in mouse macrophages as an anti-inflammatory.3 
The IC50 values were 0.1 and 0.2 nM respectively. Hence, CDDO-Me is more active 
than CDDO in its ability to inhibit INF-γ.3 Currently, there are no other 
Chapter 2 – The synthesis and biological profiling of CDDO derivatives 
 
69 
 
biological/pharmacological literature data for the other compounds shown in Figure 
2.8.  
2.3. Conclusion 
The synthesis of CDDO was a success. Initially the synthesis involved eleven steps, 
some of which involved toxic and explosive reagents. Through the use of alternative 
reagents and conditions, some of the hazards were minimised and the synthesis 
was reduced to nine steps. In total, fifteen compounds were obtained during this 
synthesis. The pharmacological potency of six of these compounds was determined 
in H4IIE-ARE cells. CDDO-Me was found to be the most active compound followed 
by CDDO, with both compounds inducing Nrf2 signalling at low nanomolar 
concentrations. This is consistent with literature data currently available for both 
compounds.2,3  
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2.4. Chemistry Experimental 
2.4.1. General 
Reactions that were air and moisture sensitive were performed under a nitrogen 
atmosphere. This was achieved with oven dried or flame dried glassware sealed 
with a rubber septa. Dry nitrogen gas was introduced via a manifold or balloon.  
Reactions were stirred using Teflon-coated magnetic stir bars. Organic solutions 
were concentrated using a Büchi rotary evaporator with a diaphragm vacuum pump. 
Anhydrous solutions and sensitive liquids were transferred via syringe. 
2.4.2. Purification of solvents and reagents 
Anhydrous solvents were obtained from commercial sources or dried and distilled 
prior to use. The distillation was under the flow of dry nitrogen. THF was distilled 
from sodium. Dichloromethane was distilled from calcium hydride. Oleanolic acid 
was obtained from Toronto Research Chemicals Inc. and Indofine Chemical 
Company Inc. All reagents were purchased from Sigma Aldrich or Alfa Aesar and 
were used without purification unless otherwise indicated.  
2.4.2.1. Purification of meta-chloroperoxybenzoic acid 
m-Chloroperbenzoic acid (~45%) was purified prior to use. Disodium hydrogen 
phosphate (4.32 g, 30.0 mmol) and potassium dihydrogen phosphate (1.18 g, 8.7 
mmol) were dissolved in 1 L of distilled water. 500 mL of buffer was added to 
commercial mCPBA (25 g). The mixture was stirred and the solid filtered off. The 
filtered solid was washed with the rest of the buffer (500 mL) and was dissolved in 
dichloromethane (200 mL). The solution was dried over anhydrous magnesium 
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sulfate, filtered and the solvent removed in vacuo. mCPBA was left to dry under 
reduced pressure overnight to give approximately 95-100% pure mCPBA as a white 
flocculent solid.  
2.4.3. Stains 
p-Anisaldehyde stain 
Concentrated sulphuric acid (2.5 mL) was added to p-anisaldehyde (15 g) in ethanol 
(250 mL) to give a clear solution of p-anisaldehyde stain. 
2.4.4. Purification of products 
Analytical thin layer chromatography (TLC) was performed with 0.25 mm Merck 
silica gel 60 F254 plates with 254 nm fluorescent indicator. Plates were visualised by 
U.V. at 254 nm or treated with p-anisaldehyde solution followed by gentle heating. 
Chromatographic purification of products was accomplished by flash column 
chromatography unless otherwise indicated. 
2.4.5. Analysis 
1H NMR spectra were measured on a Brucker AMX400 (400 MHz) nuclear magnetic 
resonance spectrometer. Solvents are indicated in the text. The data for 1H NMR 
spectra are reported as follows: chemical shifts ware described in parts per million 
(δ, ppm) downfield from an internal reference of trimethylsilane. Integration. 
Multiplicities: (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of 
doublets, dt = doublet of triplets, td = triplet of doublets and m = multiplet). 
Coupling (J, Hz). 13C NMR spectra were measured on a Brucker AMX400 (100 MHz) 
and are reported in terms of chemical shift (δ, ppm) relative to residual solvent 
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peak.  Mass spectrometry (MS) and High Resolution Mass Spectrometry (HRMS) 
were recorded on a VG analytical 7070E machine, Frisons TRIO spectrometers or 
Agilent QTOF 7200 using chemical ionisation (CI) or electron ionisation (EI). 
Micromass LCT mass spectrometer used electron spray ionisation (ESI). Reported 
mass values are within error limits of ±5 ppm. Elemental analysis (%C, %H, %N) 
were determined by the University of Liverpool Microanalysis Laboratory. The 
reported atomic percentages are within error limits of ±0.5%. Melting points were 
determined on a Gallenkamp melting point apparatus in degrees Celsius and are 
uncorrected. Infrared spectra were recorded on either a Jasco FT/IR-4200 fourier 
transform infrared spectrometer or a Bruker Alpha platinum ART and are reported 
in wavenumbers (cm-1). Single crystal X-ray data were collected on a Bruker D8 
diffractometer with an APEX CCD detector. 
2.4.6. Numbering 
Oleanolic acid 
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2.4.7. Synthesis 
Preparation of methyl 3β-hydroxy-olean-12-en-28-oate (9)22-24  
 
 
Oleanolic acid (1) (0.2 g, 0.44 mmol) was dissolved in tetrahydrofuran (2 mL) and 
methanol (0.5 mL). The solution was cooled to 0°C and (trimethylsilyl)diazomethane 
(2.0 M in hexanes, 76.6 µL, 0.48 mmol) was added slowly to the reaction. The 
reaction mixture was allowed to warm to room temperature and left to stir for 1 
hour. The solvent was removed and concentrated in vacuo and purified by flash 
column chromatography using 5% ethyl acetate in dichloromethane to give the title 
compound 9 (105 mg, 51%) as a white solid; Rf = 0.7, 20% ethyl acetate in 
dichloromethane; 1H NMR (400 MHz, CDCl3) δ 5.28 (t, J = 3.6 Hz, 1H), 3.62 (s, 3H), 
3.21 (dd, J = 11.1, 4.7 Hz, 1H), 2.86 (dd, J = 13.8, 4.2 Hz, 1H), 2.03 – 1.83 (m, 3H), 
1.74 – 1.26 (m, 16H), 1.22 – 1.14 (m, 2H), 1.13 (s, 3H), 1.05 (dd, J = 11.4, 3.9 Hz, 1H), 
0.99 (s, 3H), 0.97 (s, 1H), 0.92 (s, 3H), 0.90 (s, 3H), 0.90 (s, 3H), 0.78 (s, 3H) and 0.72 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 178.5, 143.9, 122.5, 79.2, 55.4, 51.7, 47.8, 46.9, 
46.0, 41.8, 41.4, 39.4, 38.9, 38.6, 37.2, 34.0, 33.3, 32.8, 32.5, 30.8, 28.2, 27.8, 27.3, 
26.1, 23.8, 23.6, 23.2, 18.5, 17.0, 15.7 and 15.4; HRMS (ESI) calculated for C31H50O3 
[M+Na]+ 493.3658 found 493.3668. 
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Preparation of 3β-acetoxy-olean-12-en-28-oic acid (10)1,10  
 
 
 
Under an atmosphere of nitrogen, oleanolic acid (1) (4 g, 8.76 mmol) was dissolved 
in dichloromethane (100 mL). Triethylamine (2.44 mL, 17.52 mmol), acetic 
anhydride (2.07 mL, 21.9 mmol) and 4-(dimethylamino)pyridine (10.7 mg, 87.6 
µmol) were added to the reaction and left to stir at room temperature for 12 hours. 
2 M hydrochloric acid solution was added to the reaction. The reaction mixture was 
washed with dichloromethane (3 x 100 mL). The combined organic layers were 
washed with water, brine and dried over magnesium sulfate. The solution was 
concentrated in vacuo to give crude product in which purification by flash 
chromatography using 20% ethyl acetate in hexane gave the title compound 10 
(4.13 g, 95%) as a white powder; Rf = 0.4, 20% ethyl acetate in hexane; mp = lit
25 
254.2-257.8°C found 255-257°C; 1H NMR (400 MHz, CDCl3) δ 5.27 (t, J = 3.3 Hz, 1H), 
4.59 – 4.39 (m, 1H), 2.82 (dd, J = 13.4, 3.7 Hz, 1H), 2.05 (s, 3H), 2.03 – 1.85 (m, 3H), 
1.82 – 1.16 (m, 18H), 1.12 (s, 3H), 1.10 – 1.02 (m, 2H), 0.94 (s, 3H), 0.93 (s, 3H), 0.90 
(s, 3H), 0.86 (s, 3H), 0.85 (s, 3H) and 0.74 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 184.6, 
171.2, 143.7, 122.7, 81.1, 55.4, 47.7, 46.7, 45.9, 41.6, 41.0, 39.4, 38.2, 37.8, 37.1, 
33.9, 33.2, 32.6, 32.6, 30.8, 28.2, 27.8, 26.0, 23.7, 23.6, 23.5, 23.0, 21.5, 18.3, 17.3, 
16.8 and 15.5; IR νmax (neat)/cm
-1 3178 (OH), 2943 (CH), 1726 (C=O) and 1680 (C=C); 
HRMS (ESI) calculated for C32H50O4 [M+Na]
+ 521.3607 found 521.3618. 
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Preparation of 3β-acetyloleanolic acid methyl ester (11)9 
 
 
10 (6.47 g, 12.97 mmol) was dissolved in acetone (100 mL). Potassium carbonate 
(7.17 g, 51.89 mmol) and iodomethane (3.23 mL, 51.89 mmol) were added to the 
reaction and left to stir at room temperature for 24 hours. The reaction was 
concentrated in vacuo and the residue was dissolved in dichloromethane. The 
organic layer was washed with water, brine and dried over magnesium sulfate. The 
solution was concentrated in vacuo to give crude product in which purification by 
flash chromatography using 5% ethyl acetate in hexane gave the title compound 11 
(6.48 g, 97%) as a white powder; Rf = 0.8, 20% ethyl acetate in hexane 
9 (100 mg, 212 µmol) was dissolved in anhydrous dichloromethane (50 mL) and 
purged with nitrogen. Triethylamine (59.22 µL, 425 µmol), acetic anhydride (50.2 µL, 
531 µmol) and 4-(dimethylamino)pyridine (259 µg, 2.12 µmol) were added to the 
reaction and left to stir at room temperature overnight. The reaction was 
concentrated in vacuo and the residue was dissolved in dichloromethane. The 
organic layer was washed with 2 M hydrochloric acid, water, brine and dried over 
magnesium sulfate. The solution was concentrated to give crude product which was 
purified by flash chromatography using 10% ethyl acetate in hexane to give the title 
compound 11 (99.1 mg, 91%) as a white powder; Rf = 0.8, 20% ethyl acetate in 
hexane.  
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mp = lit9 219-221°C found 218-219°C; 1H NMR (400 MHz, CDCl3) δ 5.28 (t, J = 3.6 Hz, 
1H), 4.49 (dd, J = 8.9, 7.1 Hz, 1H), 3.62 (s, 3H), 2.86 (dd, J = 13.8, 4.2 Hz, 1H), 2.05 (s, 
3H), 2.02 – 1.83 (m, 3H), 1.74 – 1.25 (m, 15H), 1.22 – 1.15 (m, 2H), 1.12 (s, 3H), 1.10 
– 0.99 (m, 2H), 0.93 (s, 3H), 0.92 (s, 3H), 0.90 (s, 3H), 0.86 (s, 3H), 0.85 (s, 3H) and 
0.72 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 178.4, 171.2, 143.9, 122.4, 81.0, 55.4, 51.7, 
47.7, 46.8, 46.0, 41.7, 41.4, 39.4, 38.2, 37.8, 37.0, 34.0, 33.2, 32.7, 32.5, 30.8, 28.2, 
27.8, 26.0, 23.8, 23.6, 23.5, 23.2, 21.5, 18.3, 17.0, 16.8 and 15.5; IR νmax (neat)/cm
-1 
2937 (CH), 2862 (COCH3) and 1726 (C=O); HRMS (ESI) calculated for C33H52O4 
[M+Na]+ 535.3763 found 535.3758; Microanalysis calculated for C33H52O4 requires C 
77.30%, H 10.22% found C 77.396%, H 10.161% 
  
Chapter 2 – The synthesis and biological profiling of CDDO derivatives 
 
77 
 
Preparation of methy-3β-acetoxy-12-oxo-olean-28-oate (2)10 
 
 
 11 (3.85 g, 7.51 mmol) was dissolved in dry dichloromethane (50 mL) and cooled to 
0°C. Pre-purified meta-chloroperoxybenzoic acid (1.55 g, 9.01 mmol) (see section 
2.4.2.1) was added to this reaction and left to stir for 12 hours at room temperature. 
The reaction was washed with sodium hydrogen carbonate solution and 
dichloromethane. The organic layer was washed with water, brine, dried over 
magnesium sulfate and filtered. The filtrate was concentrated in vacuo to obtain 
the crude product. The crude product was purified by flash chromatography using 5% 
ethyl acetate in hexane to give the title compound 2 (3.93 g, 99%) as a white 
powder; Rf = 0.56, 20% ethyl acetate in hexane; mp = lit
26 189-191°C found 187-
189°C; 1H NMR (400 MHz, CDCl3) δ 4.47 (dd, J = 11.1, 5.0 Hz, 1H), 3.68 (s, 3H), 2.79 
(dt, J = 13.5, 3.4 Hz, 1H), 2.60 (d, J = 4.3 Hz, 1H), 2.28 – 2.07 (m, 2H), 2.05 (s, 3H), 
1.97 – 1.73 (m, 3H), 1.69 – 1.14 (m, 15H), 1.13 – 0.99 (m, 2H), 0.98 (s, 3H), 0.96 (s, 
3H), 0.94 (s, 3H), 0.90 (s, 3H), 0.87 (s, 3H), 0.87 (s, 2H) and 0.86 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 211.9, 178.5, 171.1, 80.5, 55.3, 52.0, 49.7, 47.5, 41.9, 41.3, 38.6, 
37.9, 37.7, 36.9, 36.3, 34.6, 33.5, 33.1, 32.1, 31.8, 30.8, 28.0, 27.6, 23.5, 23.3, 22.8, 
21.4, 20.7, 18.3, 16.6, 16.2 and 15.4; IR νmax (neat)/cm
-1 2927 (CH), 2858 (COCH3) 
and 1724 (C=O); HRMS (ESI) calculated for C33H52O5 [M+Na]
+ 551.3712 found 
551.3711.  
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Intermediate methyl 3β-acetoxy-12,13-epoxyoleanolate (12)10,11 
 
11 (6.48 g, 12.64 mmol) was dissolved in dry dichloromethane (50 mL) and cooled 
to 0°C. Pre-purified meta-chloroperoxybenzoic acid (2.62 g, 2.62 mmol) (see section 
2.4.2.1) was added to this reaction and left to stir for 12 hours at room temperature. 
The reaction was washed with sodium hydrogen carbonate solution and 
dichloromethane. The organic layer was washed with water, brine, dried over 
magnesium sulfate and filtered. The filtrate was concentrated in vacuo to obtain 
the crude product. The crude product was purified by flash chromatography using 5% 
ethyl acetate in hexane to give the title minor compound 12 (153 mg, 2%)  as a 
white compound; Rf = 0.46, 20% ethyl acetate in hexane; 
1H NMR (400 MHz, CDCl3) 
δ 4.47 (dd, J = 10.5, 5.9 Hz, 1H), 3.68 (s, 3H), 3.16 (s, 1H), 2.04 (s, 3H), 2.06 – 1.91 (m, 
2H), 1.85 – 1.55 (m, 11H), 1.49 – 1.13 (m, 10H), 1.11 (s, 3H), 0.94 (s, 3H), 0.93 (s, 3H), 
0.84 (s, 3H), 0.82 (s, 3H), 0.81 (s, 3H) and 0.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
178.5, 171.1, 80.8, 67.4, 63.8, 55.3, 51.9, 47.9, 43.9, 41.0, 40.4, 39.3, 38.5, 38.1, 
37.8, 36.7, 34.2, 33.3, 32.7, 30.5, 29.4, 28.3, 23.9, 23.7, 23.5, 22.8, 22.8, 21.4, 20.0, 
18.0, 17.1, and 16.7; IR νmax (neat)/cm
-1 2949 (CH), 2862 (COCH3) and 1730 (C=O); 
HRMS (ESI) calculated for C33H52O5 [M+Na]
+ 551.3712 found 551.3727. 
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Preparation of methyl 3β-acetoxy-12-oxoolean-9(11)-en-28-oate (3)27,28 
 
 
Ketone 2 (12.31 g, 23.28 mmol) was dissolved in acetonitrile (100 mL). 48% 
Hydrobromic acid (1.0 mL, 8.85 mmol) was then added to the reaction. The reaction 
mixture was heated to 35°C and 1.0 M of bromine in acetonitrile (25.14 mL, 25.14 
mmol) was added to the reaction and left to stir at 35°C for 18 hours. A further 1.0 
M of bromine in acetonitrile (25.14 mL, 25.14 mmol) was added dropwise to the 
reaction mixture and left to stir for a further 1 hour at 35°C. The reaction was 
cooled to room temperature and the reaction was diluted with ethyl acetate. The 
solution was worked up with water and sodium bicarbonate. The organic layer was 
then washed with saturated sodium sulfite in water, brine and dried over 
magnesium sulfate. The solution was filtered and dried in vacuo to give the crude 
product. The crude product was re-crystallised using methanol and water to obtain 
title compound 3 (12.11 g, 99%) as a white solid; Rf = 0.33, 20% ethyl acetate in 
hexane; mp = lit28 208-209 found 207-208°C; 1H NMR (400 MHz, CDCl3) δ 5.74 (s, 
1H), 4.48 (dd, J = 11.7, 4.7 Hz, 1H), 3.68 (s, 3H), 3.02 (dt, J = 13.6, 3.6 Hz, 1H), 2.84 (d, 
J = 4.7 Hz, 1H), 2.06 (s, 3H), 1.99 – 1.56 (m, 12H), 1.55 – 1.11 (m, 7H), 1.24 (s, 3H), 
1.21 (s, 3H), 1.00 (s, 3H), 0.99 (s, 3H), 0.91 (s, 3H), 0.90 (s, 3H) and 0.90 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 200.6, 178.4, 178.0, 171.0, 123.0, 79.8, 51.9, 50.4, 49.5, 
47.4, 45.3, 41.7, 39.9, 38.3, 36.2, 35.9, 34.6, 33.4, 33.0, 32.9, 31.6, 30.7, 28.1, 28.1, 
24.0, 24.0, 23.8, 23.2, 22.7, 21.8, 21.4, 17.9 and 16.8; IR νmax (neat)/cm
-1 2946 (CH), 
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2862 (COCH3), 1734 (C=O), 1720 (C=O) and 1663 (C=C); HRMS (ESI) calculated for 
C33H50O5 [M+Na]
+ 549.3556 found 549.3561; Microanalysis Calculated for C33H50O5 
requires C 75.25%, H 9.57% found C 75.15%, H 9.505% 
Crystal and Refinement Data 
C33H50O5 
M = 526.73 
 =  0.078 mm-1 
colourless prism 
Orthorhombic 
space group P212121 (No. 19) 
a = 7.6639(9) 
 b = 11.5570(14) 
c = 33.092(4) Å 
V = 2931.0(6) Å3 
Z = 4  
Dc = 1.194 g/cm
3 
T = 100(2) K  
17865 reflections collected, 
5771 unique  
Rint = 0.0206 
Final GooF = 1.034 
R1 = 0.0326, wR2 = 0.0849 
543 parameters, 0 restraints 
Absolute structure parameter 
= -0.3(7) 
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Preparation of methyl 3β-hydroxy-12-oxoolean-9(11)-en-28-oate (13)28 
 
 
Acetyl 3 (1.7 g, 3.23 mmol) was dissolved in methanol (50 mL). Potassium hydroxide 
(5 g, 90.33 mmol) was added to the reaction mixture and refluxed for 1 hour. The 
reaction was cooled to room temperature and 6.0 M hydrochloric acid was used for 
the work up and extracted three times in dichloromethane: diethyl ether (1:2, 3 x 
50 mL). The combined organic layers were washed with water, brine and dried over 
magnesium sulfate. The solution was filtered and the solvent was removed under 
reduced pressure to give the title compound 13 (1.55 g, 99%) as a white solid; Rf = 
0.11, 20% ethyl acetate in hexane; mp = lit28 233°C found 232-233°C; 1H NMR (400 
MHz, CDCl3) δ 5.75 (s, 1H), 3.68 (s, 3H), 3.22 (dd, J = 11.6, 4.6 Hz, 1H), 3.02 (dt, J = 
13.7, 3.6 Hz, 1H), 2.84 (d, J = 4.7 Hz, 1H), 2.00 – 1.56 (m, 14H), 1.53 – 1.25 (m, 6H), 
1.24 (s, 3H), 1.18 (s, 3H), 1.03 (s, 3H), 1.00 (s, 3H), 0.99 – 0.97 (m, 2H), 0.89 (s, 4H) 
and 0.83 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 200.8, 178.5, 178.5, 122.9, 78.1, 52.0, 
50.3, 49.6, 47.4, 45.4, 41.8, 40.1, 39.4, 36.5, 35.9, 34.6, 33.4, 33.0, 32.9, 31.6, 30.8, 
28.2, 27.6, 24.0, 23.8, 23.2, 22.8, 21.9, 18.1 and 15.7; IR νmax (neat)/cm
-1 3299 (OH), 
2943 (CH), 2867 (COCH3), 1721 (C=O) and 1658 (C=C); HRMS (ESI) calculated for 
C31H48O4 [M+Na]
+ 507.3450 found 507.3445. 
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Preparation of methyl 3,12-dioxoolean-9(11)-en-28-oate (4)3 
 
Preparation of Jones reagent: 2.5 g of CrO3 was dissolved in 2.5 mL of conc. H2SO4. 
The mixture was cooled to 0°C and 75 mL of cold water was added drop wise to 
obtain a maroon coloured solution. 
 
Alcohol 13 (2.6 g, 5.36 mmol) was dissolved in acetone (50 mL). The reaction 
mixture was cooled to 0°C. The Jones reagent was added drop wise to the reaction 
until a colour change from green to light orange/brown colour was observed. The 
mixture was stirred at room temperature for 10 minutes. The acetone was removed 
by vacuo and worked up in dichloromethane:diethyl ether (1:2, 3 x 50 mL) and 
water. The combined organic layers were washed with water, brine, dried over 
magnesium sulfate and filtered. The solvent was removed in vacuo to give the title 
compound 4 (2.57 g, 99%) as a white solid product; Rf = 0.22, 20% ethyl acetate in 
hexane; mp = 102-105°C; 1H NMR (400 MHz, CDCl3) δ 5.79 (s, 1H), 3.69 (s, 3H), 3.03 
(dt, J = 13.6, 3.5 Hz, 1H), 2.89 (d, J = 4.7 Hz, 1H), 2.65 (ddd, J = 15.8, 11.0, 7.2 Hz, 1H), 
2.48 (ddd, J = 15.8, 7.0, 3.8 Hz, 1H), 2.21 (ddd, J = 13.3, 7.3, 3.9 Hz, 1H), 1.95 – 1.56 
(m, 10H), 1.54 – 1.43 (m, 3H), 1.31 (s, 3H), 1.28 (s, 3H), 1.26 – 1.15 (m, 3H), 1.13 (s, 
3H), 1.09 (s, 3H), 1.01 (s, 3H), 1.00 (s, 3H) and 0.89 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 216.0, 200.2, 178.4, 176.7, 124.2, 52.0, 51.1, 49.7, 47.7, 47.4, 45.5, 41.9, 39.6, 
37.2, 36.0, 34.6, 34.3, 33.4, 33.0, 32.1, 31.7, 30.8, 28.3, 26.4, 23.9, 23.7, 23.2, 22.9, 
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21.8, 21.6 and 19.3; IR νmax (neat)/cm
-1 2945 (CH), 2870 (COCH3), 1720 (C=O), 1709 
(C=O) and 1659 (C=C); HRMS (ESI) calculated for C31H46O4 [M+Na]
+ 505.3294 found 
505.3282;  
Preparation of methyl 2-hydroxymethylene-3,12-dioxoolean-9(11)-en-28-oate (5)3 
 
4 (1.34 g, 2.78 mmol) dissolved in anhydrous toluene (10 mL). Ethyl formate (1 mL, 
12.49 mmol) and sodium methoxide (907.34 mg, 16.80 mmol) were added to the 
reaction and stirred at room temperature for 2 hours. The reaction was diluted with 
dichloromethane: diethyl ether (1:2, 50 mL) and washed with 5% hydrochloric acid 
(3 x 50 mL). The combined aqueous layers were washed with dichloromethane: 
diethyl ether (1:2, 3 x 50 mL). The combined organic layers were washed with water, 
brine, dried over magnesium sulfate and filtered. The solution was concentrated in 
vacuo and purified by flash chromatography using 2% ethyl acetate in hexane to 
give the title compound 5 (1.39 g, 98%) as a white powder; Rf = 0.37, 20% ethyl 
acetate in hexane; 1H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 2.5 Hz, 1H), 5.90 (s, 1H), 
3.70 (s, 3H), 3.04 (dt, J = 13.4, 3.4 Hz, 1H), 2.92 (d, J = 4.7 Hz, 1H), 2.62 (d, J = 14.4 
Hz, 1H), 2.29 (d, J = 14.4 Hz, 1H), 1.97 – 1.79 (m, 3H), 1.77 – 1.58 (m, 7H), 1.56 – 
1.30 (m, 6H), 1.28 (s, 3H), 1.26 (s, 3H), 1.18 (s, 3H), 1.17 (s, 3H), 1.02 (s, 3H), 1.01 (s, 
3H) and 0.90 (s, 3H);  13C NMR (100 MHz, CDCl3) δ 200.2, 190.2, 188.2, 178.4, 175.8, 
171.3, 124.4, 105.1, 52.0, 49.6, 48.2, 47.4, 45.5, 41.9, 40.5, 39.2, 37.1, 35.9, 34.6, 
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33.4, 32.9, 31.6, 31.4, 30.8, 28.3, 28.3, 23.5, 23.2, 23.1, 22.8, 21.7, 20.9 and 19.0; 
HRMS (ESI) calculated for C32H46O5 [M+Na]
+ 533.3243 found 533.3265. 
Preparation of methyl 12-oxoisoxazolo[4,5-b]olean-9(11)-en-28-oate (6)3 
 
 
5 (1.27 g, 2.49 mmol) was dissolved in ethanol:water (9:1, 20 mL). NH2OH∙HCl (1.75 
g, 24.87 mmol) was added to the reaction and refluxed for 1 hour. The solvent was 
removed in vacuo and the crude product was extracted with ethyl acetate (3 x 100 
mL). The combined organic layers were washed with water (3 x 100 mL), brine, 
dried over magnesium sulfate and filtered. The crude product was concentrated in 
vacuo and purified by flash chromatography using 2% ethyl acetate in hexane to 
give the title compound 6 (1.09 g, 86%) as a white powder; Rf = 0.29, 20% ethyl 
acetate in hexane; 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 5.89 (s, 1H), 3.70 (s, 3H), 
3.05 (dt, J = 13.6, 3.5 Hz, 1H), 2.93 (d, J = 4.7 Hz, 1H), 2.79 (d, J = 15.1 Hz, 1H), 2.40 
(d, J = 15.1 Hz, 1H), 1.96 – 1.61 (m, 9H), 1.56 – 1.45 (m, 4H), 1.35 (s, 3H), 1.29 (s, 3H), 
1.27 (s, 3H), 1.24 – 1.19 (m, 2H), 1.16 (s, 3H), 1.03 (s, 3H), 1.01 (s, 3H) and 0.90 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 200.2, 178.4, 176.2, 172.2, 150.4, 124.7, 108.7, 
52.0, 49.8, 49.7, 47.4, 45.8, 41.9, 41.4, 36.0, 35.3, 34.6, 33.8, 33.4, 33.0, 31.6, 31.4, 
30.8, 28.9, 28.4, 24.7, 23.2, 23.2, 22.9, 21.8, 21.6 and 18.4; HRMS (ESI) calculated 
for C32H45NO4 [M+Na]
+ 530.3246 found 530.3248. 
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Preparation of methyl 2-cyano-3,12-dioxoolean-9(11)-en-28-oate (14)3,29 
 
 
 
4 (0.2 g, 414 µmol) was dissolved in dry tetrahydrofuran. The solution was cooled to 
-78°C, flushed with nitrogen and nitrogen balloon attached. Lithium 
diisopropylamide (66.58 mg, 0.31 mL, 621 µmmol, 2.0 M in heptanes/THF/ethyl 
benzene) was added drop wise to the reaction and left to stir at room temperature 
for 20 minutes. p-toluenesulfonyl cyanide (150 mg, 828 µmol) was dissolved in dry 
tetrahydrofuran in a dry flask. The flask was cooled to -78°C and the solution 
containing 4 was transferred drop wise to the flask. The reaction was left to stir for 
5 minutes and quenched with ammonia solution. The solution was acidified with 5% 
hydrogen chloride solution and extracted with ethyl acetate (3 x 50 mL). Combined 
organic layers were washed with water brine and dried over magnesium sulfate. 
Solvent was removed in vacuo and purified by flash chromatography using 5% ethyl 
acetate in hexane to give the title compound 14 (185 mg, 88%) as a white powder; 
Rf = 0.3, 30% ethyl acetate in hexane. 
6 (0.938 g, 1.85 mmol) was dissolved in methanol (40 mL) and diethyl ether (160 
mL). The solution was cooled to 0°C and sodium methoxide (3.40 g, 62.84 mmol) 
was added to reaction. The reaction was left to stir at room temperature for 45 
minutes. The mixture was diluted in dichloromethane:diethyl ether (1:2, 50 mL) and 
washed with 5% HCl (3 x 50 mL). The combined acidic washings were extracted with 
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dichloromethane:diethyl ether (1:2, 3 x 50 mL). The combined organic layers were 
washed with water, brine, dried over magnesium sulfate and filtered. The solvent 
was removed in vacuo and purified by flash chromatography using 2% ethyl acetate 
in hexane to give the title compound 14 (653.9 mg, 70%) as a white powder. Rf = 
0.09, 20% ethyl acetate in hexane. 
1H NMR (400 MHz, CDCl3) δ 5.80 – 5.70 (m, 1H), 3.69 (s, 3H), 3.08 – 2.98 (m, 1H), 
2.95 – 2.86 (m, 1H), 2.43 (d, J = 15.3 Hz, 1H), 2.25 (d, J = 15.3 Hz, 1H), 1.94 – 1.55 (m, 
12H), 1.53 – 1.37 (m, 4H), 1.25 (s, 3H), 1.22 (s, 3H), 1.20 (s, 3H), 1.12 (s, 3H), 1.00 (s, 
6H) and 0.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 200.0, 178.4, 175.1, 124.5, 52.0, 
49.7, 48.5, 47.4, 45.5, 42.3, 41.9, 39.6, 38.7, 38.6, 38.1, 37.5, 36.0, 34.6, 33.4, 33.0, 
32.9, 31.6, 31.3, 30.8, 28.3, 28.0, 24.1, 23.2, 23.1, 21.7, 20.0 and 18.9; IR νmax 
(neat)/cm-1 2949 (CH), 2869 (COCH3), 2207 (CN), 1722 (C=O) and 1659 (C=C); HRMS 
(ESI) calculated for C32H45NO4 [M+Na]+ 530.3246 found 530.3233. 
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Preparation of methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (7)3,30 
 
 
14 (2.6 g, 5.13 mmol) was dissolved in anhydrous benzene. 2,3-Dichloro-5,6-
dicyanobenzoquinone (2.0 g, 8.82 mmol) was added to the solution of 14 and 
refluxed for 30 minutes. The solution was cooled and the insoluble matter was 
filtered. Benzene was removed in vacuo and the crude product was recrystallised 
from methanol and water to obtain the title compound 7 (2.25 g, 87%) as a white 
solid product; Rf = 0.3, 30% ethyl acetate in hexane; mp = lit
30 228°C found 228-
230°C; 1H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 5.97 (s, 1H), 3.70 (s, 3H), 3.04 (dt, J 
= 13.6, 3.7 Hz, 1H), 2.94 (d, J = 4.7 Hz, 1H), 1.96 – 1.63 (m, 9H), 1.60 – 1.50 (m, 3H), 
1.49 (s, 3H), 1.33 (s, 3H), 1.30 – 1.20 (m, 3H), 1.26 (s, 3H), 1.17 (s, 3H), 1.01 (s, 3H), 
1.00 (s, 3H) and 0.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 199.0, 196.7, 178.3, 168.5, 
165.9, 124.1, 114.7, 114.5, 52.0, 49.8, 47.8, 47.3, 45.8, 45.1, 42.6, 42.2, 35.8, 34.5, 
33.3, 32.8, 31.7, 31.6, 30.7, 28.1, 27.1, 26.7, 24.7, 23.2, 22.7, 21.7, 21.7 and 18.3; IR 
νmax (neat)/cm
-1 2947 (CH), 2868 (COCH3) 2234 (CN), 1720 (CO), 1688 (C=C) and 
1663 (C=C);  HRMS (ESI) calculated for C32H43NO4 [M+Na]
+ 528.3090 found 528.3101. 
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Preparation of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (8)3,31 
 
 
 
 
7 (1.26 g, 2.49 mmol) was dissolved in anhydrous DMF (20 mL). Lithium iodide was 
added to the reaction and left to reflux overnight. The reaction was cooled and 
water (50 mL) was added. 5% HCl was added to the solution and washed with ethyl 
acetate (3 x 50 mL). The combined organic layers were washed with water (3 x 
50mL), brine (3 x 50 mL) and dried over magnesium sulfate. The solution was 
filtered and the solvent was removed under vacuum. The crude product was 
purified by flash chromatography using 5% ethyl acetate in hexane to give the title 
compound 8 (538.5 mg, 44%); Rf = 0.08, 1:1 ethyl acetate in hexane; mp = lit
31 283-
288°C found 296-298°C; 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 6.01 (s, 1H), 3.08 – 
2.95 (m, 2H), 2.00 – 1.87 (m, 2H), 1.83 – 1.68 (m, 6H), 1.62 – 1.51 (m, 3H), 1.49 (s, 
3H), 1.35 (s, 3H), 1.32 – 1.19 (m, 4H), 1.26 (s, 3H), 1.17 (s, 3H), 1.03 (s, 3H), 1.00 (s, 
3H), 0.91 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 198.9, 196.7, 183.9, 168.7, 165.9, 
124.1, 114.6, 114.5, 49.8, 47.7, 47.1, 45.8, 45.1, 42.6, 42.2, 35.7, 34.4, 33.3, 33.0, 
31.7, 31.4, 30.7, 28.0, 27.0, 26.7, 24.7, 23.1, 22.5, 21.7 and 18.3; IR νmax (neat)/cm
-1 
2944, 1723, 1688 and 1663;  HRMS (ESI) calculated for C31H41NO4 [M+Na]+ 
514.2933 found 514.2916. 
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Preparation of 2-cyano-3,12-dioxooleana-9(11)-en-28-oic acid (15) 
 
Isolated from previous procedure to give the title compound 15 (95 mg, 6%);  1H 
NMR (400 MHz, CDCl3) δ 5.79 – 5.70 (m, 1H), 3.03 – 2.96 (m, 1H), 2.93 (d, J = 4.7 Hz, 
1H), 2.42 (d, J = 15.2 Hz, 1H), 2.25 (d, J = 15.2 Hz, 1H), 2.00 – 1.86 (m, 3H), 1.82 – 
1.54 (m, 11H), 1.52 – 1.40 (m, 3H), 1.26 (s, 3H), 1.22 (s, 3H), 1.21 (s, 3H), 1.12 (s, 3H), 
1.00 (s, 6H) and 0.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 199.7, 175.1, 171.6, 124.5, 
49.7, 48.6, 48.5, 47.2, 45.6, 41.9, 39.6, 38.8, 38.7, 38.1, 37.5, 35.9, 34.6, 33.3, 33.1, 
33.0, 31.6, 31.3, 30.8, 28.2, 28.0, 24.1, 23.20, 23.16, 21.7, 20.0 and 18.9; HRMS (ESI) 
calculated for C31H43NO4 [M+Na]+ 516.3090 found 516.3113. 
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2.5. Biological experimental 
2.5.1. Materials 
H4IIE cells stably expressing the ARE8L-reporter, were provided by Prof. Alex 
Odermatt (Department of Pharmaceutical Sciences, University of Basel, 
Switzerland). Nunclon Δ cell culture flasks and multiwall plates were from Nalge-
Nunc International (c/o VWR International, Lutterworth, UK). Precision Plus Protein 
Kaleidoscope standards, non-fat dry milk, the GS-800 calibrated imaging 
densitrometer were from Bio-Rad (Hemel Hempstead, UK).  
Fetal bovine serum (FBS), trypsin 0.25% EDTA, The XCell Sure Lock mini-cell, 
NuPAGE Novex 4-12% Bis-Tris gels, NuPAGE LDS sample buffer and sample reducing 
agent were from Life Technologies (Paisley, UK). TotalLab Quantity One software 
was from TotalLab Ltd (Newcastle Upon Tyne, UK). The MRX microplate reader was 
from Dynatech Laboratories (Billingshort, UK). The Varioskan Flash and SkanIT 
software were from Thermo Scientific (Hemel Hempstead, UK). Western Lightening 
chemiluminescence reagents were from PerkinElmer (Beaconsfield, UK). Hyperfilm 
ECL and nitrocellulose blotting membrane (Hybond ECL) were from Amersham 
(Little Chalfont, UK). The rabbit anti-Nrf2 antibody was from Abcam (Cambridge, 
UK). Bright-Glo luciferase assay system and glo lysis buffer were from Promega 
(Southampton, UK). Dulbecco's modified eagle medium (DMEM), penicillin-
streptomycin solution, dimethyl sulfoxide (DMSO),  3-(N-
morpholino)propanesulfonic acid (MOPS), mouse anti-actin primary antibody, 
rabbit anti-mouse HRP conjugated secondary antibody, goat anti-rabbit Horseradish 
peroxidase (HRP) conjugated secondary antibody, Kodak developer and fixer 
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solutions, bicinchoninic acid solution, copper(II) sulphate solution, Bovine serum 
albumin, ponceau S solution, Tween 20, phosphate buffered saline (PBS) tablets, 
radioimmunoprecipitation assay (RIPA) buffer solution, MEM non-essential amino 
acid solution and 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer 
100X were from Sigma-Aldrich (Poole, UK). All other reagents were of analytical or 
molecular grade, and were from Sigma-Aldrich. 
2.5.2. Cell culture 
H4IIE-ARE cells were maintained in a humidified incubator, at 37°C, in a 5% carbon 
dioxide (CO2) atmosphere. The cells were incubated in Dulbecco’s modified eagle’s 
medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 
1mM HEPES and 1 x non-essential amino acids. The culture medium was antibiotic 
free.  
75 cm2 Nunclon Δ culture flasks were used and cells were passaged at 
approximately 80% confluence, every 3-4 days. Unsupplemented DMEM was used 
to wash the cells prior to 1 minute incubation at room temperature with 5 mL 
trypsin. The trypsin was removed and the cells were further incubated for 5 
minutes at 37°C, facilitating detachment from the flask surface. Cells were re-
suspended in 5 mL growth media and passed through a 21-gauge needle several 
times to ensure cells were individually suspended. For continuation, cells were re-
seeded at a cells:growth medium ratio of 2:10. 
2.5.3. Plating 
For the analysis of Nrf2 levels by Western blot or luciferase reporter activity, a 10 μL 
aliquot of the cell suspension was transferred to the edge of a haemocytometer 
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and allowed to spread evenly across the surface by capillary action. Cells were 
visualised using the 20 X objective of a light microscope. The cells were counted 
within the central 5 x 5 square (equivalent to 0.1 mm3). The original cell density was 
calculated as follows: 
Number of cells counted = cells per 0.1 mm3 x 10,000 = cells per 1 cm3 = cells per 1 mL 
For the analysis of Nrf2 levels by western blot, H4IIE-ARE cells were seeded in a 
sterile Nunclon ∆ flat bottom 12 well plate (3.2 cm2), at 300,000 cells/well, in a total 
volume of 2 mL growth medium and allowed to grow overnight.  
For the analysis of luciferase reporter activity, H4IIE-ARE cells were seeded in sterile 
Nunclon ∆ flat bottom 98 well plates, at 20,000 cells/well, in a total volume of 0.2 
mL growth medium and allowed to grow overnight.  
2.5.4. Treatment of cells for Nrf2 western blot analysis 
CDDO-Me was dissolved in DMSO at 200x the required final concentration. Under 
sterile conditions, H4IIE-ARE cells were exposed to 10 µL of DMSO, 10 µL of MG132 
at 2 mM (giving final concentration of 10 µM) or 10 µL of CDDO-Me concentrations 
(i.e. 1:200 dilution) to give the required final concentrations as indicated. The 
concentration of DMSO in the cell culture medium was 0.5% (volume/volume; v/v). 
The cells were returned to a humidified incubator (37°C, 5% CO2) for one hour. 
2.5.5. Treatment of cells for luciferase activity assay. 
CDDO derivatives were dissolved in DMSO at 200x the required final concentration. 
Under sterile conditions, H4IIE-ARE cells were exposed to 1 µL of DMSO or 1 µL of 
CDDO derivatives (i.e. 1:200 dilution). The concentration of DMSO in the cell culture 
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medium was 0.5% (v/v). The cells were returned to a humidified incubator (37°C, 5% 
CO2) for 24 hours. 
2.5.6. Preparation of cells for luciferase reporter assay 
Following compound exposure, the media was removed and 100 µL of 1x Glo Lysis 
Buffer was added to each well. The plate was shaken for 5 minutes at 700 rpm to 
promote cell lysis. 80 µL of the cell lysate was transferred to a white 96 well flat 
bottom microplate and 20 µL of Bright-Glo luciferase reagent was added to each 
well. The Plate was shaken at 700 rpm for 15 seconds prior to quantification of 
luminescence on a Varioskan Flash Spectra Luminometer.  
2.5.7. Preparation of cells for Nrf2 western blot analysis 
Following compound exposure, the media was removed and 500 µL of phosphate 
buffered saline pH 7 (PBS) was added to each well. The cells were dislodged from 
the well surface by pipetting PBS several times. The cell suspension was transferred 
into 0.5 mL microcentrifuge tubes and centrifuged at 1000 g, room temperature, 
for 5 minutes. The pellet was washed in 200 µL PBS, centrifuged at 1000 g, room 
temperature for 5 minutes and resuspended in 40 µL RIPA buffer per sample. All 
samples were stored at -80°C. 
2.5.8. Protein determination 
The protein content of the cell lysates was determined using the bicinchoninic acid 
(BCA) protein assay. The BCA assay involves the reduction of Cu(II) to Cu(I) by 
proteins in a concentration dependent manner. Two molecules of bicinchoninic acid 
chelates the Cu(I) ion, forming a purple Cu(I) complex. This complex has a maximum 
absorbance at 562 nm in which the absorbance is directly proportional to protein 
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concentration.32 A stock solution of (2 mg/mL) bovine serum albumin (BSA) was 
diluted in water to give 2000, 1500, 1000, 750, 500, 250 and 125 µg/mL where 9 µL 
was used in a 96 well plate for a standard curve. 2 µL of cell lysate was used per 
sample and 250 µL of BCA assay solution (1:50 solution of copper(II) sulphate: 
bicinchoninic acid) was added to each well. The plate was incubated at 37°C for 30 
minutes prior to absorption measurement at 570 nm. 
2.5.9. Western blot analysis 
2.5.9.1. 3-(N-morpholino)propanesulphonic acid (MOPS) running buffer 
50 mM MOPS, 50 mM tris base, 3.5 mM sodium dodecyl sulphate and 1 mM EDTA. 
2.5.9.2. Transfer buffer 
0.2 M glycine and 25 mM Tris base in 20% methanol 
2.5.9.3. Tris-buffered saline solution (TBS-Tween) 
 0.15 M NaCl, 25 mM tris base, 3 mM KCl, pH 7.0 supplemented with 0.1% v/v 
Tween 20 
2.5.9.4. Method 
Whole cell lysates (20 µg) were denatured with the addition of 5 µL loading buffer 
(70% (v/v) NuPAGE sample loading buffer, 30% (v/v) NuPAGE reducing agent) and 
incubated at 80°C for 5 minutes. The samples were loaded onto pre-cast 4-12% 
NuPAGE Novex bis-tris polyacrylamide gels, alongside 3 µL of PrecisionPlus protein 
Kaleidoscope standards. The samples were resolved by electrophoresis in an XCell 
Surelock mini-cell, using MOPS running buffer, at 90 V for 10 minutes, followed by 
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60 minutes at 170 V. The separated proteins were transferred to a nitrocellulose 
membrane in a transfer apparatus, using transfer buffer, at 230 mA for 1 hour. 
Membranes were stained for 10 seconds with Ponceau S solution to ensure that the 
transfer was successful. The membrane was cut across the 50 kDa marker 
(membrane containing protein >50 kDa is referred to as top half of membrane) and 
the top half of the membrane was blocked overnight at 4°C on an orbital shaker in 
TBS-Tween and 10% (weight/volume; w/v) non-fat dry milk. The bottom half of the 
membrane was left in TBS-Tween overnight at 4°C on an orbital shaker. The blocked 
top half of the membrane was sealed in bag at 4°C on an orbital shaker for 3 hours 
with rabbit anti-mouse Nrf2 antibody (1:400 in 2 mL TBS-Tween containing 2% (w/v) 
non- fat dry milk). The bottom half of the membrane was blocked for 1 hour as 
described above and was exposed to rabbit anti-β-actin antibody (1:200,000 in 
TBS-Tween containing 2% (w/v) non-fat dry milk) for 1 hour. Following 12 washes in 
TBS-Tween (5 minute intervals), the membranes were probed for 1 hour with goat 
anti-rabbit (1:10,000 in TBS-Tween containing 2% (w/v) non-fat dry milk), or rabbit 
anti-mouse (1:10,000 in TBS-Tween containing 2% (w/v) non-fat dry milk) 
horseradish peroxidase (HRP) -conjugated secondary antisera. A further 6 washes in 
TBS-Tween (10 minute intervals) was performed prior to visualisation with Western 
Lightening chemiluminescence reagents and exposure to Hyperfilm ECL under 
darkroom conditions, using a Kodak BioMax MS intensifying screen. Films were 
developed using Kodak developer and fixer solutions. Films were scanned using a 
GS-800 calibrated imaging densitometer, immunoreactive band volumes were 
quantified using TotalLab Quantity One software, in accordance with the 
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manufacturer’s instructions, and normalised to β-actin, which was probed as a 
loading control. 
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3.1 Introduction 
As discussed in the previous chapter, CDDO-Me is one of the most potent activators 
of the transcription factor, Nrf2. However, the molecular mechanisms that underly 
its potency are still unknown. As detailed in chapter 1, Nrf2 is regulated by Keap1. 
In the presence of chemical/oxidative stress, Keap1 undergoes redox modifications 
that render it unable to repress Nrf2, culminating in the induction of Nrf2 regulated 
genes. The currently accepted mechanism of action for CDDO-Me and its 
derivatives as inducers of Nrf2 is that reversible interactions via 1,4 conjugate 
addition to cysteine residues within Keap1 triggers the up-regulation of cell defence 
signalling. 
SAR studies by the Sporn group led to the identification and optimization of 
important pharmacophores in oleanolic acid, and ultimately led to the discovery of 
CDDO. This involved the optimisation of both A and C rings with the introduction of 
α,β unsaturated ketones (also known as Michael acceptors) at essential positions.1-5 
An electron withdrawing group within the A ring at the C-2 position was also found 
to be important. Different derivatives of CDDO were also discovered following SAR 
studies on the carboxylic acid group, yielding CDDO-Me and CDDO-Im6 (Figure 3.1). 
These compounds were initially tested as anti-inflammatory agents and specifically 
for their ability to block IFN-γ-dependent induction of inducible nitric oxide 
synthase (iNOS).1-5,7 It was later recognised that these compounds could also induce 
phase 2 cell defence responses.7 Phase 2 responses are highly associated with the 
Keap1-Nrf2 pathway (as explained in previous chapters) and biological experiments 
confirmed that these compounds are potent inducers of Nrf2.7 
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Figure 3.1: Chemical structure of oleanolic acid along with carbon and ring 
assignment. Important CDDO derivatives CDDO-Me and CDDO-Im.  
NMR and UV studies have demonstrated that CDDO can potentially react with thiols 
via 1,4 conjugate addition.8 There are two potential pharmacophores that may 
facilitate this reaction, both being the α,β unsaturated ketones. Variable 
temperature NMR experiments have demonstrated that these reactions are also 
highly reversible in nature.8  
Radiolabelled dexamethasone 21-mesylate (Dex-mes) 16 (Figure 3.2) has previously 
been shown to directly modify Keap1 cysteines 257, 273, 288, 297 and 613 in vitro.7 
Importantly, pre-incubation of Keap1 with CDDO inhibits labelling of the protein by 
16, indicating, albeit indirectly, that CDDO is capable of modifying Keap1. Other 
competition experiments with Keap1 involve an analogue of sulforaphane 18, which 
enables covalent binding to cysteine residues within Keap1. This will be discussed in 
more detail below. 
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Figure 3.2: Chemical structures of dexamethasone 21-mesylate, sulforaphane and 
analogue of sulforaphane. 
The strategy used by Ahn et al to produce an irreversible analogue of sulforaphane 
involved the identification of the potential active pharmacophore(s) and an 
understanding of the chemical mechanism of action. In this case, the active 
pharmacophore of sulforaphane is the highly reactive isothiocyanate that forms 
dithiocarbamate products with sulfhydryl groups. This is through an enzyme 
catalysed reaction by glutathione transferase or via a non-enzymatic route with 
sulfhydryl nucleophiles (Figure 3.3).9,10 The formation with dithiocarbamate is 
kinetically labile thus rendering the adduct formation of potential targets reversible. 
This reversibility therefore hinders the isolation and characterisation of 
modifications of these compounds.  
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Figure 3.3: Reversible chemical mechanism of sulforaphane. The reversible 
mechanism between the isothiocyanate group and a thiol on a protein is due to 
kinetic labile formation of dithiocarbamate. The sulfoxide group is highlighted in 
red. The isothiocyanate group is highlighted in purple and the four carbon length 
chain separating the isothiocyanate group and the sulfoxide group is highlighted in 
blue. 
SAR studies with sulforaphane have revealed that the sulfoxide group and the 
length of the chain separating the sulfoxide and isothiocyanate groups are 
important in retaining their ability to induce the phase II cytoprotective enzyme, 
NAD(P)H:quinone oxidoreductase (NQO1).11 
Mass spectroscopy experiments have revealed that a sulfoxythiocarbamate CoA 
analogue (19) selectively targets cysteine residues to form stable thiocarbamate 
adducts that can be readily isolated. Ahn et al therefore replaced the reversible 
isothiocyanate functional group of sulforaphane with an irreversible 
sulfoxythiocarbamate group which enabled retention of the natural products 
chemoprotective properties as well as facilitating mechanistic analysis. However, 
unlike the isothiocyanate, the sulfoxythiocarbamate group requires alkyl 
substitution on the sulphur atom (R1 group, Figure 3.4) and to the nitrogen atom 
located in the sulfoxythiocarbamate (R2 group, Figure 3.4). These substitutions 
provide chemical stability and reduce hydrolytic cleavage. This chemical approach 
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led to the design and synthesis of 18, which was shown to be capable of binding to 
cysteine 273, 288 and 613 of Keap1.11 
 
Figure 3.4: Chemical structure of the CoA sulfoxythiocarbamate and the template 
for the sulforaphane sulfoxythiocarbamate. 
Studies by Dinkova-Kostova et al, using a UV spectroscopic method, have 
demonstrated that CDDO (8) derivatives react with Keap1 which result in a red shift 
from 256 to 266 nm.7 Despite this spectroscopic evidence, attempts to obtain an 
adduct from the interaction between CDDO (8) and Keap1 have been unsuccessful, 
which is possibly due to the reversible nature of these compounds. 
Site directed mutagenesis of cysteine 151 of Keap1 has been shown to diminish the 
ability of CDDO derivatives to induce Nrf2 in cells indicating that cysteine 151 of 
Keap1 plays an important role in transducing the signal for activation of Nrf2 
signalling by these compounds.12,13 However, the ability of CDDO-Im to induce Nrf2 
is unaltered in embryonic fibroblasts derived from transgenic mice expressing a 
Keap1-Cys-151 mutant.14 As a result of this conflicting data, the precise nature of 
the interaction between CDDO derivatives and components of the Keap1-Nrf2 
pathway requires clarification in order to support the ongoing optimisation of these 
compounds as therapeutic agents. 
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3.1.1 Aims 
Experiments have demonstrated that CDDO undergoes highly reversible 
interactions with thiols and potentially bind to Keap1 as discussed above. It is 
currently unclear if the ability of CDDO to induce Nrf2 is due to its reversibility or its 
high affinity for a currently unknown molecular target(s). 
Inspired by the strategy used by Ahn et al,11 the aim of this chapter is to exploit the 
known SAR of CDDO and its derivatives to design and synthesize a novel analogue 
capable of undergoing irreversible reaction with thiols. Such a compound would 
represent an excellent tool with which to examine the ability of this compound 
class to modify Keap1, and potentially identify other molecular targets. 
  
Chapter 3 – Design and synthesis of irreversible analogues of CDDO  
 
109 
 
3.2 Results and discussion 
3.2.1 NMR evidence for the reversible interaction of CDDO-Me with β-
mercaptoethanol or N-acetyl cysteine 
CDDO-Me contains two α,β unsaturated ketones that can potentially react with 
thiols via 1,4-conjugate addition as shown in Figure 3.5. 
 
Figure 3.5: Chemical reaction of CDDO-Me with a simple thiol via conjugate 
addition on A or C rings  
To further examine the above mechanism, proton NMR coupled with temperature 
variation was utilised to determine if one Michael acceptor is more susceptible to 
attack over the other. 
The experiment involved the use of deuterated dimethyl sulfoxide (DMSO-d6), 
CDDO-Me and the addition of varying amounts of β-mercaptoethanol (β-ME) or N-
acetyl cysteine (NAC) (up to 2 equivalents). As shown in Figure 3.6, CDDO-Me reacts 
via conjugate addition with β-ME and NAC. Initially, both Michael acceptors appear 
to react with β-ME and NAC, due to the equal loss of the proton signals with 
increasing amounts of β-ME or NAC. However, closer observation indicates that the 
Michael acceptor in the C ring does not react with the thiol. This is indicated by an 
upfield shift of the vinylic proton on the C ring, giving a singlet at 5.85 ppm or 5.81 
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ppm respectively. The lack of reaction between β-ME or NAC on the C ring could be 
due to steric hindrance as the double bond is less susceptible to thiol attack at the C 
ring compared to the A ring. 
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To further investigate the type of interaction causing the up-field shift of the vinylic 
proton, molecular modelling was adopted for this study. Molecular models can give 
an indication of bond distance between two atoms and can predict NMR proton 
shifts for the vinylic proton. To simplify the model, the D and E rings were removed 
from the modelling experiments. Figure 3.7 shows the simplified structure and 
space filled model. The sulphur and vinylic proton are in close proximity such that 
the van der Waals radius of the sulphur (highlighted in yellow in Figure 3.7) 
interacts with the vinylic proton (highlighted in purple in Figure 3.7) causing a 
shielding effect. Due to this shielding effect an up-field shift of the vinylic proton is 
observed.  
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Figure 3.7: Molecule A (see Table 3.1) rendered as sticks with transparent spheres 
(carbon – grey, hydrogen – white, nitrogen – blue, oxygen – red, vinylic proton – 
purple, sulphur – yellow). Images generated by PyMol (http://pymol.org) 
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Since the site of thiol addition is uncertain (ie α and β attack) all possible products 
were modelled including the enol intermediates. In total, six possible thiol addition 
products were modelled (two enol [A and B] and four ketone [C-F]); the results are 
presented in Table 3.1. The bond distances between the sulphur-hydrogen (vinylic) 
atoms are between 3.2-2.5 Å. The vinylic proton from experimental NMR is located 
at 5.85 ppm. From the modelling experiments, the enol form (Table 3.1, A and B) is 
predicted as the closer set out of the six possible products. The predicted NMR 
proton shift for the vinylic proton is closer to the enol which results from an alpha 
thiol attack (A) giving a predicted NMR proton shift at 5.66 ppm. Although the 
modelling data suggests that A is the major product due to thiol attack, it cannot 
rule out the other potential products as the molecular model is a guide and cannot 
give experimental value. 
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Variable temperature NMR (VT-NMR) was used to determine if the interaction 
between CDDO-Me and the model thiols was reversible. The temperature of the 
NMR sample was increased to 37°C and then to 50°C. The sample was left to 
stabilise prior to spectra analysis at the two temperature points (Figure 3.6B and 
Figure 3.6D). The data demonstrates that CDDO-Me is a reversible thiol modifier as 
peaks A and B increase in signal intensity, while peak C decreases upon heating. 
Upon cooling the reaction back to room temperature (25°C), CDDO-Me was capable 
of reacting with β-ME or NAC once again. These results are consistent with 
published literature.8 
3.2.2 Mass spectrometric evidence for the interaction of CDDO-Me with 
thiols 
In order to confirm the NMR data, aliquot of the reactions was analysed by direct 
infusion mass spectrometry (MS). The data presented in Figure 3.8 confirms that 
one thiol addition is present between CDDO-Me and β-ME or NAC. This is shown at 
peaks 583.9 m/z (Figure 3.8A) and 669.4 m/z (Figure 3.8B) respectively. The 
abundance of the two adducts were low, which is possibly due to the reversible 
nature of the reactions, consistent with the NMR data. A mass corresponding to a 
double thiol adduct was not detected in either reaction. 
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3.2.3 Synthesis of an irreversible analogue of CDDO-Me 
3.2.3.1 Methyl 3,12-dioxooleana-1,9(11)-dien-28-oate (DDO-Me) 
The cyano group is a highly electron withdrawing group and renders the α,β 
unsaturated ketone more susceptible to nucleophilic attack. In addition, the cyano 
group can also stabilise a negative charge more effectively following reversibility. As 
a result, removal of the cyano group should enable the irreversible formation of a 
ketone shown in Figure 3.9. 
 
Figure 3.9: Reversible and irreversible nucleophilic attack and the effect of a cyano 
withdrawing group. 
The SAR defined as a result of the full synthesis of CDDO (chapter two) has enabled 
the development and synthesis of 21. 
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Scheme 3.1: Reagents and conditions: (i) DDQ (1.7 equiv), Benzene, reflux, 15 mins; 
(ii) phenylselenyl chloride, ethyl acetate, r.t., 2.5 hours; (iii) THF with H2O, 30% H2O2 
Initial synthesis of 21 involved intermediate 4 and 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ). (Detailed synthesis of 4 can be found in chapter two). 
Unfortunately, only starting material was recovered from the reaction. However, 
the use of phenylselenyl chloride followed by oxidation with hydrogen peroxide 
gave a 57% yield of 21 (Scheme 3.1).  
The ability of 21 to induce Nrf2 signalling was determined with the Nrf2-sensitive 
luciferase reporter assay described in chapter two. The EC200 for DDO-Me (21) was 
shown to be 1500 x less potent than the parent compound CDDO-Me. This data 
highlights the importance of the cyano group within ring A for driving the high 
potency of CDDO-Me as an inducer of Nrf2. 
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Compound Structure 
Concentration that induces 
Nrf2 reporter to 200% (EC200) 
CDDO-Me 
 
0.62 nM ± 0.02 
DDO-Me (21) 
 
0.90 µM ± 0.08 
Table 3.2: Relative potencies of CDDO-Me and DDO-Me as inducers of an Nrf2-
regulated luciferase reporter transgene in H4IIE-ARE cells 
3.2.3.2 NMR evidence for the irreversible interaction of DDO-Me with β-
mercaptoethanol or N-acetyl cysteine 
The incubation of DDO-Me in DMSO-d6 and up to 2 equivalents of β-ME or NAC 
resulted in no reaction after 5 days (data not shown). Given that CDDO-Me reacted 
readily with thiols at room temperature, this data indicates that the loss of the 
cyano group at C-2 renders these compounds incapable of reacting with thiol 
groups under the conditions described. Despite this, DDO-Me is able to induce Nrf2 
signalling albeit less potently than CDDO-Me. The full crystal structure of Keap1 is 
currently unknown, however, important cysteine residues could be in close 
proximity to basic amino acids, enabling deprotonation of cysteine thiols and 
allowing the formation of a thiolate anion. The thiolate anion is more nucleophilic 
in nature than that of a general thiol group and therefore should attack Michael 
acceptors more readily. An example of such a case is the cysteine protease enzyme 
of the papain family where Cys-25 and His-159 are present in the active site. The 
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His-159 deprotonates the cysteine forming a thiolate anion and both Cys-25 and 
His-159 are present as an ion pair.15,16 
To confirm if an anion is required for a thiol to react with DDO-Me, 1 equivalent of 
an organic base, in this case triethylamine (TEA), was added to the NMR reactions. 
The samples were left at room temperature and proton NMR spectras were taken 
at set time intervals. For β-ME the reaction reached equilibrium after 2 days (Figure 
3.10A), while for NAC the time taken for the sample to reach a stable equilibrium 
was up to 4 days (Figure 3.10B). The upfield shift of proton labelled as D in Figure 
3.10A and Figure 3.10B was used as a reference for the progression of the reaction 
with thiols. This data further confirms that the C ring is not reactive with thiols, and 
that a more reactive thiolate anion is required for a reaction with DDO-Me to be 
observed. The data show that the A ring reacts with the thiolate anions, whilst VT-
NMR at 37°C and 50°C confirmed that these reactions were not reversible. 
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3.2.3.3 Molecular modelling for the irreversible interaction of DDO-Me with β-
mercaptoethanol 
 As observed in the NMR experiments with CDDO-Me, van der Waals interaction 
between the sulphur and hydrogen located on the Michael acceptor in the C ring 
resulted in an up-field shift in proton signal. The model image is shown in Figure 
3.11. Similar to CDDO-Me, molecular modelling was utilised to provide an 
understanding of which product is formed (Table 3.3). The experimental proton 
shift is located at 5.86 ppm. Comparing the predicted proton shifts in Table 3.3 to 
those observed in the experiment, it is clear that K and I are the closer match 
compared to H and J. The reactive point in which thiol addition occurs contains an 
adjacent beta methyl. This causes a steric hindrance and therefore the thiol 
addition occurs from the alpha face. Similar reactions with steroidal compounds 
also produce selective alpha additions due to an adjacent beta methyl.17 
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Figure 3.11: Molecule K (see Table 3.3) rendered as sticks with transparent spheres 
(carbon – grey, hydrogen – white, nitrogen – blue, oxygen – red, vinylic proton – 
purple, sulphur – yellow). Images generated by PyMol (http://pymol.org) 
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3.2.3.4 Mass Spectrometry evidence for the interaction of DDO-Me with thiols 
An aliquot of the NMR samples was analysed by MS. The NMR data presented in 
Figure 3.10 confirms that only one thiol addition is present between DDO-Me and 
β-ME or NAC. The DDO-Me-β-ME adduct was detected at peak 559.6 m/z (Figure 
3.12A) and the DDO-Me-NAC adduct at 644.6 m/z (Figure 3.12B). As for reactions 
with CDDO-Me (see 3.2.2) and consistent with the NMR data, a mass corresponding 
to a double thiol adduct was not detected in either reaction. 
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3.2.4 Synthesis of epoxide derivatives of CDDO-Me and DDO-Me 
In light of the relatively poor thiol reactivity of DDO-Me and its low potency as a 
Nrf2 inducer, and in order to diversify the overall chemical strategy, an alternative 
irreversible analogue of CDDO-Me was designed, based on the introduction of an 
epoxide functional group. The angles of the bonds within the three membered ring 
(60° compared with 109.5° for standard tetrahedral geometry) renders this 
functional group highly strained (Figure 3.13).18,19 The mechanism by which this 
functional group interacts with a thiol is shown below, with the highly strained 
epoxide opened up by nucleophilic attack. The resulting alkoxide can then be 
protonated to give a stable alcohol group, and as such, an irreversible thiol adduct 
is formed. 
 
Figure 3.13: Chemical mechanism of an epoxide functional group during 
nucleophilic attack. 
Incorporation of the epoxide functional group was attempted using DDO-Me and 
CDDO-Me as starting materials. DDO-Epoxide (22) required the use of hydrogen 
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peroxide and a base, giving 22 in a 49% yield.  In an attempt to form CDDO-Epoxide 
(23) hydrogen peroxide and a base were utilized, however, this approach did not 
yield the required product, and therefore an alternative procedure was required. 
The use of iodosobenzene in anhydrous dichloromethane (DCM) yielded CDDO-
Epoxide in 75% (Scheme 3.2).  
 
Scheme 3.2: Chemical conditions and reagents required for the synthesis of DDO-
Epoxide and CDDO-Epoxide. 
The stereochemistry of the epoxide located on 22 and 23 is uncertain despite 
comparing proton and carbon NMR to patent literature data.20 
3.2.5 Confirming the stereochemistry of CDDO-Epoxide and DDO-Epoxide 
It is currently assumed that the epoxide is in the alpha position as shown in Scheme 
3.2 (22 and 23). However, patent literature did not provide detailed evidence for 
the assignment of the epoxides stereochemistry. NMR Nuclear Overhauser Effect 
(nOe) has been used to confirm the stereochemistry of the epoxides. nOe 
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experiments measure interactions through space between close range nuclei (2-4 
Å).21 Assuming that the proton on C-1 is in the beta position (epoxide in the alpha), 
NMR nOe experiments between C-25 β-methyl protons and C-1 β-proton would 
produce an nOe signal when the protons on the methyl are irradiated (Figure 3.14, 
22a and 23a). However, if the proton on C-1 is in the alpha position and the epoxide 
is in the beta, then no nOe signal will be observed as the distance between the C-25 
protons and C-1 exceed the 2-4 Å distance required for an interaction to occur 
(Figure 3.14, 22b and 23b). 
 
Figure 3.14: DDO-Epoxide and CDDO-Epoxide and the possible stereochemistry of 
the epoxides including numbering of the protons of interest. 22a and 23a represent 
the epoxide in the alpha position while 22b and 23b represent the epoxide in the 
beta position. 
nOe experiments require a viscous solvent; therefore DMSO-d6 was used for these 
experiments. The C-25 methyl protons and the C-1 proton were identified for both 
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DDO-Epoxide and CDDO-Epoxide. The C-25 methyl protons were irradiated and an 
nOe signal for the C-1 and C-11 protons were observed (Figure 3.15, blue spectra). 
This confirms that the alpha epoxides were obtained. To further confirm this result, 
the C-1 proton was irradiated. nOe signals were observed for C-11 and C-25 methyl 
protons (Figure 3.15, green spectra). 
Similar epoxides have also been synthesised containing a steroidal back bone. This 
reaction also yielded the alpha epoxide due to the adjacent beta methyl group.22 
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Figure 3.15: nOe experiments for DDO-Epoxide (A) and CDDO-Epoxide (B).  
Irradiation at C-25 demonstrates that C-1 is in the beta position (blue spectra). 
Irradiation of the C-1 nuclei further confirms that C-1 proton is in the beta position 
due to the nOe signal of C-25 (green spectra). 
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The ability of 22 and 23 to induce Nrf2 signalling was determined using the Nrf2 
sensitive luciferase reporter assay. The data is shown in Table 3.4 and Graph 3.1, 
along with CDDO-Me and 21. The EC200 values for 21 and 22 were in the micro 
molar range, while those for CDDO-Me and 23 were in the nanomolar range. 22 
was approximately 17 times less active than 21 as an inducer of Nrf2. Surprisingly, 
23 was approximately 3 times less potent than CDDO-Me. This questions whether 
the formation of a reversible covalent bond via the α,β unsaturated ketone located 
on the A ring is the primary determinant of the potency of these compounds as 
inducers of Nrf2. 23 was selected for NMR studies as this was the most active of the 
two epoxide containing compounds. 
Compound Structure 
Concentration that 
induces Nrf2 reporter to 
200% (EC200) 
CDDO-Me (7) 
 
0.62 nM ± 0.02 
DDO-Me (21) 
 
0.90 µM ± 0.08 
DDO-Epoxide (22) 
 
15.42 µM ± 0.58 
CDDO-Epoxide (23) 
 
2.11 nM ± 0.24 
Table 3.4: Relative potencies of CDDO-Me, DDO-Me, DDO-Epoxide and CDDO-
Epoxide as inducers of an Nrf2-regulated luciferase reporter transgene in H4IIE-ARE 
cells. 
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3.2.6 NMR evidence for the interaction of CDDO-Epoxide with β-
mercaptoethanol 
A proton NMR was obtained for CDDO-Epoxide in DMSO-d6 following the addition 
of β-ME and triethylamine, as shown in Figure 3.16A. In contrast to CDDO-Me, 
CDDO-Epoxide did not react instantly and required addition of triethylamine to 
promote covalent interaction with β-ME. However, the reaction proceeded 
relatively quickly compared to DDO-Me. Once equilibrium was reached, proton VT-
NMR (Figure 3.16B) was performed. Heating of the sample did not result in the 
reversion of the reaction, indicating its stability.  
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Figure 3.16: Proton NMR and proton VT-NMR; (A): 24 hours monitoring of the 
reaction of CDDO-Epoxide (23) and β-mercaptoethanol in the presence of 
triethylamine; (B): Heating of the sample did not reverse thiol addition. 
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3.2.6.1 Molecular modelling for the interaction of CDDO-Epoxide with β-
mercaptoethanol 
Similar to the previous NMR experiments, the vinylic proton is shifted upfield from 
6.34 ppm to 6.23 ppm. This interaction between vinylic proton and sulphur was 
modelled and the results are shown in Table 3.5. The exact confirmation of the 
epoxide is in the alpha position as determined earlier in the chapter. However, for 
completeness, both alpha and beta CDDO-Epoxides were modelled (L and K from 
Table 3.5). The experimental vinylic proton is located at 6.34 ppm. Comparing this 
with the model, this value is closest to the alpha epoxide model L. If this is true, the 
addition of a thiol will result in the beta addition of the thiol (N). Both alpha and 
beta addition of the compounds are modelled. The experimental proton shift (6.23 
ppm) is closest to N (5.59 ppm) giving further confidence that the CDDO-Epoxide 
assignment, along with the predicted thiol adducts, are correct. 
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3.2.6.2 nOe experiments for the interaction of CDDO-Epoxide with β-
mercaptoethanol 
In addition to the molecular modelling, nOe experiments were performed. The C-25 
β-methyl protons were located at similar chemical shifts to pure CDDO-Epoxide. 
(Figure 3.17) 
 
Figure 3.17: Proton NMR for CDDO-Epoxide compared with the CDDO-Epoxide-β-
mercaptoethanol reaction mixture.  The C-25 methyl proton signal is highlighted.  
The irradiation of the C-25 methyl proton signal did not produce a nOe signal (data 
not shown). This further supports the model predictions where β-mercaptoethanol 
attacks from the opposite side of the epoxide resulting in a beta addition of the 
thiol. 
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3.2.6.3 Mass Spectrometry evidence for the interaction of CDDO-Epoxide with β-
mercaptoethanol 
An aliquot of the sample was analysed by MS. A peak corresponding to the CDDO-
Epoxide-β-Me adduct was detected at 602.39 m/z, as opposed to the expected 600 
m/z (Figure 3.18). The reaction was performed in deuterated DMSO, therefore, a 
possible explanation is the addition of deuterium during the rearrangement of the 
epoxide and deuterium exchange between the hydroxyl group located on β-
mercaptoethanol. The mass spectra data also confirmed the starting material was 
detected at 522.41 m/z. Mass spectrometry confirmed that a stable CDDO-Epoxide-
thiol adduct was formed, justifying further experimentation to define the value of 
CDDO-Epoxide as a chemical tool for defining the target(s) of this compound class in 
cells.  
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3.2.7 Mass spectrometry evidence for the interaction of CDDO-Epoxide 
with GSTP1 
Glutathione-S-transferase pi (GSTP1) catalyses the conjugation of glutathione to 
xenobiotic substrates therefore facilitating their detoxification. GSTP1 contains four 
cysteine residues with divergent reactivity, and thus represents a model protein for 
characterising site specific modification, especially for soft electrophiles.23 GSTP1 
was therefore used to determine the capacity of CDDO-Epoxide to form stable and 
detectable adducts with a protein. 
Tandem MS, in which molecules are fragmented by collision induced dissociation, is 
a powerful tool for identifying proteins and peptide sequencing. Fragmentation of 
peptide lengths can be predicted due to the typical fragmentation pattern.24 There 
are 6 fragmentation patterns along the peptide backbone and are each labelled a, b, 
c along with their respected counterpart x, y, z as shown in Figure 3.19. 
 
Figure 3.19: Nomenclature of fragment ions observed along the peptide backbone 
during tandem MS.24 
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The peptide sequence of GSTP1 is known and therefore small peptide sequences 
can be predicted during tryptic digestion. To determine if an amino acid has been 
modified within a peptide sequence, the small peptide must contain an additional 
mass similar to that of the compound used. This modified peptide is subjected to 
tandem MS revealing the individual amino acids and hence revealing the modified 
amino acid.24  In this case, the fragmentation of the peptide observed is the b and y 
ions as shown in Figure 3.20. 
 
Figure 3.20: Fragmentation of the amide bond revealing the b and y ions. 
Following incubation of GSTP1-His with CDDO-Epoxide for 24h, the reaction mixture 
was subjected to tandem MS. CDDO-Epoxide was found to have modified Cys-47 
and Cys-14 of the protein. Cys-101 and Cys-169 may have also been modified by 
CDDO-Epoxide, however, they could not be detected due to the size of the peptide 
fragments resulting from tryptic digestion. This was due to Cys-101 being too small 
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and Cys-169 too large for detection on the LCMS). (Figure 3.21) This data provides 
proof of principle that CDDO-Epoxide can be used to identify the site(s) of 
modification of proteins by this compound class. 
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3.3 Conclusion 
NMR and VT-NMR analysis has provided a detailed insight into the chemical 
mechanism of action of CDDO-Me as a reversible thiol modifier. Chemical 
manipulation of key functional groups has enabled the synthesis of the irreversible 
analogues, DDO-Me and CDDO-Epoxide. In particular, CDDO-Epoxide exhibits 
relatively high potency as an inducer of Nrf2 and undergoes stable thiol addition 
readily in the presence of base. Additional evidence of irreversible binding of DDO-
Me and CDDO-Epoxide has been generated following reaction with the model 
protein GSTP1, further supporting the use of these probes to define the molecular 
targets of CDDO-Me and its derivatives in cells. 
The epoxide probe is currently being used by collaborators to determine the site(s) 
of modification following incubation of the compound with purified recombinant 
Keap1 protein in vitro. Preliminary data indicates that Cys-257, Cys-273, Cys-288, 
Cys-434, Cys-489 and Cys-613 of Keap1 are modified by CDDO-Epoxide under these 
conditions. The preliminary results are shown in Figure 3.22 A to F respectively. This 
is the first time that the specific sites of interaction of a triterpenoid with 
components of the Nrf2 pathway have been identified. Importantly, previous work 
has shown that site-direct mutagenesis of Cys-273 and Cys-288 renders Keap1 
unable to repress Nrf2, leading to an induction of Nrf2 signalling.25,26 Therefore, it is 
plausible that the direct modification of these cysteine residues underlies the ability 
of CDDO-Epoxide and other triterpenoids, to activate Nrf2. 
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This future work will reveal whether these important cysteines located on Keap1 is 
a molecular target for CDDO-Me and its derivatives. If Keap1 is not the molecular 
target, CDDO-Epoxide can be used to identify alternative cysteine containing 
targets due to its capacity to undergo irreversible interaction with thiols. 
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Figure 3.22: Preliminary LCMS evidence for the modification of Keap1 with CDDO-
Epoxide. CDDO-Epoxide bound to (A) Cys-257; (B) Cys-273; (C) Cys-288; (D) Cys-
434; (E) Cys-489 and (F) Cys-613. 
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3.4 Chemistry Experimental 
3.4.1 General 
See section 2.4.1 
3.4.2 Purification of solvents and reagents 
Anhydrous solvents were obtained from commercial sources or dried and distilled 
prior to use. The distillation was under the flow of dry nitrogen. THF was distilled 
from sodium and benzophenone. Dichloromethane was distilled from calcium 
hydride. Oleanolic acid was obtained from Toronto Research Chemicals Inc. and 
Indofine chemical company Inc. HPLC or LCMS grade solvents were purchased from 
Fisher. All reagents were purchased from Sigma Aldrich or Alfa Aesar and were used 
without any purification unless otherwise indicated.  
3.4.2.1 Stains 
p-Anisaldehyde stain 
Concentrated sulphuric acid (2.5 mL) was added to p-anisaldehyde (15 g) in ethanol 
(250 mL) to give a clear solution of p-anisaldehyde stain.  
Potassium permanganate 
Potassium permanganate (3 g) and potassium carbonate (20 g) were dissolved in 5% 
sodium hydroxide (5 mL) and water (300 mL). 
3.4.3 Purification of products 
See section 2.4.4 
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3.4.4 Analysis 
See section 2.4.5 
3.4.5 Numbering 
Oleanolic acid 
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3.4.6 Synthesis 
Preparation of methyl 3,12-dioxooleana-1,9(11)-dien-28-oate (21)3 
 
For the synthesis of 4 see section 2.4.7. 4 (200 mg, 414 µmol) was dissolved in ethyl 
acetate (25 mL). Phenylselenyl chloride (87 mg, 456 µmol) was added to the 
reaction and left to stir at room temperature for 2.5 hours. 5 mL of water was 
added to the reaction. The water was removed via a separating funnel and THF (15 
mL) was added to the organic layer along with hydrogen peroxide (30%, 0.33 mL). 
The reaction was left to stir for a further hour at room temperature. The reaction 
was washed with water (3 x 50 mL), brine (50 mL) and dried over magnesium 
sulfate. The solvent was removed in vacuo and purified by flash chromatography 
using 2% ethyl acetate in hexane to give the title compound 21 (114.5 mg, 57%) as a 
white powder; Rf = 0.19, 20% ethyl acetate in hexane; mp = 182-183°C; 
1H NMR 
(400 MHz, CDCl3) δ 7.33 (d, J = 10.5 Hz, 1H), 6.00 (s, 1H), 5.92 (d, J = 10.5 Hz, 1H), 
3.70 (s, 3H), 3.04 (dt, J = 13.4, 3.5 Hz, 1H), 2.92 (d, J = 4.7 Hz, 1H), 2.02 – 1.64 (m, 
10H), 1.62 – 1.44 (m, 5H), 1.42 (s, 3H), 1.31 (s, 3H), 1.19 (s, 3H), 1.12 (s, 3H), 1.01 (s, 
3H), 1.00 (s, 3H) and 0.89 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 203.6, 199.7, 178.4, 
171.6, 154.9, 126.0, 123.8, 52.0, 49.8, 48.5, 47.4, 45.8, 44.8, 42.2, 41.9, 36.0, 34.6, 
33.4, 33.0, 32.2, 31.7, 30.8, 28.2, 27.3, 27.0, 24.7, 23.2, 22.8, 21.8, 21.7 and 18.5; IR 
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νmax (neat)/cm
-1 2945 (CH), 2861 (COCH3), 1716 (CO), 1673(C=C) and 1654 (C=C); 
HRMS (ESI) calculated for C31H44O4 [M+Na]
+ 503.3137 found 503.3138. 
Preparation of methyl 3,12-dioxo-1,2-epoxyolean-9(11)-en-28-oate (22)20 
 
21 (200 mg, 416 µmol) was dissolved in methanol (5 mL). Hydrogen peroxide (30%, 
200 µL, 2.0 mmol) and sodium hydroxide (10% w/v) were added successively and 
monitored using TLC analysis. The reaction was completed in 4 hours. Ethyl acetate 
(100 mL) was added to the reaction mixture and washed with water, sodium 
thiosulfate solution (5% w/v, 100 mL) and dried over magnesium sulfate. The 
solution was concentrated to give a crude product in which purification by flash 
chromatography using 20% ethyl acetate in hexane to give the title compound 22 
(101.2 mg, 49%) as a white powder; mp = 116-118°C; 1H NMR (400 MHz, CDCl3) δ 
6.12 (s, 1H), 3.92 (d, J = 4.5 Hz, 1H), 3.70 (s, 3H), 3.44 (d, J = 4.5 Hz, 1H), 3.05 (dt, J = 
7.3, 3.9 Hz, 1H), 2.93 (d, J = 4.5 Hz, 1H), 2.13 – 2.06 (m, 1H), 1.98 – 1.79 (m, 2H), 
1.77 – 1.40 (m, 9H), 1.40 – 1.27 (m, 3H), 1.26 (s, 3H), 1.20 (s, 3H), 1.14 (s, 3H), 1.10 
(s, 3H), 1.05 (s, 3H), 1.00 (s, 3H) and 0.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 211.2, 
199.6, 178.4, 171.2, 124.5, 62.6, 56.6, 52.0, 49.8, 47.4, 45.7, 44.8, 42.4, 42.0, 41.1, 
35.9, 34.6, 33.4, 32.9, 31.8, 31.6, 30.8, 28.3, 28.0, 23.9, 23.2, 23.0, 22.8, 21.8, 21.2 
and 18.5; IR νmax (neat)/cm
-1 2946 (CH), 2870 (COCH3), 1721 (CO), 1704 (C=C) and 
1661 (C=C); HRMS (ESI) calculated for C31H44O5 [M+Na]
+ 519.3086 found 519.3086. 
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Preparation of methyl 2β-cyano-3,12-dioxo-1,2-epoxyolean-9(11)-en-28-oate 
(23)20,27 
 
Preparation of Iodosylbenzene27: Sodium hydroxide (1.88 M, 532 mL) was added 
drop wise to (diacetoxyiodo)benzene (1.19 g, 4.09 mmol) at room temperature. The 
yellow mixture was stirred for three hours at room temperature and filtered under 
vacuum. The filtrate was washed with water until the washings were neutral. The 
yellow solid was dried and stored at room temperature until required. 
CDDO-Me (50.0 mg, 98.9 µmol) was dissolved in chloroform (50 mL). 
Iodosylbenzene (89.2 mg, 405.4 mmol) was added to the reaction and left to stir for 
12 hours. The reaction mixture was washed with water (50 mL), brine and dried 
over magnesium sulfate. The solution was concentrated to give crude product in 
which purification by flash chromatography using 30% ethyl acetate in hexane gave 
the title compound 23 (38.8 mg, 75%) as a white powder; Rf = 0.21, 20% ethyl 
acetate in hexane; mp = 142-143°C; 1H NMR (400 MHz, CDCl3) δ 6.08 (s, 1H), 4.35 (s, 
1H), 3.70 (s, 3H), 3.04 (dt, J = 6.7, 3.7 Hz, 1H), 2.94 (d, J = 4.6 Hz, 1H), 2.02 – 1.79 (m, 
3H), 1.77 – 1.44 (m, 10H), 1.39 – 1.28 (m, 2H), 1.27 (s, 6H), 1.19 (s, 3H), 1.12 (s, 3H), 
1.08 (s, 3H), 1.00 (s, 3H) and 0.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 202.5, 198.9, 
178.3, 168.7, 125.0, 113.7, 69.2, 53.3, 52.0, 49.8, 47.3, 45.7, 45.2, 42.6, 42.1, 41.0, 
35.9, 34.6, 33.4, 32.9, 31.6, 31.5, 30.8, 28.3, 28.1, 24.0, 23.2, 22.9, 22.8, 21.7, 21.5 
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and 18.4; IR νmax (neat)/cm
-1 2947 (CH), 2870 (COCH3), 1715 (CO), 1663 (C=C), 1242, 
906 and 810; HRMS (ESI) calculated for C32H43NO5 [M+Na]
+ 544.3039 found 
544.3047. 
3.4.7 NMR and VT-NMR experiments 
For NMR and VT-NMR experiments with simple thiols, proton NMR spectra were 
obtained on a Brucker DPX400 (1H, 400 MHz). Deuterated DMSO (DMSO-d6) was 
obtained from Cambridge Isotope Laboratories Inc (Leicestershire, UK). 
Proton spectras were acquired at 25°C unless stated otherwise. NMR samples were 
locked and shimmed for each addition of thiol or base prior to obtaining a proton 
spectrum. CDDO derivatives were weighed out exactly between 5-10 mg and 750 µL 
of DMSO-d6 was added. The required equivalent of thiol (β-mercaptoethanol or N-
acetyl cysteine) was added to the NMR reaction and proton NMR spectra were 
obtained. If required, one equivalent of triethylamine was added and proton 
spectras were acquired at set time points at 25°C. VT-NMR required heating of the 
probe and sample to 37°C or 50°C. Once the required temperature was reached, 
the sample was left for 3 minutes to equilibrate prior to obtaining a proton 
spectrum. Cooling of the sample from 50°C required setting the probe to 25°C and 
leaving the sample to reach the required temperature prior to obtaining a proton 
spectrum. 
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3.4.8 Mass spectra analysis for NMR samples 
β-mercaptoethanol or N-acetyl cysteine adducts were dissolved in 50% 
methanol/0.1% formic acid to a concentration of between 0.25 and 25 M and 
infused at 5 l/min directly into a QTRAP 4000 hybrid quadrupole-linear ion trap 
mass spectrometer (AB Sciex, Foster City, CA, USA) fitted with a turboion source. 
The ionspray potential was set to 5500 V in positive ion mode and the interface 
heater was turned off. Ions of m/z 583.9, 559.6 and 601.2 (ion found at 602.4) 
corresponding to the β-mercaptoethanol adducts of CDDO-Me, DDO-Me and 
CDDO-Epoxide respectively, were selected manually for fragmentation to generate 
full product ion scans (EPI) to aid structure confirmation. Ions of m/z 669.4 and 
644.6 corresponded to the N-acetyl cysteine adducts of CDDO-Me, and DDO-Me 
respectively. 
3.4.9 Molecular modelling experiments 
Calculations were performed using Spartan14 (http://wavefun.com/ 
products/spartan.html). Structure optimisations were carried out using density 
functional theory (DFT) in the gas phase using the B3LYP functional. For all the 
optimisations the 6-31G* basis set were used for all atoms. 
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3.5 Biological experimental 
3.5.1 Materials 
H4IIE cells stably expressing the ARE8L-reporter were provided by Prof. Alex 
Odermatt (Department of Pharmaceutical Sciences, University of Basel, 
Switzerland). Nunclon Δ cell culture flasks and multiwall plates were from Nalge-
Nunc International (c/o VWR International, Lutterworth, UK). Fetal bovine serum 
(FBS) and trypsin 0.25% EDTA were from Life Technologies (Paisley, UK). The MRX 
microplate reader was from Dynatech Laboratories (Billingshort, UK). The Varioskan 
Flash and SkanIT software were from Thermo Scientific (Hemel Hempstead, UK). 
Bright-Glo luciferase assay system, glo lysis buffer and isopropyl β-D-1-
thiogalactopyranoside were from Promega (Southampton, UK).  
Soniprep 150 was from MSE (London, UK). Beckman DU 640 spectrophotometer 
was from Backman Coulter (High Wycombe, UK). Dulbecco's modified Eagle 
medium (DMEM), Dimethyl Sulfoxide (DMSO), Phosphate buffered saline (PBS) 
tablets, LB broth, Minimum essential Medium (MEM) non-essential amino acid 
solution, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer 100X 
and HIS-beads were from Sigma-Aldrich (Poole, UK). All other reagents were of 
analytical or molecular grade, and were from Sigma-Aldrich. 
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3.5.2 Cell culture 
See section 2.5.2 
3.5.3 Plating 
See section 2.5.3 
3.5.4 Treatment of cells for luciferase activity assay 
See section 2.5.5 
3.5.5 Preparation of cells for luciferase reporter assay 
See section 2.5.6 
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3.5.6 LCMS with recombinant His-GSTP with CDDO-Epoxide 
3.5.6.1 Isopropyl β-D-1-thiogalactopyranoside solution (IPTG) 
476.6 mg of Isopropyl β-D-1-thiogalactopyranoside was dissolved in 20 mL of 
distilled water to obtain 100 mM 
3.5.6.2 6 x His Buffer 
0.5 M sodium chloride, 20 mM disodium phosphate and 20 mM imidazole dissolved 
up in distilled water. 
3.5.6.3 Preparation of His-GSTP 
BL21 E. Coli cells expressing His-GSTP were obtained from co-workers and used as 
described previously.23 A starter culture of 50 µL of glycerol stock and 20 mL 
lysogeny broth (LB) supplemented with 100 µg/mL ampicillin was incubated in a 
shaking incubator at 220 rpm at 37°C overnight. The following day, the culture 
volume was adjusted to 1 L with LB supplemented with 100 µg/mL ampicillin and 
incubated at 220 rpm at 37°C for 2-3 hours. Bacterial growth was determined using 
optical density readings measured at 600 nm (OD600). Aliquot samples were taken 
from the culture every hour and OD600 readings were compared to a blank LB 
sample. The OD600 measurement identifies which stage of growth the bacteria are 
in, with 0.4 indicating that the cells are in an exponential growth phase. When an 
OD600 reading of 0.4 was reached, 10 mL of 100 mM of IPTG was added to induce 
the expression of GSTP1 which is under the control of the lac operator. The culture 
was left to shake at 150 rpm at room temperature for 24 hours. 
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The bacteria were pelleted in 50 mL tubes at 5000 g for 5 minutes and LB broth 
removed. Pellets were vortexed in 10 mL 6x HIS buffer and 4 mL aliquots were 
subjected to sonication (3 x 1 min with 30 sec rest between sonications) to lyse cells. 
The supernatant was aliquoted into 1.5 mL tubes and pelleted at 18,000 g for 10 
minutes. Pellets were collected, pooled and subjected to freeze thaw at -80°C for 2-
3 hours. The supernatant was again aliquoted into 1.5 mL tubes, pelleted at 18,000 
g for 10 mins and pellets were collected and pooled. The supernatant was passed 
through a 0.45 µm filter. The lysate was aliquoted in 1.5 mL and frozen at -80°C 
until required.  
3.5.6.4 Incubation of GSTP1 with CDDO-Epoxide 
The 6X histidine residues on GSTP1 enabled protein purification via the affinity for 
nickel beads. Nickel beads were washed in triplicate with 6X His buffer. The 
bacterial lysate was added to the beads to give a 1:1 ratio and left to rotate at room 
temperature for 15 mins. A blank sample (nickel beads plus 6X His buffer) was used 
as a negative control for protein determination. Beads were pelleted and washed 
with 1 mL 6X His buffer five times to remove bacterial lysate. A BCA assay was used 
to determine the amount of GSTP1 bound to 10 µL of beads via referenced to a BSA 
standard curve. 
Using 50 µL of beads, the GSTP1 protein was exposed to a 100:1 molar excess of 
CDDO-Epoxide in PBS (pH 8.4) made up to 1 mL. Samples were rotated at 37°C for 
24 hours. Following this incubation, the beads were washed twice with PBS (pH 8.4) 
to remove all traces of CDDO-Epoxide, and then washed twice with 0.5 mL 25 mM 
ammonium bicarbonate, before being resuspended in 90 µL 25 mM ammonium 
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bicarbonate. A 400 µg/µL stock solution of sequence-grade modified trypsin was 
diluted 1:10 with 25 mM ammonium bicarbonate and 10 µl was added to the beads 
to a final concentration of 4 µg/µL. Trypsin digestion of the sample was performed 
overnight at 37˚C. 
The tryptic digest was vortexed and centrifuged at 14,000rpm for 1 minute. The 
supernatant containing GSTP1 peptides was removed into a new eppendorf and 
dried using a speedvac at 37°c for 90 minutes. The samples were then re-suspended 
in 20 µL 0.1% trifluoroacetic acid (TFA) and prepared using ZipTips.  
3.5.6.5 ZipTip protocol 
C18 tips were wet in 2 x 10 µL 100% acetonitrile (ACN), followed by washing in 4 x 10 
µL 0.1% TFA, 10 µL of the samples was then drawn up and released 10 times. 
Following this, the tip was washed again in 3 x 10 µL 0.1% TFA and the sample was 
eluted into a fresh eppendorf in 10 µL 50% ACN/0.1% TFA. This was repeated in 
triplicate with fresh C18 tips per sample. The samples were then dried again with a 
speedvac at 37°C for 30 minutes. 
3.5.6.6 LCMS analysis 
Following protein reduction, alkylation and digestion, samples were de-salted by 
reversed phase chromatography using ZipTips (Millipore). Samples were delivered 
into a Triple TOF 5600 mass spectrometer (AB Sciex) by automated in-line reversed 
phase liquid chromatography (LC) using an Eksigent NanoUltra cHiPLC System 
mounted with microfluidic trap and analytical column (15 cm × 75 μm) packed with 
ChromXP C18-CL 3μm. A NanoSpray III source was fitted with a 10 μm inner 
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diameter PicoTip emitter (New Objective). Samples were loaded in 0.1% formic acid 
onto the trap which was then washed with 2% ACN/0.1% FA for 10mins at 2L/min 
before switching in-line with the analytical column.  A gradient of 2-50% (v/v) ACN, 
0.1% (v/v) FA over 90 min was applied to the column at a flow rate of 300 nL/min. 
Spectra were acquired automatically in positive ion mode using information-
dependent acquisition powered by Analyst TF 1.5.1 software, using mass ranges of 
400-1600 atomic mass units (amu) in MS and 100-1400 amu in MS/MS. Up to 25 
MS/MS spectra were acquired per cycle (approx 10 Hz) using a threshold of 100 
counts per sec, with dynamic exclusion for 12 secs and rolling collision energy. The 
instrument was automatically calibrated after every fifth sample using a beta-
galactosidase digest. Protein sequence coverage was determined using ProteinPilot 
software v4.0 using the ParagonTM algorithm28 and the most recent version of the 
SwissProt database. Carboxyamidomethyl (+57.0 amu) was selected as a variable 
modification. Drug-modified peptides were identified using PeakView software to 
extract parent ions of the appropriate peptide plus drug m/z (extracted ion count, 
XIC). 
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4.1 Introduction 
In 2012, an estimated 207 million cases of malaria and 627,000 associated deaths 
were thought to have occurred.1 Many of these deaths were among children under 
the age of five.1 Malaria is a preventable and treatable mosquito borne disease. 
However, the suboptimal use of traditional drugs such as chloroquine and 
sulfadoxine-pyrimethamine based antimalarials has led to the emergence of 
resistant strains of the parasite and the re-emergence of malaria in areas where the 
disease had previously been eradicated.2 Artemisinin based combination therapies 
(ACT) are now recommended as the first line treatment for malaria in many 
endemic regions.3-5 Artemisinin is a sesquiterpene lactone extracted from the 
Chinese herb Artemisia annua. The key pharmacophore of artemisinin is the 
endoperoxide containing 1,2,4-trioxane unit.2 (Figure 4.1). 
 
Figure 4.1: Structure of artemisinin, chloroquine, sulfadoxine and pyrimethamine. 
Artemisinin contains the active pharmacophore endoperoxide bridge highlighted in 
red. 
As discussed in chapter 1, it has been established that iron(II) salts reductively 
activate the peroxide bond within artemisinin. The activation of the peroxide bond 
leads to the formation of oxy radical intermediates that undergo rearrangement to 
form primary or/and secondary carbon centred radicals (Figure 4.2). It has been 
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proposed that the carbon-centred radicals interact with vital cellular components 
within the malaria parasite, resulting in its death. 
 
Figure 4.2: Suggested chemical mechanism underlying the antimalarial action of 
artemisinin, based on the formation of the primary and secondary carbon-centred 
radicals. 
Artemisinin is a highly active antimalarial drug. However, there are many 
disadvantages to the use of artemisinin, including poor bioavailability, high cost of 
synthesis and the recent emergence of resistance.5,6 A great deal of effort to 
develop synthetic alternatives to the artemisinin class of antimalarials has resulted 
in the discovery of the trioxolane and tetraoxane classes. Structure relationship 
activity (SAR) studies of both trioxolanes and tetraoxanes have identified a stable 
general template. Both classes contain an adamantyl group to stabilise the 
endoperoxide as well as a variable polar or non-polar group7 (Figure 4.3). 
Compounds in both classes, including OZ277 trioxolane and RKA182 tetraoxane 
(Figure 4.3) have shown impressive antimalarial activities in pre-clinical tests.8-10 
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Figure 4.3: Trioxolane and tetraoxane template. Adamantyl group highlighted in 
blue, endoperoxide pharmacophore highlighted in red and the variable group in 
black. Chemical structure for trioxolane OZ277 and tetraoxane RKA182 are also 
shown. 
Despite their impressive antimalarial activity, the mechanism of action and 
molecular targets of trioxolanes and tetraoxanes are still unclear. For example, 
there is conflicting evidence for the role of sarco/endoplasmic reticulum calcium 
ATPase of P. falciparum (PfATP6).11-13 Recent studies by Haynes and Monti have 
proposed a non-iron mediated mechanism of bioactivation.14,15 This involves the 
flavin adenine dinucleotide (FAD), which is reduced by NADPH flavin reductase to 
give FADH2. This in turn reduces the antimalarial drug methylene blue (MB) to 
leucomethylene blue (LMB). MB has a synergistic pharmacological effect when 
administrated in combination with artemisinin. Therefore, it is suggested that 
artemisinins/endoperoxides oxidise LMB or FADH2 to give MB or FAD. It is 
postulated that this interferes with the NADPH reduction of flavin cofactors in 
parasite flavin disulphide reductases, thus generating lethal ROS.14,15 A summary of 
this mechanism is shown in Scheme 4.1 and Scheme 4.2  
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Scheme 4.1: (A) Chemical structures for FAD, FADH2, MB and LMB; (B) The overall 
schematic mechanism of MB and artemisinin; (C) Chemical mechanism of FADH2 or 
LMB with artemisinin.14,15 
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Scheme 4.2: Scheme is adapted from Haynes et al.15 (A) Normal process: As part of 
the pentose phosphate pathway, glucose 6-phosphate is converted to 6-
phosphono-gluconolactone by glucose-6-phosphate dehydrogenase (G6PD), with 
NADPH generated from NADP+. Glutathione reductase (GR) converts oxidised 
glutathione (GSSH) to its reduced form (GSH) and NADPH to NADP+, whilst 
converting the cofactor FAD to FADH2. Thioredoxin in its oxidised state (TrxS)2 is 
reduced to TrxSH via thioredoxin reductase, using FAD and FADH2 as cofactors; (B) 
Endoperoxide conditions: Artemisinins/endoperoxides are proposed to interfere 
with the NADPH pathway by disrupting the equilibrium of the flavin cofactors 
resulting in elevated ROS generation and subsequently oxidative stress.  
This provides an alternative mechanism of activation for the endoperoxide classes; 
however, further additional biological support for this proposal is required. It is 
suggested that both trioxolane and tetraoxane classes have a similar mechanism of 
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action to that of artemisinin.2 Studies with artemisinin and trioxolanes have 
revealed that primary and secondary carbon-centred radicals can be produced 
when activated with iron(II) salts.16 However, the artemisinin and trioxolane classes 
have also been shown to react with heme and tetraphenylporphyrins.17 Adducts 
detected were formed via the primary carbon-centred radical pathway and no 
adducts for the secondary radical pathway were detected.  
Kumura et al have shown a requirement for oxygen in the oxidative degradation of 
unsaturated phospholipids in the presence of iron(II) salt with artemisinins but not 
with tetraoxanes.18 This suggests that the two endoperoxide classes may have 
different modes of action despite their similar antimalarial activities. The chemical 
mechanism of action for the tetraoxane class of antimalarials therefore requires 
further investigation. The importance of understanding the ferrous ion reactivity of 
these important classes of antimalarials will be key for the production of new 
endoperoxide derivatives that can provide good exposures in malaria infected 
patients and exhibit improved safety profiles. 
4.1.1 Aims 
The aims of the project were to prepare a range of tetraoxane analogues and 
subsequently assess their activity in malaria parasites in vitro. In addition to 
establishing the antimalarial profile in P. falciparum, we also planned to investigate 
the biomimetic Fe(II) chemistry of key exemplar molecules. The final aim was to 
investigate the oxidative degradation of phospholipids by the Fe(II) / tetraoxane 
combination. 
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4.2 Results and discussion 
4.2.1 Chemical synthesis of unsymmetrical dispiro-1,2,4,5-tetraoxanes 
As discussed in chapter 1, OZ277 is a 1,2,4-trioxolane derivative with impressive 
antimalarial activity but poor stability in the plasma of malaria patients, resulting in 
a short half-life.8 OZ439 is a second generation trioxolane with improved 
pharmacokinetics and in vivo antimalarial activity due to enhanced lipophilicity and 
stability.19 As a result of the unacceptable short half-life of OZ277, OZ439 was 
favoured as a lead compound. The enhanced stability of OZ439 may be due to its 
lipophilicity, which has the potential to promote plasma protein binding. Based on 
this information, it was hypothesised that the synthesis of a phenyl amide 
tetraoxane would yield a compound with increased lipophilicity and stability. The 
phenyl amide also provides an active ultra violet (UV) chromophore, which is useful 
for aiding product identification during degradation studies. The overall rationale is 
highlighted in Scheme 4.3. 
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Scheme 4.3: Overall rationale for the synthesis of lipophilic phenyl amide 
tetraoxanes, inspired by OZ277, RKA182 and OZ439.  
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The synthesis of unsymmetrical dispiro-1,2,4,5-tetraoxanes involves a seven step 
synthesis (Scheme 4.4). 
 
Scheme 4.4: Reagents and conditions: (i) Toluene, Ph3P=CHCO2Et reflux 18 hours, 
87%; (ii) H2, Pd/C (1.1 equiv), EtOAc, 91%; (iii) 1M HCl 56%; (iv) H2O2, acetonitrile, 
Formic acid, 0°C, 30 mins; (v) Re2O7 (2%), H2O2, DCM, r.t , 37%; (vi) MeOH, KOH, 1 
hour, 70°C, H2O, HCl, DCM, 98%; (vii) NEt3 (1.5 equiv), ClCO2Me (1.1 equiv), DCM, 
0°C, 1 Hour; (viii) HNR1 (1.1 equiv), 30 mins 0°C to r.t. 
The first step involves a Wittig reaction between 1,4, cyclohexanedione 
monoethylketal acetal (24) and ethyl (triphenylphosphoranylidene)acetate (33) 
resulting in the formation of 25 with a 87% yield (Scheme 4.5). Hydrogenation of 25 
in the presence of palladium on carbon gives compound 26 in a 91% yield. 
Hydrolysis with 1 M hydrochloric acid gives ethyl 2-(4-oxocyclohexyl)acetate (27) in 
a 56% yield.  
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Scheme 4.5: Reagents and conditions: (i) Toluene, Ph3P=CHCO2Et reflux 18 hours, 
87%; Chemical mechanism for the Wittig reaction. 
Formation of the 1,2,4,5-tetraoxanes involves a two step procedure where ethyl 2-
(4-oxocyclohexyl)acetate (27) is first reacted to form ethyl 2-(4,4-
dihydroperoxycyclohexyl)acetate (28) using H2O2 and formic acid in acetonitrile. 28 
was not purified due to instability and was reacted with 2-adamantanone (29) and 
Re2O7 in dichloromethane to produce the unsymmetrical dispiro-1,2,4,5-tetraoxane 
(30), in a 37% yield over two steps. Hydrolysis of 30 into the tetraoxane acid (31) 
gave the acid template. A mixed anhydride amide coupling reaction with the 
corresponding amine gave the required compounds in reasonable yields (Table 4.1). 
The chemical mechanism of action is shown in Scheme 4.6. 
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Scheme 4.6: Chemical mechanism of action for the mixed anhydride amide coupling 
reaction 
 
Compound R Yield (%) Compound R Yield (%) 
34 
 
78 38 
 
70 
35 
 
71 39 
 
74 
36 
 
40 40 
 
65 
37 
 
65 41 
 
75 
Table 4.1: Synthesised unsymmetrical dispiro-1,2,4,5-tetraoxanes including 
percentage yields and chemical structures.  
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Seven of the compounds were submitted to the Liverpool School of Tropical 
Medicine and were tested for their ability to inhibit the proliferation of Plasmodium 
falciparum 3D7 (chloroquine sensitive) strain in vitro. Data generated from this 
study is presented in Table 4.2 
 
 
Compound R 
In vitro IC50 
(nM) 
 
Compound R 
In vitro IC50 
(nM) 
31  185.7 ± 34.1 37 
 
5.0 ± 0.5 
34 
 
3.8 ± 1.0 38 
 
11.7 ± 2.4 
35 
 
3.0 ± 1.3 39 
 
5.0 ± 1.3 
36 
 
12.0 ± 3.0 41 
 
17.4 ± 5.5 
Table 4.2: The concentrations of unsymmetrical dispiro-1,2,4,5-tetraoxanes that 
provoke a 50% inhibition (IC50) of the proliferation of Plasmodium falciparum 3D7 
strain in vitro. 
All compounds that were submitted for testing were active against the P. 
falciparum 3D7 strain. The most active compound within this series was compound 
35 giving an IC50 of 3.0 ± 1.3 nM. The removal of the carbon linker between the 
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amide and phenyl groups (compound 34) slightly reduced antimalarial activity 
compared to compound 35. Substituting the fluoro group with chlorine (36 and 37) 
reduced antimalarial activity. However, the chlorine derivatives further confirmed 
that a carbon linker is required between the amide and the phenyl group to obtain 
greater antimalarial activity. Para substituted methoxy, trifluoromethyl and 
substitution of the phenyl for the cyclohexyl ring did not improve antimalarial 
activity. Compound 35 was therefore selected for use in experiments designed to 
examine the radical pathway of tetraoxanes by activation with an inorganic iron(II). 
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4.2.2 Investigating the radical pathway of tetraoxanes  
Activation of the endoperoxide tetraoxane by inorganic ferrous iron (iron(II) salts) is 
hypothesised to generate primary or secondary carbon-centred radicals. The 
proposed chemical mechanism is shown in Scheme 4.7. 
 
Scheme 4.7: Proposed mechanism of endoperoxide activation by iron(II) for the 
tetraoxane class. The chemical mechanism for the formation of primary (left route) 
and secondary (right route) carbon-centred radials is depicted. 
The degradation of the tetraoxane compound 35 was performed in an attempt to 
isolate products that have resulted from carbon-centred radical formation.  A range 
of iron(II) salts were used under a variety of different conditions to obtain the 
optimal yield. Iron(II) acetate under two different conditions (DCM/acetonitrile or 
THF) mainly produced low turnover of the tetraoxane and as a result a different 
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iron salt was explored. The use of iron(II) gluconate or iron(II) sulphate resulted in 
an improved reaction turnover. For experiments involving iron(II) gluconate, 
dimethylformamide (DMF) and water were used as the solvent in an attempt to 
mimic biological conditions. The incubation time was varied in order to determine 
the optimal conditions for full turnover. The degradation of the tetraoxane was 
monitored by thin layer chromatography (TLC). The overall turnover (96%) was 
maintained when the incubation period was reduced from 24 hours to 7 hours. 
Purification by flash chromatography and HPLC yielded three of the four predicted 
reaction products (29, 42, and 44). This suggests that iron(II) salt-mediated 
degradation of tetraoxanes follows the two proposed chemical routes (Scheme 4.7) . 
The primary and secondary carbon-centred radicals are generated in approximately 
equal amounts as isolation of 42 and 44 were obtained at approximately 1:1. 
The postulated acid product 43 associated with the formation of a secondary 
carbon-centred radical was not observed under any of the conditions used despite 
isolation of the predicted ketone counterpart 44. A lactone product 45 was 
obtained in similar ratios to the ketone counterpart 44 (Scheme 4.8). Further 
examination with LCMS revealed that the lactone 45 was indeed generated under 
these conditions. Such a lactone could be formed via intramolecular attack on the 
peroxy ester function by the C-radical centre of 35a resulting in the loss of FeO3+ 
and the formation of lactone 45 (Scheme 4.8). 
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Scheme 4.8: Secondary carbon-centred radical pathway and the mechanism which 
results in the formation of lactone 45 following iron(II) salt-mediated degradation of 
tetraoxane 35. 
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In addition to the four products (29, 42, 44 and 45) obtained during the degradation 
experiments, a fifth product was obtained. Chemical analysis suggested that this 
product was an aldehyde (46). Proton NMR indicated that a single proton triplet 
was located at 9.77 ppm. This represents a de-shielded CH group next to a CH2. The 
corresponding carbon NMR along with HMQC and DEPT135 confirmed that the 
carbon located at 202.2 ppm was that of an aldehyde. Mass spectrometry also 
confirmed an aldehyde was present. Fragmentation during ionisation on MS 
resulted in a mass loss of 18 m/z which is commonly associated with the presence 
of aldehydes, ketones and primary alcohols.20 A proposed chemical mechanism is 
shown in Scheme 4.9 where intramolecular 1-5 hydrogen abstraction of 35b results 
in the loss of carbon dioxide and the formation of 35c. 35c R5earranges to give 
compound 29 and the corresponding aldehyde 46. Although the aldehyde is 
obtained during the degradation experiments, it may not fully represent the 
chemical mechanism of action under in vivo conditions as 2 equivalents of iron(II) 
were used during these in vitro experiments. 
Despite some contention, the radical pathway for the activation of endoperoxide 
tetraoxanes by iron-mediated decomposition is currently the most convincing 
mechanism of action for this class of antimalarials. Primary and secondary carbon-
centre radicals can alkylate vital parasitic proteins resulting in cell death. However, 
the identity of such biological targets is currently unclear and requires further 
examination. 
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Scheme 4.9: Primary carbon-centred radical pathway and the mechanism which 
results in the formation of lactone 42 and 29. Further intramolecular 1-5 hydrogen 
abstraction results in the formation of 35c and eventually the aldehyde 46. 
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4.2.3 Reactivity of tetraoxanes with iron(II) and phosphatidylcholine (PC) 
The capacity of the tetraoxanes to alkylate proteins via the formation of carbon 
centred radicals has been met with scepticism. The capacity of the tetraoxanes to 
react with biologically relevant lipid targets is therefore of interest as an alternative 
mechanism of action. Tilley et al have examined the lipid environment within 
Plasmodium falciparum. The study identified that phosphatidylcholine (PC)(47) was 
present in the parasite food vacuole.21 The food vacuole is the site of haemoglobin 
degradation and the site of heme production.11 The lipid bilayer is a well-known 
target for many reactive oxygen species (ROS). The generation of ROS can lead to 
oxidative cleavage and lipid peroxidation, culminating in cell damage and death.2 
Kumura et al have reported that tetraoxane salts (48) can induce oxidative 
degradation of PC in the presence of an iron(II) salt. Several PC degradation 
products were identified, however, the authors did not propose any chemical 
mechanisms for their formation.18 The symmetrical tetraoxane salt (48) used by 
Kumura is structurally different from the unsymmetrical more lipid soluble 1,2,4,5-
tetraoxanes. Therefore, examining the reactivity of unsymmetrical tetraoxanes in 
the presence of biological relevant lipids is vital for understanding the potential 
mechanism of action of compounds within this class. 
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Figure 4.4: Chemical structure of 2-linoleoyl-1-palmitoyl-sn-phosphatidylcholine2 
and the symmetrical salt previously studied by Kumura.18 
During the purification of the degradation products, flash column chromatograph 
and ultraviolet detection by high performance liquid chromatography (HPLC-UV) 
was used to obtain analytical standards for compounds 35, 42, 44 and 45. 
Compound 43 was synthesised and provided by co-workers.2 This enabled the use 
of liquid chromatography with mass spectral analysis (LCMS), and calibration of 
reverse phase column conditions, by using the standard compounds as references. 
The retention times of each compound were determined. This data is shown in 
Figure 4.5. 
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Figure 4.5: LCMS calibration data for the isolated tetraoxane degradation products. 
Each figure shows the chemical structure and the mass relevant to the compound, 
along with the retention time. 
Following the determination of retention times for the chemically purified 
standards, a degradation mixture analysed by LCMS was used to ensure correlation 
between the retention times of the degradation products and the standards. Data is 
shown in Figure 4.6. 
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Figure 4.6: LCMS analysis of tetraoxane 35 reacted with FeSO4. The resulting 
degradation products had similar retention times to the chemically purified 
references. 
The degradation reaction mixture was produced with iron(II) sulphate in 
acetonitrile:water. This condition was used by Kumura et al for the reaction of PC 
with the endoperoxides.18 During LCMS analysis, acid 43 was detected at 7.78 
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minutes. This is also the retention time of the lactone 45 and therefore the 
observation of 43 is due to ionisation and rearrangement of the lactone. Acid 43 
has an expected retention time of 13.70 minutes. Compounds 29, 42, 44 and 45 
were detected at the expected times compared to standards. 
Reactions of 2-linoleoyl-1-palmitoyl-sn-glycero-phosphatidylcholine (PC 47) with 
tetraoxane 35 in the presence of iron(II) sulphate were analysed using mass 
spectrometry (MS). MS data was compared to native PC and indicated the 
formation of several products (Figure 4.7). The predominant degradation products 
had m/z 622.2, 650.6, 666.5 and 788.6. All of these ions were detected by Kumura 
et al.18 The bis-allylic hydrogen located at C-11 of the linoleic acid within PC is likely 
to be abstracted by the tetraoxane radicals formed during activation of iron(II) salt. 
The proposed mechanisms for the formation of each of the PC oxidation products 
are depicted in Figure 4.8. This is based on the examination of linoleic acid 
peroxidation by Spiteller et al.22  
Product P1 is derived from the C-9 capture of oxygen followed by peroxyl radical H-
abstraction from another molecule of PC, which results in a radical chain reaction. 
Homolytic cleavage of the hydroperoxide followed by fragmentation forms a carbon 
centred radical on C-8, which is capable of abstracting an hydrogen to produce the 
product P1. Fragmentation resulting in the loss of the phosphorus group during MS 
analysis resulted in the fragment P2. The product P4 is formed via the Hock 
rearrangement resulting in the generation of an aldehyde P3. P3 undergoes 
oxidation under the reaction conditions to provide P4. Product P5 is derived from 
PC and the C-13 oxygen capture. Reductive activation by ferrous iron produces a 
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peroxy epoxide that can undergo hydrogen abstraction and oxidation to produce a 
gem dihydroperoxide. The gem dihydroperoxide undergoes rearrangement to 
release hydrogen peroxide yielding product P5. 
As shown earlier, tetraoxane are able to generate primary and secondary carbon 
centred radicals once exposed to iron(II) salts. To further understand the 
mechanistic pathway of tetraoxane degradation, LCMS analysis was performed to 
determine which of the carbon-centred radical species is responsible for hydrogen 
abstraction of the bis-allylic hydrogen located at C11 of the linoleic acid within PC. 
This analysis resulted in the detection of the acid 42 and the lactone 45 and their 
respective counterpart 29 and 44 resulting from the degradation of tetraoxane 35 
(Figure 4.9). The acid 43 is only generated if hydrogen abstraction of PC occurs via 
the secondary carbon centred radical pathway, however, 43 was not detected 
under these reaction conditions and only the lactone 45 was detected. Hence, 
hydrogen abstraction did not occur. Therefore, the data obtained strongly suggests 
that the primary carbon-centred radical is primarily responsible for hydrogen 
abstraction of PC.  
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Figure 4.7: (A) MS spectra of the products resulting from the reaction of PC and 
iron(II) sulphate in the absence of tetraoxane 35; (B) MS spectra of the products 
resulting from the reaction of PC, iron(II) sulphate and tetraoxane 35. The 
predominant degradation products had m/z 622.2, 666.5 and 788.6. 
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Figure 4.8: Proposed mechanisms for tetraoxane mediated lipid peroxidation, as 
suggested by Kumura et al.18 
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Figure 4.9: LCMS spectra of the products resulting from the reaction of PC, iron(II) 
sulphate and tetraoxane 35. The tetraoxane by products resulting from the 
formation of primary and secondary carbon-centre radicals were detected at the 
expected retention times. 
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4.3 Conclusion 
The synthesis of unsymmetrical dispiro-1,2,4,5-tetraoxanes has produced seven 
novel tetraoxane compounds that are active in the low nanomolar range against 
the 3D7 strain of P. falciparum. Degradation studies involving tetraoxanes in the 
presence of inorganic iron under various conditions have produced three of the 
predicted degradation products. Two additional degradation products were also 
obtained. This study has therefore demonstrated that both primary and secondary 
carbon centred radicals can be formed under such conditions. Reactions of PC with 
tetraoxane in the presence of iron(II) confirmed that lipids such as PC could be an 
alternative molecular target for this class of antimalarials.  
Secondary carbon-centred radicals derived from an iron(II) activated tetraoxane 
have been shown to bind to heme porphyrin8. Therefore it was of interest to 
determine if secondary carbon-centred radicals are also responsible for the 
hydrogen abstraction of PC. Based on this study it is clear that hydrogen abstraction 
of PC is exclusively mediated through the primary carbon-centred radicals 
generated by the tetraoxane when exposed to iron(II) salts. Surprisingly, previous 
work has shown that artemisinins do not provoke lipid peroxidation,2 suggesting 
that tetraoxanes and artemisinins may have different chemical mechanisms of 
action as antimalarials. 
One suggested mechanism of action could be similar to chloroquine, which was 
developed in the mid 20th century from quinine. Chloroquine accumulates within 
the parasite food vacuole and inhibits hemozoin biocrystallization, causing an 
accumulation of cytotoxic heme which kills the parasite via an oxidation 
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process.23,24 Studies by Sugioka et al have demonstrated that a ferriprotoporphyrin 
IX-chloroquine complex promotes heme-catalysed lipid peroxidation.25 Tetraoxanes 
have been shown to bind to heme porphyrin and could therefore have a similar 
mechanism to that of chloroquine whereby hemozoin biocrystallization is inhibited, 
resulting in heme catalysed lipid peroxidation. 
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4.4 Chemistry Experimental 
4.4.1 General 
See section 2.4.1 
4.4.2 Purification of solvents and reagents 
See section 3.4.2 
4.4.2.1 Stains 
See section 3.4.2.1 
4.4.3 Purification of products 
4.4.3.1 General 
See section 2.4.4 
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4.4.3.2 HPLC-UV purification 
HPLC system consists of Gilson 305 and 306 pumps, 811C low-volume dynamic 
mixer, 119 UV detector and 805 manometric module (Gilson, Inc. USA). The 
software used was Clarity version 2.6.5.517 (DataApex Ltd, Prague, The Czech 
Republic). Samples were dissolved in 70%  Methanol, 30% water and filtered using 
13 mm 0.2 µm PTFE membrane syringe filters (c/o VWR International, Lutterworth, 
UK) prior to injection. The solutions (2 mL) were chromatographed at room 
temperature on an Eurospher 100-5 C18 column (250 × 20 mm i.d.; Knauer 
advanced scientific instruments, Hegauer Weg, Berlin, Germany) by gradient elution 
with methanol (70-95% over 15 min; 70% from 15 min to 30 min) in water. The 
eluent flow rate was 5.0 mL/min using UV detection set at 254 nm. 
4.4.4 Analysis 
See section 2.4.5 
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4.4.5 Synthesis of unsymmetrical dispiro-1,2,4,5-tetraoxanes 
Preparation of Ethyl 2-(1,4-dioxaspiro[4.5]decan-8-ylidene)acetate (25)7  
 
A solution of 1,4-cyclohexanedione monoethylene acetal (24)(10 g, 64 mmol) and 
ethyl 2-(triphenylphosphoranylidene)acetate (33)(24.54 g, 70.4 mmol) in toluene 
was refluxed under nitrogen for 16 hours. The solvent was removed under vacuum 
and the crude product purified via flash column chromatography using 5% ethyl 
acetate in hexane to give the title compound 25 (12.69 g, 88%) as a colourless oil; Rf 
= 0.53, 20% ethyl acetate in hexane; 1H NMR (400 MHz, CDCl3) δ 5.66 (s, 1H), 4.14 
(q, J = 7.1 Hz, 2H), 3.97 (s, 4H), 3.03 – 2.97 (m, 2H), 2.42 – 2.32 (m, 2H), 1.83 – 1.70 
(m, 4H) and 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.3, 160.1, 114.2, 
107.8, 64.3, 59.4, 35.7, 34.9, 34.5, 25.9 and 14.2; IR νmax (neat)/cm
-1 2934 (CH), 2860 
(COCH2), 1710 (CO) and 1150 (C-O-C); MS (CI) C12H18O4 [M+NH4]
+ m/z 244.1. 
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Preparation of ethyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetate (26)7 
 
In the absence of light palladium on carbon (10% w/w, 6.56 g, 61.7 mmol) in 
anhydrous ethyl acetate was added to a solution of 25 (12.7 g, 56.1 mmol) and 
stirred in an hydrogen atmosphere at room temperature for 16 hours. The reaction 
was filtered through a pad of celite and washed with ethyl acetate. The solvent was 
removed under vacuum to give the title compound 26 (11.73 g, 92%) as a clear 
yellow oil; Rf = 0.75, 50% ethyl acetate in hexane; 
1H NMR (400 MHz, CDCl3) δ 4.13 
(d, J = 7.0 Hz, 2H), 3.94 (s, 4H), 2.23 (d, J = 7.0 Hz, 2H), 1.76 – 1.70 (m, 1H), 1.61 – 
1.51 (m, 2H), 1.30 – 1.23 (m, 3H) and 1.26 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 173.0, 108.6, 64.2, 60.2, 41.0, 34.2, 33.4, 29.9 and 14.2. MS (CI) C12H20O4 
[M+H]+ m/z 229.1. 
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Preparation of ethyl 2-(4-oxocyclohexyl)acetate (27)8 
 
A solution of hydrochloric acid (1 M, 300 mL) was added to compound 26 (11.73 g, 
51.8 mmol) and left to stir at room temperature for 4.5 hours. Saturated sodium 
carbonate was added to the reaction to neutralise the acid. The resulting solution 
was worked up with dichoromethane (300 mL), dried over magnesium sulfate and 
the solvent removed under vacuum. The crude product was purified via flash 
column chromatography using 20% ethyl acetate in hexane to give the title 
compound 27 (5.33 g, 56%) as a colourless oil; Rf = 0.5, 50% ethyl acetate to hexane; 
1H NMR (400 MHz, CDCl3) δ 4.15 (q, J = 7.1 Hz, 2H), 2.41 – 2.33 (m, 5H), 2.32 (s, 2H), 
2.15 – 2.06 (m, 2H), 1.56 – 143 (m, 2H) and 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 210.8, 172.1, 60.2, 40.3, 40.0, 32.8, 32.2 and 14.0; MS (CI) C10H16O3 
[M+NH4]
+ m/z 202.1. 
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Preparation of ethyl dispiro [cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo 
[3.3.1.13,7] decan]-4-ylacetate (30)8  
 
A solution of 26 (1 g, 5.43 mmol) in acetonitrile (50 mL) was cooled on an ice bath 
to 0°C. Formic acid in acetonitrile (1:1 mix, 10 mL, 133 mmol) along with hydrogen 
peroxide solution (30% w/w, 6 mL, 59.7 mmol) was added to the reaction and left 
to stir for 30 minutes. The reaction was monitored by TLC to ensure all starting 
material was converted. Rf = 0.65, 50% ethyl acetate to hexane. The reaction was 
quenched with water and washed with dichloromethane (3 x 50 mL). The organic 
layers were combined and the solvent was removed in vacuo to obtain 
intermediate 28. Under a nitrogen atmosphere, 28 was re-dissolved in anhydrous 
dichloromethane (50 mL). Adamantanone (29) (1.09 g, 7.23 mmol) in anhydrous 
dichloromethane (50 mL) was added to the stirring reaction containing 5. 
Rhenium(VII) oxide (70 mg, 144.58 µmol) was added to the reaction and left to stir 
for 30 minutes. The solvent was removed in vacuo and the crude product was 
purified via flash chromatography using 20% ethyl acetate in hexane to give the 
title compound 30 (470 mg, 37%) as a white solid; Rf = 0.85, 20% ethyl acetate to 
hexane; mp = lit8 60-62°C found 61-63°C 1H NMR (400 MHz, CDCl3) δ 4.12 (q, J = 7.1 
Hz, 2H), 2.23 (d, J = 6.7 Hz, 2H), 2.16 – 1.80 (m, 9H), 1.79 – 1.46 (m, 12H), 1.43 – 
1.17 (m, 2H) and 1.25 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.8, 110.6, 
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107.8, 60.4, 40.9, 37.1, 33.8, 33.3, 27.2 and 14.4; HRMS (ESI) calculated for C20H30O6 
[M+Na]+ 389.1940 found 389.1920. 
Preparation of dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo[3.3.1.13,7] 
decan]-4-ylacetic acid (31)8 
 
Potassium hydroxide (1.2 g, 21.46 mmol) was dissolved in a small amount of 
methanol and added to a stirring solution of 30 (1.43 g, 3.90 mmol) in methanol (50 
mL) and refluxed for 1 hour. The solution was allowed to cool to room temperature 
and concentrated under reduced pressure. The resulting residue was dissolved in 
water (50 mL) and worked up in dichloromethane (150 mL), dried over magnesium 
sulfate and the solvent was removed under vacuum to give the title compound 31 
(1.30 g, 98%) as a white solid; Rf = 0, 1:1 Ethyl acetate:hexane; mp = lit26 119-121°C 
found 166-170°C; 1H NMR (400 MHz, CDCl3) δ 2.34 – 2.24 (m, 2H), 2.20 – 1.47 (m, 
21H) and 1.44 – 1.23 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 178.9, 110.6, 107.7, 40.5, 
37.1, 33.6, 33.3 and 27.2; IR νmax (neat)/cm
-1 2930, 2907, 2858 and 1697; HRMS (ESI) 
calculated for C18H26O6 [M+Na]
+ 361.1627 found 361.1609; Microanalysis calculated 
for C18H26O6 requires C 63.89%, H 7.74%, found C 63.635%, H 7.65%.  
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General procedure 1 
To a dry flask, Compound 31 was dissolved in anhydrous dichloromethane (50 mL) 
and stirred under a nitrogen atmosphere prior to cooling to 0°C. Triethylamine (1.5 
equivalent) and methyl chloroformate (1.1 equivalent) was added to the reaction 
and left to stir at 0°C for 1 hour. The required amine (1 equivalent) was added to 
the reaction mixture and left to stir for 30 minutes at 0°C then at room temperature 
for a further 1 hour. The reaction mixture was washed with dichloromethane (3 x 
50 mL), water (50 mL), brine (50 mL) and dried over magnesium sulfate. The 
reaction was concentrated under reduced pressure and purified via flash column 
chromatography. 
 
  
Chapter 4 – Examination of the role of ferrous iron and phosphatidylcholine in the 
bioactivation of novel tetraoxane antimalarials 
205 
 
Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo 
[3.3.1.13,7]decan]-4-yl)-N-(4-fluorophenyl)acetamide (34) 
 
31 (200 mg, 0.6 mmol) was synthesised according to general procedure 1. 4-
Fluoroaniline (56 µL, 0.6 mmol) was used in the coupling step. 34 was purified via 
flash column chromatography using 5% ethyl acetate in dichloromethane to give 
the title compound 34 (201.7 mg, 79%) as a white solid; Rf = 1, 50% ethyl acetate to 
dichloromethane; mp = 162-163°C; 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.43 (m, 2H), 
7.15 (s, 1H), 7.01 (t, J = 8.6 Hz, 2H), 2.25 (d, J = 7.0 Hz, 2H), 2.17 – 1.49 (m, 21H) and 
1.33 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 170.2, 133.8 (d, J = 2.1 Hz), 121.8 (d, J = 
7.8 Hz), 115.8 (d, J = 22.5 Hz), 110.6, 107.8, 44.3, 37.1, 34.3, 33.30, 33.27, 27.20 and 
27.18; IR νmax (neat)/cm
-1 3292 (CONH), 3267 (CONH), 2920 (Ar-H), 2856 (CH), 
1655(C=C), 1543 (C=C) and 1508 (C=C); ERMS (ESI) calculated for C24H30FNO5 
[M+Na]+ 454.2006 found 454.1992; Microanalysis calculated for C24H30FNO5 
requires C 66.80%, H 7.01%, N 3.25%, found C 66.68%, H 7.05%, N 3.21%. 
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Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo 
[3.3.1.13,7]decan]-4-yl)-N-(4-fluorobenzyl)acetamide (35)2 
 
31 (203.4 mg, 601 µmol) was synthesised according to general procedure 1. 4-
Fluorobenzylamine (68.7 µL, 601 µmol) was used in the coupling step. 35 was 
purified via flash column chromatography using 3% ethyl acetate in 
dichloromethane to give the title compound 35 (189.6 mg, 71%) as a white solid: Rf 
= 0.78, 50% ethyl acetate in dichloromethane; mp = lit2 140°C found 150-152°C; 1H 
NMR (400 MHz, CDCl3) δ 7.36 – 7.20 (m, 2H), 7.16 – 6.98 (m, 2H), 5.70 (s, 1H), 4.41 
(d, J = 5.7 Hz, 2H), 2.11 (d, J = 7.1 Hz, 2H), 2.09 – 1.43 (m, 21H) and 1.25 (s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 171.8, 134.2 (d, J = 3.7 Hz), 129.6 (d, J = 8.1 Hz), 115.7 (d, J 
= 21.5 Hz), 110.6, 107.8, 43.5, 43.0, 37.1, 34.2, 33.3 and 27.2. IR νmax (neat)/cm
-1 
3242 (CONH), 2918 (Ar-H), 2856 (CH), 1631 (C=C), 1545 (C=C), 1510 (C=C) and 1225 
(CF); ERMS (ESI) calculated for C25H32FNO5 [M+Na]
+ 468.2162 found 468.2149; 
Microanalysis calculated for C25H32FNO5 requires C 67.40%, H 7.24%, N 3.14%, 
found C 67.68%, H 7.27%, N 3.16%. 
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Preparation of N-(4-chlorophenyl)-2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-
6',2''-tricyclo[3.3.1.13,7]decan]-4-yl)acetamide (36) 
 
31 (200 mg, 591.02 µmol) was synthesised according to general procedure 1. 4-
Chloroaniline (52.7 µL, 591.02 µmol) was used in the coupling step. 36 was purified 
via flash column chromatography using 5% ethyl acetate in dichloromethane to give 
the title compound 36 (107 mg, 40%) as a white solid: Rf = 0.95, 50% ethyl acetate 
in dichloromethane; mp = 169-171°C;  1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.8 Hz, 
2H), 7.28 (d, J = 8.8 Hz, 2H), 2.26 (d, J = 6.9 Hz, 2H), 2.11 – 1.46 (m, 21H) and 1.43 – 
1.23 (m, 3H);13C NMR (100 MHz, CDCl3) δ 170.2, 169.2, 136.4, 129.5, 129.2, 121.1, 
110.7, 107.8, 44.4, 37.1, 34.2, 33.3, 27.2 and 27.2; IR νmax (neat)/cm
-1 3232 (CONH), 
2931 (Ar-H), 2858 (CH), 1651 (C=C),  1543 (C=C), 1493 (C=C) and 825 (C-Cl); ERMS 
(ESI) calculated for C24H30ClNO5 [M+Na]
+ 470.1710 and 472.1681 found 470.1715 
and 472.1693; Microanalysis calculated for C24H30ClNO5 requires C 64.35%, H 6.75%, 
N 3.13%, found C 64.58 %, H 6.83%, N 3.01%. 
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Preparation of  N-(4-chlorobenzyl)-2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-
6',2''-tricyclo[3.3.1.13,7]decan]-4-yl)acetamide (37) 
 
31 (200 mg, 591.02 µmol) was synthesised according to general procedure 1. 4-
Chlorobenzylamine (71.9 µL, 591.02 µmol) was used in the coupling step. 37 was 
purified via flash column chromatography using 5% ethyl acetate in 
dichloromethane to give the title compound 37 (177.9 mg, 65%) as a white solid; Rf 
= 0.73, 50% ethyl acetate in dichloromethane; mp = 159-160°C; 1H NMR (400 MHz, 
CDCl3) δ 7.33 – 7.28 (m, 2H), 7.20 (d, J = 8.5 Hz, 2H), 4.41 (d, J = 5.8 Hz, 2H), 2.12 (d, 
J = 7.1 Hz, 2H), 2.07 – 1.43 (m, 21H) and 1.38 – 1.15 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 171.8, 137.0, 133.5, 129.3, 129.0, 110.6, 107.8, 43.4, 43.0, 37.1, 34.2, 33.3 
and 27.2; IR νmax (neat)/cm
-1 3278 (CONH), 2927 (Ar-H), 2862 (CH), 1643 (C=C), 1543 
(C=C), 1493 (C=C), and 825 (C-Cl); ERMS (ESI) calculated for C25H32ClNO5 [M+Na]
+ 
484.1867 found 484.1880; Microanalysis calculated for C25H32ClNO5 requires C 
65.00%, H 6.98%, N 3.03%, found C 64.60 %, H 6.92%, N 2.88%. 
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Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo 
[3.3.1.13,7]decan]-4-yl)-N-(4-(trifluoromethyl)phenyl)acetamide (38) 
 
31 (203.3 mg, 601 µmol) was synthesised according to general procedure 1. 4-
(Trifluoromethyl)aniline (75.5 µL, 601 µmol) was used in the coupling step. 38 was 
purified via flash column chromatography using 3% ethyl acetate in 
dichloromethane to give the title compound (203.3 mg, 70%) as a white solid: Rf = 
0.95, 50% ethyl acetate in dichloromethane; mp = 157-160°C; 1H NMR (400 MHz, 
CDCl3) δ 7.65 (d, J = 8.5 Hz, 2H), 7.58 (d, J = 8.7 Hz, 2H), 2.30 (d, J = 6.6 Hz, 2H), 2.20 
– 1.50 (m, 21H) and 1.34 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 170.8, 140.9, 126.4 (q, 
J = 3.5 Hz), 126.1, 123.8 (q, J = 271.8 Hz), 119.6, 110.7, 107.7, 44.4, 37.0, 34.2, 33.3, 
33.2 and 27.1; IR νmax (neat)/cm
-1 3359 (CONH), 3309 (CONH), 2920 (Ar-H), 2858 
(CH), 1664 (C=C), 1603 (C=C), 1531 (C=C), 1323 (CF), 748 (CF) and 613 (CF); ERMS 
(ESI) calculated for C25H30F3NO5 [M+Na]
+ 504.1974 found 504.1960. 
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Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo 
[3.3.1.13,7]decan]-4-yl)-N-(4-methoxyphenyl)acetamide (39) 
 
31 (203.3 mg, 599.6 µmol) was synthesised according to general procedure 1. 4-
Methoxyaniline (69 µL, 599.6 µmol) was used in the coupling step. 39 was purified 
via flash column chromatography using 3% ethyl acetate in dichloromethane to give 
the title compound 39 (170.9 mg, 64%) as a white solid: Rf = 0.83, 50% ethyl acetate 
in dichloromethane; mp = 174-175°C; 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.9 Hz, 
2H), 7.03 (s, 1H), 6.86 (d, J = 8.9 Hz, 2H), 3.79 (s, 3H), 2.24 (d, J = 6.9 Hz, 2H), 2.15 – 
1.47 (m, 21H) and 1.33 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 170.0, 156.6, 130.9, 
121.9, 114.3, 110.6, 107.8, 55.6, 44.3, 37.1, 34.3, 33.3 and 27.2; IR νmax (neat)/cm
-1 
3234 (CONH), 2914 (Ar-H), 2856 (CH), 1649 (C=C), 1543 (C=C), 1510 (C=C), 1246 (C-
O-C) and 1041 (C-O-C); ERMS (ESI) calculated for C25H33NO6 [M+Na]
+ 466.2206 
found 466.2215; Microanalysis calculated for C25H33NO6 requires C 67.70%, H 7.50%, 
N 3.16%, found C 67.50%, H 7.51%, N 3.12%. 
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Preparation of 2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-tricyclo 
[3.3.1.13,7]decan]-4-yl)-N-(4-(trifluoromethoxy)phenyl)acetamide (40) 
 
31 (250.2 mg, 739.37 µmol) was synthesised according to general procedure 1. 4-
(Trifluoromethoxy)aniline (99 µL, 739.37 µmol) was used in the coupling step. 40 
was purified via flash column chromatography using 5% ethyl acetate in 
dichloromethane to give the title compound 40 (237.5 mg, 65%) as a white solid: Rf 
= 0.85, 50% ethyl acetate in dichloromethane;  mp = 115-118°C; 1H NMR (400 MHz, 
CDCl3) δ 7.54 (d, J = 9.0 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 2.27 (d, J = 6.9 Hz, 2H), 2.12 
– 1.47 (m, 21H) and 1.42 – 1.17 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 170.3, 136.5, 
121.9, 121.1, 110.7, 107.7, 44.3, 37.1, 34.2, 33.3, 33.3, 27.2 and 27.2; IR νmax 
(neat)/cm-1 3308 (CONH), 2935 (Ar-H), 2860 (CH), 1658 (C=C), 1532 (C=C), 1509 
(C=C), 1273 (C-O-C), 1150 (CF) and 685 (CF); ERMS (ESI) calculated for C25H30F3NO6 
[M+Na]+ 520.1923 found 520.1934; Microanalysis calculated for C25H30F3NO6 
requires C 60.35%, H 6.08%, N 2.82%, found C 60.93 %, H 6.375%, N 2.405%. 
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Preparation of N-cyclohexyl-2-(dispiro[cyclohexane-1,3'-[1,2,4,5]tetroxane-6',2''-
tricyclo[3.3.1.13,7]decan]-4-yl)acetamide (41) 
 
31 (200 mg, 591.02 µmol) was synthesised according to general procedure 1. 
Cyclohexylamine (68 µL, 591.02 µmol) was used in the coupling step. 41 was 
purified via flash column chromatography using 5% ethyl acetate in 
dichloromethane to give the title compound 41 (185.8 mg, 75%) as a white solid: Rf 
= 0.78, 50% ethyl acetate in dichloromethane; mp = 174-176°C; 1H NMR (400 MHz, 
CDCl3) δ 5.31 (d, J = 8.0 Hz, 1H), 4.00 – 3.53 (m, 1H), 2.03 (d, J = 7.1 Hz, 2H) and 2.42 
– 1.03 (m, 30H); 13C NMR (100 MHz, CDCl3) δ 170.9, 110.6, 107.9, 48.2, 43.9, 37.1, 
34.3, 33.4, 33.3, 27.2, 25.6 and 25.0; IR νmax (neat)/cm
-1 3246 (CONH), 2925 (Ar-H) 
and 2854 (CH); ERMS (ESI) calculated for C24H37NO5 [M+Na]
+ 442.2569 found 
442.2565; Microanalysis calculated for C24H37NO5 requires C 68.71%, H 8.89%, N 
3.34%, found C 68.60%, H 8.92%, N 3.30%. 
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4.4.6 Determination of P. falciparum IC50 values 
This procedure is described in Antoine et al.27 
 
4.4.7 Degradation of unsymmetrical dispiro-1,2,4,5-tetraoxanes with 
iron(II) salts 
The tetraoxane that was used for the degradation experiments was 35 unless 
stated otherwise.  
Degradation procedure 1 
To a solution of the tetraoxane (200 mg) in anhydrous DCM (50 mL), anhydrous 
acetonitrile (10 mL) and iron(II) acetate (1.5 equivalent) was added. The reaction 
was left to stir under nitrogen at 35°C for 24 hours. The solvent was removed to 
give crude product. Purification via flash column chromatography using 10% ethyl 
acetate in dichloromethane to give the desired product. 
Degradation procedure 2 
To a solution of the tetraoxane (200 mg) in anhydrous THF (25 mL), Fe(OAc)2 (2 
equivalents) was added to the reaction and left to stir under nitrogen at room 
temperature for 24 hours. Water and DCM was added to the reaction. The organic 
layer was washed with water, brine and dried over magnesium sulfate. The solution 
was filtered and solvent removed to give crude product. Purification via flash 
column chromatography using 10% ethyl acetate in dichloromethane to give the 
desired product. 
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Degradation procedure 3 
To a solution of the tetraoxane (200 mg) in DMF (75 mL), iron(II) gluconate was 
added. The reaction was left to stir under nitrogen for 7-24 hours at room 
temperature. DMF was removed in vacuo and the crude product was extracted with 
dichloromethane (3 x 20 mL). The combined organic extracts were washed with 
brine, dried over magnesium sulfate, and concentrated in vacuo to give the crude 
product. Purification via flash column chromatography using 10% ethyl acetate in 
dichloromethane to give the desired product. 
Degradation procedure 4 
Tetraoxane (100 mg) was dissolved in a 1:1 mixture of acetonitrile:water (30 mL). 
Iron(II) sulphate heptahydrate (18 eq) was added to the mixture and left to stir 
under nitrogen for 24 hours. The solvent was removed and re-dissolved in ethyl 
acetate and DCM and dried over magnesium sulfate. The solution was filtered, 
solvent removed and purified via flash column chromatography using 10% ethyl 
acetate in dichloromethane. 
Preparation of 4-ethyl-6-((4-fluorobenzyl)amino)-6-oxohexanoic acid (42) 
 
Tetraoxane 35 (201.4 mg, 452 µmol) was used with degradation procedure 1, 2, 3 
and 4. An analytically pure sample was further purified using HPLC-UV to obtain the 
title compound 42 (56.4 mg) as a hydroscopic white solid; Rf = 0.05, 50% ethyl 
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acetate in dichloromethane; HPLC-UV retention time = 14.5 minutes; 1H NMR (400 
MHz, CD3OD) δ 7.35 – 7.25 (m, 2H), 7.08 – 6.98 (m, 2H), 4.34 (s, 2H), 2.23 (s, 2H), 
2.18 (d, J = 7.0 Hz, 2H), 1.90 – 1.79 (m, 1H), 1.67 – 1.54 (m, 2H), 1.41 – 1.26 (m, 3H) 
and 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, MD3OD) δ 198.7, 175.6, 163.5 (d, J = 
243.7 Hz), 136.2 (d, J = 3.1 Hz), 130.6 (d, J = 8.2 Hz), 116.1 (d, J = 21.6 Hz), 43.4, 41.4, 
37.8, 30.4, 27.0 and 11.0; IR νmax (neat)/cm
-1 3295 (CONH), 2923 (Ar-H), 2880 (CH), 
1685 (CONH), 1630 (C=C), 1545 (C=C), 1510 (C=C), 1218 (CF) and 677 (CF); ERMS 
(ESI) calculated for C15H20FNO3 [M+Na]
+ 304.1325 found 304.1319. 
Preparation of N-(4-fluorobenzyl)-2-(4-oxocyclohexyl)acetamide (44) 
 
Tetraoxane 35 (201.4 mg, 452 µmol) was used with degradation procedure 1, 2, 3 
and 4. An analytically pure sample was further purified using HPLC-UV to obtain the 
title compound 44 (61.2 mg) as a white solid; Rf = 0.28, 50% ethyl acetate in 
dichloromethane; HPLC-UV retention time = 15.8 minutes; mp = 149°C; 1H NMR 
(400 MHz, CDCl3) δ 7.31 – 7.20 (m, 2H), 7.07 – 6.97 (m, 2H), 5.89 (s, 1H), 4.42 (d, J = 
5.8 Hz, 2H), 2.45 – 2.31 (m, 5H), 2.20 (d, J = 7.1 Hz, 2H), 2.13 – 2.05 (m, 2H) and 1.51 
– 1.35 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 211.6, 171.5, 162.3 (d, J = 246.1 Hz), 
134.1 (d, J = 3.2 Hz), 129.6 (d, J = 8.0 Hz), 115.7 (d, J = 21.5 Hz), 43.1, 42.8, 40.8, 33.6 
and 32.7; IR νmax (neat)/cm
-1 3251 (CONH), 3074 (Ar-H), 2937 (CH), 1710 (C=O), 
1635 (C=C), 1559 (C=C), 1508 (C=C), 1218 (CF) and 747 (CF); ERMS (ESI) calculated 
for C15H18FNO2 [M+Na]
+ 286.1219 found 286.1216; 
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Preparation of  4-oxatricyclo[4.3.1.13,8]undecan-5-one (45) 
 
Degradation procedure 1 was used along with (diadamanetetraoxane) (204.3 mg, 
614.6 µmol) as the tetraoxane to give the title compound (45) (91 mg, 89%) as a 
white solid; Tetraoxane 35 was used in degradation procedures 2, 3 and 4 to give 
the title compound 45 as a white solid. Rf = 0.19, 50% ethyl acetate in 
dichloromethane; 1H NMR (400 MHz, CDCl3) δ 4.49 (s, 1H), 3.08 (s, 1H) and 2.20 – 
1.63 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 179.2, 73.3, 41.3, 35.9, 33.9, 31.0 and 
25.9; ; IR νmax (neat)/cm
-1 2919 (C-H), 2860, 1824 (C=O); MS (CI) C10H14O2 [M+NH4]
+ 
m/z 184.1. 
Preparation of 3-ethyl-N-(4-fluorobenzyl)-5-oxopentanamide (46) 
 
Tetraoxane 35 (201.4 mg, 452 µmol) was used with degradation procedure 1, 2, 3 
and 4. An analytically pure sample was further purified via column chromatography 
to obtain the title compound (20 mg) as a white solid; Rf = 0.5, 50% ethyl acetate in 
dichloromethane, stain yellow in p-anisaldehyde; 1H NMR (400 MHz, CDCl3) δ 9.77 
(t, J = 1.9 Hz, 1H), 7.28 – 7.22 (m, 2H), 7.03 – 6.95 (m, 2H), 5.07 (d, J = 14.8 Hz, 1H), 
4.95 – 4.90 (m, 1H), 4.25 (d, J = 14.8 Hz, 1H), 2.64 (ddd, J = 17.3, 4.7, 2.1 Hz, 1H), 
2.05 – 1.95 (m, 3H), 1.50 – 1.40 (m, 1H), 1.37 – 1.29 (m, 2H) and 0.92 (t, J = 7.4 Hz, 
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3H); 13C NMR (100 MHz, CDCl3) δ 202.2, 170.7, 162.3 (d, J = 245.6 Hz), 133.4 (d, J = 
3.1 Hz), 130.0 (d, J = 8.0 Hz), 115.6 (d, J = 21.4 Hz), 46.7, 38.8, 36.9, 28.8, 28.6 and 
11.0; ERMS (ESI) calculated for C14H18FNO2 [M+Na]
+ 274.1219 found 274.1227. 
4.4.8 Reactions of PC with tetraoxane and iron(II) salt 
A solution of 2-linoleoyl-1-palmitoyl-sn-glycero-phosphatidylcholine (PC) in water (1 
mL, 0.83 μmol) was added to an aqueous solution of iron(II) gluconate (1 mL, 7.2 
μmol) and tetraoxane 35 in ethanol (1 mL, 6.81 μmol). [Note: for the control sample, 
absolute ethanol (1 mL) was added]. Solutions were stirred for 24 hours at 38°C. 
Reactions were quenched with 50% phatic acid (20 μL) and 1 µL of butylated 
hydroxytoluene was added. The reaction was extracted in chloroform:methanol 
mixture (1:2, 2 mL) and the chloroform layer was analysed using electrospray 
ionisation mass spectra analysis. The organic layer was concentrated under reduced 
pressure and LCMS analysis was performed to obtain degradation data. 
4.4.8.1 LCMS analysis 
Aliquots of the solutions (10-20 L) were chromatographed at room temperature 
on an Agilent 5-m ZORBAX Eclipse XDB-C18 column (150  4.6 mm i.d.; Agilent 
Technologies, Santa Clara, CA, USA) by gradient elution with acetonitrile (20-60% 
over 15 min; 60% for 10 min) in 0.1% formic acid (v/v). The eluent flow rate was 1.0 
mL/min. Full-scanning positive-ion spectra were acquired with an AB Sciex 2000 
mass spectrometer.   
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5.1 Introduction 
Drug target identification and validation can be complicated due to the vast 
number of potential targets within a complex biological system. As discussed in 
detail in Chapter 1, the physical binding of a drug to a relevant protein responsible 
for the pharmacological response is the perfect scenario during target identification 
and validation. However, obtaining such proof can be a challenge as detection of a 
drug target interaction generally requires high abundance of the target protein and 
a high affinity between the drug and the target.1,2 For compounds and targets that 
do not meet these criteria, alternative methods are required, such as manipulation 
of the biological systems (i.e. increasing/decreasing the expression of a gene 
resulting in a phenotypic change),2 chemical modification of the drug to enhance 
selectivity (increasing affinity towards a specific protein)3 and labelling of potential 
proteins.4  
The design and synthesis of chemical probes provides a unique tool for 
interrogating biological mechanisms. Such chemical probes are generally bespoke 
and consists of three elements.4 
i. The parent drug containing the pharmacophore or warhead 
ii. A tag which enables detection or purification 
iii. A linker connecting the parent drug with the tag 
The purification of probe-protein complexes enables the use of proteomic 
strategies to identify potential drug targets (Figure 5.1). 
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Warhead Linker Tag 
Electrophile Peptide Biotin 
Pharmacophore Alkyl Fluorophore 
 Cleavable Radioisotope 
Figure 5.1: The three key elements of a chemical probe.4 
5.1.1 Biotin tag 
The biotin tag is commonly used in the synthesis of chemical probes. The 
interaction between avidin/streptavidin and biotin is the strongest biological non-
covalent interaction known.5 The ability to form a fast and stable interaction 
between biotin and avidin/streptavidin over a range of temperatures and pH has 
enabled the identification of the biological targets of numerous compounds that 
was previously difficult with traditional techniques.5  
An example of this kind of probe is the serine hydrolase probe FP-Biotin6 and the 
cysteine protease probe DCG-04.7 The mechanism of FP-Biotin involves the 
substitution of fluorine located on the phosphorous in FP-Biotin with the hydroxyl 
group located on serine. The DCG-04 probe contains an epoxide, which upon 
electrophilic attack by cysteine forms an irreversible interaction. Biotin 
avidin/streptavidin pull-down allows for the purification of the target protein. The 
mechanism of action is shown in Figure 5.2. 
 
 
Chapter 5 – Design and synthesis of click functionalised derivatives of artemisinin 
and CDDO as probes for investigating chemical mechanism of action 
 
226 
 
 
Figure 5.2: The chemical structures and mechanism of action of the serine 
protease probe FP-Biotin and cysteine protease probe DCG-04.6,7 
There are many other examples of biotinylated probes (BP) for investigating 
molecular targets including a wide range of probes dedicated to protease 
inhibitors.4,8 The majority of these probes require an irreversible mechanism which 
limits the approach somewhat, as most drugs operate through a reversible 
interaction as described in detail in Chapter 1.6,8 However, there are examples 
where BPs have been used to characterise protein interactions that are reversible. 
An example of a reversible BPs is the potent inhibitor of γ-secretase, L-685,485., 
which has been shown to mimic the transition state of the aspartate protease 
catalytic process. This discovery was facilitated through the use of a biotinylated 
derivative of L-685,485 (Figure 5.3).8 Another example is the biotinylated CBS9106 
probe that is found to inhibit CRM1. CRM1 is responsible for the nuclear export of 
cargo proteins. The inhibition of CRM1 results in the arrest of cell cycle and 
induction of apoptosis (Figure 5.3).9  
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Figure 5.3: Chemical structures for reversible CBS9106 and L-685,458 and their 
biotin functionalised counterparts.8,9 
Reversible BPs provide an ideal tool for isolating and identifying drug targets as they 
mimic natural binding interactions with the molecular target. However, due to their 
reversible nature, the successful pull down of molecular target(s) is often difficult. 
This is due to stringent washing during purification which result in the disruption of 
the equilibrium between the molecular target and the BP.3 A solution to this 
problem is the use of photoaffinity labelling.  
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5.1.2 Photoaffinity labelling 
Photoaffinity labelling (PAL) involves the use of a photoreactive group and upon 
irradiation, a highly reactive intermediate is formed which is capable of covalently 
binding with the nearest fragment of a biomolecule.10 PAL was first introduced in 
the 1960s and development of different photophores has resulted in three types of 
photoreactive classes that are regularly incorporated in PAL probes. These are 
benzophenones, arylazides and diazirines (Figure 5.4).10,11 
 
Figure 5.4: Chemical structure of common photoreactive groups; benzophenones, 
arylazides and diazirines. 
Despite the use of a photoreactive tag, the probe still requires a purification tag  
such as biotin or reporter group (fluorescent, radioactive, chromophore or immune) 
to enable detection and measurement of the molecular target.10 An example of this 
is the use of the matrix metalloproteinase (MMP) inhibitor, ilomastat (Figure 5.5). 
The MMPs are zinc-dependent proteases and are known to play important roles in 
a number of pathological processes.8,11  Ilomastat is a broad reversible inhibitor of 
MMPs.12 Due to the reversibility of ilomastat, analysis of the MMP family was 
inaccessible. The PAL derivative of ilomastat (Figure 5.5) enabled the covalent 
binding, purification and identification of the MMPs. This allowed the use of 
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standard genomic and proteomic methods to identify and analyse the MMP family. 
The mechanism of the photoaffinity tag is shown in Figure 5.5B 
 
 
Figure 5.5: (A) Chemical structure of Ilomastat and the photoaffinity derivative of 
Ilomastat (Ilomastat-PAL). (B) The mechanism of metallohydrolase labelling with 
Ilomastat-PAL. 
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5.1.3 Synthesised tagged probes 
The artemisinin semi synthetic derivatives (artemether 49 and artesunate 50) are 
considered to be the forefront of malaria chemotherapy.13 CDDO derivatives (CDDO 
8, CDDO-Me 7 and CDDO-Im 51) are some of the most potent inducers of Nrf2 and 
exhibit a wide range of properties including anti-inflammatory and anti-cancer 
activity.14 
 
Figure 5.6: Chemical structures of artemether, artesunate, CDDO, CDDO-Me and 
CDDO-Im 
Studies of the chemical mechanism of action of artemisinin endoperoxides and the 
CDDO class have highlighted the important pharmacophores such as the free 
radical chemistry of endoperoxides15 and the reversible 1,4 conjugate addition of 
the α,β unsaturated ketone in CDDO.16 However, little is known about the biological 
target(s) of these compounds and the mechanisms responsible for their therapeutic 
effects. Attempts to formally identify the target proteins through a proteomic 
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approach have led to the synthesis of biotin tagged probes. Biotin tagged 
artemisinin 52, fluorescently tagged artemisinin 53 and biotinylated CDDO 
derivatives 54 were synthesised by O’Neill et al13,17 and Honda et al18 respectively.  
 
Figure 5.7: Chemical structures of the artemisinin biotin probe, artemisinin 
fluorescent probe and CDDO-Me biotin probe. 
Biotylated CDDO derivatives have been shown to interact directly with Cys-179 of 
the inhibitor of nuclear factor kappa B kinase (IKKβ), which is responsible for the 
activation of the pro-inflammatory transcription factor, nuclear factor kappa B (NF-
κB).19 CDDO-Me-Biotin was incubated with wild type (WT-IKKβ) recombinant-IKKβ 
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and IKKβ with a Cys-179 mutation (C179A-IKKβ). Analysis using SDS-PAGE and a 
streptavidin peroxidase reporter demonstrated labelling of WT-IKKβ, but not 
C179A-IKKβ by CDDO-Me-Biotin that was consistent with the ability of the probe to 
inhibit NF-κB.19 CDDO-Me-Biotin were also use to determine the interaction with 
Cys-1077 of Janus-activated kinase-1 (JAK1) and Cys-259 of signal transducer and 
activator of transcription 3 (STAT3), which regulate apoptosis and cell cycle 
progression.20 Determining the interaction with JAK1 and STAT3 required the use of 
pull down purification with streptavidin-beads followed by immunoblotting. The 
chemical interaction with these and other targets may explain the 
pharmacodynamics effects of CDDO and its analogues. However, such an approach 
has failed to identify compounds of the Keap1-Nrf2 pathway as direct targets of this 
compound class, despite their potency as inducers of Nrf2. 
Fluorescently tagged artemisinin containing an acridine moiety conjugated to the 
artemisinin framework through a C-10 ether link has demonstrated that artemisinin 
can covalently bind within the malaria parasite.17,21 However, direct formal 
identification of the target site(s) has yet to be performed and therefore further 
investigation is required. 
The successful identification of potential target proteins with biotinylated probes is 
important for interrogating biological mechanisms. However there are many 
disadvantages to using biotin tags within probes. For example, detection of 
potential targets maybe hindered due to the steric bulk of the linker and biotin tag. 
Cell permeability of the probe could also be affected due to the increase in 
molecular size.  
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It is often assumed that direct interaction with a single target is responsible for the 
pharmacological effects of a molecule. Consideration of off-target protein 
interaction is also important in the safe development of drugs and due to the harsh 
conditions required to disrupt the biotin-streptavidin bond, these off-target 
proteins could be missed with conventional proteomic approaches.2,4  
Activity based protein profiling (ABPP) was developed and applied by the Cravatt 
group.22 This method involves the functionalization of small molecules with alkyne 
or azide instead of bulky acridine and biotin. (Scheme 5.1) The alkyne and 
counterpart azide probes rely on copper (I) catalysed cycloaddition that was initially 
developed by Sharpless et al and is well known as “click chemistry”.23 This click 
chemistry was adapted from the Huisgen 1,3-dipolar cycloaddition which required 
elevated temperatures to overcome the activation energy required for the 
formation of triazoles.24 Sharpless et al25 and Meldal et al26 developed the click 
chemistry by introduction of a copper(I) catalyst. This enabled the reaction to 
proceed selectively giving the 1,4 substituted [1,2,3]-triazole at ambient 
temperatures due to lowering of the activation barrier when copper(I) is used as a 
catalyst.24 The utilisation of such groups overcomes the disadvantages of the bulky 
biotin/streptavidin and fluorescent tags. The chemical mechanism of the click 
reaction is shown in Scheme 5.1. 
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Scheme 5.1: Chemical structure of alkyne and azide with the chemical mechanism 
of action for copper (I) catalysed click reaction 
In the absence of copper(I), no reaction is observed as demonstrated by Meldal et 
al.26 Copper(I) has undesirable toxic side effects at low concentrations.27 Therefore, 
for this click chemistry to be useful for in vitro and in vivo applications, the 
development of a copper-free reaction is therefore advantageous.27 Bertozzi et al 
developed a substituted cyclooctyne that possess electron withdrawing fluorine 
substituents together with a strained alkyne group to promote cycloaddition.28 
Since then a range of copper-free reagents has been developed including 4-
dibenzocyclooctynol (DIBO),  dibenzocyclooctyne group (DBCO) and difluorinated 
cyclooctyne (DIFO) (Figure 5.8).27,28 
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Figure 5.8: Chemical structures for copper-free click probes, 4-
dibenzocyclooctynol (DIBO), dibenzocyclooctyne group (DBCO) and difluorinated 
cyclooctyne (DIFO). 
Applying the click chemistry technique requires the bespoke synthesis of the drug 
containing the alkyne (or azide) functional group and treatment of cells to label the 
target protein(s). The complementary part to the click functionalised drug is also 
known as the reporter tag. The reporter tag can contain a fluorescent group that 
allows for analysis of tagged proteins or a biotin group which enables protein 
enrichment by streptavidin pull down and mass spectral analysis. This is shown in 
Figure 5.9. 
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Figure 5.9: The ABPP method for analysis of drug target interactions via 
fluorescent detection or MS/MS detection.2-4,29 
5.1.4 Aims 
The aims of this chapter are to design and synthesize novel reversible and 
irreversible functionalised probes for the artemisinin and CDDO class of compounds 
that are also pharmacologically active within their relevant contexts. These probes 
could be used to identify protein targets and perhaps resolve mechanisms of action. 
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5.2 Results and discussion 
5.2.1 The chemical synthesis of artemisinin click probes 
In order to link the click tag to the artemisinin moiety, an N-amide link was utilised. 
Chemical modification at the C-10 position within artemisinin to produce the amide 
link would provide metabolic stability compared with the C-10-ether link. Previous 
studies have demonstrated that cytochrome P450 converts the ether link back to 
dihydroartemisinin (55, DHA).30 
 
Figure 5.10: Chemical structure of dihydroartemisinin 
The generation of artemisinin click probes involves a 5 step synthesis from 
commercially available semi-synthetic DHA (55). (Scheme 5.2). 
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Scheme 5.2: Reagents and conditions: (i) BzCl (1.6 equiv), pyridine (6.5 equiv), 
DCM, 0°C, 16 hours, 94%; (ii) allyltrimethylsilane (5 equiv), ZnCl2 (1.5 equiv), 4 Å 
molecular sieves, 1,2-dichloroethane, 0°C, 3 hours, 38%; (iii) O3, methanol, -78°C, 1 
hour; (iv) PPh3 (2 equiv), -78°C to r.t., overnight, 60%; (v) NaH2PO4 (0.26 equiv), 
NaClO2 (1.95 equiv), 2-methyl-2-butene [2.0M in THF] (11.7 equiv), t-BuOH:H2O 
[5:1 ratio], r.t. 2 hours, 100%; (vi) EDCI (3 equiv), DMAP (5 equiv), alkyne or azide 
amine (3 equiv), DCM, r.t. overnight, 81%; 
The first step involves the acylation of dihydroartemisinin (55) with benzoyl chloride 
in DCM and pyridine to produce dihydroartemisinin 10α-benzoate (56a) with a yield 
of 94%. 56a is selectively formed under these conditions due the geometry of the 
10 position. Studies by Haynes et al have revealed that the 10-α 
diastereoisomer  (56a) is in the equatorial position while the 10-β diastereoisomer 
(56b) is in the axial position resulting in 1,3 diaxial interaction with the C-8, thus, 
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the steric effect raises the energy of the transition state for an acylation reaction to 
occur.31 This is shown in Figure 5.11 
  
 
Figure 5.11: (A) The 10-α diastereoisomer in the equatorial position. (B) The 10-β 
diastereoisomer in the axial position and the highlighted 1,3 diaxial steric 
interaction between C-10 and C-8. 
The synthesis of 57a involves 56a reacting with allyltrimethylsilane and zinc chloride 
as catalyst, selectively yielding 10β-allyldeoxoartemisinin (57a) in 47%. 10α-
allyldeoxoartemisinin 57b is not formed due to the orientation of the oxonium 
intermediate 60 resulting in the axial attack of the allyltrimethylsilane as depicted in 
Scheme 5.3. During the synthesis of 57a, a small amount of anhydroartemisinin 61 
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was formed making purification difficult due to similar Rf values. HPLC was required 
to obtain 57a. This was also reported in O’Neill et al.32  
 
Scheme 5.3: Chemical mechanism for Lewis acid catalysed reaction with 
allyltrimethylsilane via the oxonium ion intermediate. Chemical structures for 10α-
allyldeoxoartemisinin 57b and the anhydroartemisinin 61. 
Ozonolysis of the 57a followed by reduction with triphenylphosphine afforded 58 in 
60% yield. The mechanism for the ozonolysis reaction is shown in Figure 5.7. 
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Scheme 5.4: Chemical mechanism for ozonolysis of 57a to give the aldehyde 58 
Pinnick oxidation of 58 yielded carboxylic acid 59. The mechanism is shown in 
Scheme 5.5. 
 
Scheme 5.5: Chemical mechanism for Pinnick oxidation of 58 to give 59 
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The coupling of the alkyne or azide click tag to the artemisinin moiety required the 
use of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) 
commonly used for the formation of amide bonds. EDCI is a water soluble 
carbodiimide and does not require activation prior to use. The alkyne amine 62 was 
selected for coupling with the artemisinin moiety forming 63. The mechanism is 
depicted in Scheme 5.6 where the formation of the urea 64 is a by produce of EDCI. 
 
Scheme 5.6: Chemical mechanism for amide coupling with EDCI between 62 and 
59 
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In addition to the alkyne artemisinin click probe 63, a control is required to ensure 
activity and any substituent pull down experiments are not due to the presence of 
the alkyne side chain. In order to achieve this, the endoperoxide bridge is reduced 
to produce deoxyartemisinin. This is obtained in four steps from 59. 
 
Scheme 5.7: Reagents and conditions: (i) EDCI (3 equiv), DMAP (5 equiv), DCM, 
EtOH (3 equiv), r.t. overnight, 44%; (ii) Zn dust (3 x 1.5 equiv at 24 hour intervals), 
acetic acid, r.t., 72h, 38%; (iii) NaOH (15% w/v), EtOH, 3 hours, r.t., 80%; (iv) EDCI 
(3 equiv), DMAP (5 equiv), propargylamine (3 equiv), DCM, r.t. overnight, 34%. 
Prior to reduction of the endoperoxide within 59, protection of the carboxylic acid 
is required. This was achieved by using EDCI, 4-dimethylaminopyridine (DMAP) and 
ethanol to obtain the ethyl ester artemisinin 65 in 44% yield. 65 in acetic acid 
followed by addition of zinc dust over 72 hour yielding 66 in 38%. The endoperoxide 
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is reduced due to the oxophilic nature of zinc. A pair of electrons from zinc is 
donated to the endoperoxide which is cleaved and a bidentate species (69) is 
formed. Rearrangement of 69 to give the intermediate (70) enables the liberation 
of ZnO. The resulting ZnO dissolves in the acetic acid to give Zn(OAc)2 and yielding 
deoxyartemisinin (66). This is shown in Scheme 5.8 
 
Scheme 5.8: The chemical mechanism of action for the formation of 
deoxyartemisinin. Zinc donates a pair of electrons into the endoperoxide forming a 
bidenate species 69. This rearranges to give 70 and elimination of ZnO gives the 
desired product 66. 
Deprotection of the carboxylic acid with sodium hydroxide yields 67 in 80%. 
Coupling of proparglyamine with EDCI as described earlier yielded the alkyne 
deoxyartemisinin 68 in 34% yield. 
The two artemisinin click probes obtained from the synthesis described above were 
submitted to the Liverpool School of Tropical Medicine to test their ability to inhibit 
the proliferation of Plasmodium falciparum 3D7 (chloroquine sensitive) strain in 
vitro. This data is shown in Figure 5.12 
 
 
Chapter 5 – Design and synthesis of click functionalised derivatives of artemisinin 
and CDDO as probes for investigating chemical mechanism of action 
 
245 
 
 
Figure 5.12: Artemisinin, DHA (55), artemisinin click probes 63 and 68 and the 
concentration that provoke a 50% inhibition (IC50) of the proliferation 
of Plasmodium falciparum 3D7 strain in vitro 
The artemisinin click probe 63 was active against 3D7 strain of P. falciparum giving 
an IC50 of 31.0 ± 3.8 nM. As expected, the deoxyartemisinin click probe 68 was 
inactive. Comparing 63 to artemisinin and DHA, the click probe is 1.5 times less 
active than artemisinin and 10 times less active than DHA. These data indicate that 
the novel click probes are suitable for proteomic studies and further emphasises 
the importance of the endoperoxide functional group to maintain the antimalarial 
activity of artemisinins.  
5.2.1.1 Preliminary parasite protein identification with artemisinin click probes 
The artemisinin click probes 68 and 63 were used by colleagues at the Liverpool 
School of Tropical Medicine to identify parasite target proteins. The technique used 
is based on a fully automated LC-MS/MS–based protocol known as the 
multidimensional protein Identification Technology (MudPIT).33 Following LC-
MS/MS analysis of samples prepared for P. falciparum exposed in vitro to 68 or 63 
for 1-24 hours, Mascot search algorithms were used to match peptides to proteins 
based on sequence coverage. Semi quantification using exponentially modified 
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protein abundance index (emPAI) allowed approximate relative quantification of 
proteins in a mixture.34 The preliminary data has so far identified a number of 
candidate target proteins including ornithine δ-aminotransferase (OAT), L-lactate 
dehydrogenase, enolase and V-type proton ATPase catalytic subunit, which are 
redox-active proteins that play a crucial role in the maintenance and control of 
redox reactions. An example of this is the thioredoxin-mediated control of OAT 
activity for coordinating ornithine homeostasis, polyamine synthesis, proline 
synthesis, and mitotic cell division in rapidly growing cells. This pathway also has 
links to the suggested non-heme mediated mechanism proposed by Haynes et al.35 
As described in more detail in Chapter 4, Haynes et al suggested that the FADH2 and 
FAD pathway is involved in the non-heme mediated cleavage of the endoperoxide 
bridge and is also linked to the thioredoxin pathway. Despite this being preliminary 
data, the artemisinin click probes have identified several potential Plasmodia 
molecular targets. Of those identified the interacting patterns of the thioredoxin 
pathway represents potential targets for chemotherapeutic intervention, given that 
existing antimalarial drugs do not specifically target this pathway. 
Further work is underway within the group to complete the characterisation of the 
plasmodia molecular targets of the artemisinins, tetraoxanes and trioxolanes.  It will 
be important to determine if the classes of endoperoxide have common and/or 
unique molecular targets, which may become promising targets for next-generation 
antimalarial drugs. Further work will also involve artemisinin resistant parasites and 
mammalian cells to define the level of selectivity and potential to interact with the 
appropriate mammalian-falciparum counterparts, in order to better understand the 
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risk:benefit of the use of these drugs in humans, and to determine the potential for 
enhancing pharmacological efficacy whist minimising off-target toxicity to the host. 
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5.2.2 The chemical synthesis of CDDO and DDO click probes. 
As described in Chapter 3, irreversible probes are important tools as they enable 
the use of traditional techniques for determining molecular targets where previous 
attempts with the original compound have failed. The concept of irreversible 
probes was adopted and this resulted in the design and synthesis of DDO-Me and 
CDDO-Epoxide. Both of these probes were active as inducers of the Nrf2 sensitive 
luciferase reporter assay. As discussed earlier, biotinylated CDDO derivatives have 
been used to identify three molecular targets that contain cysteine residues, IKKβ at 
Cys-179, JAK1 at Cys-1077 and STAT3 at Cys-259. Despite this discovery, direct 
evidence for interaction with components of the Keap1-Nrf2 pathway has yet to be 
produced. In order to investigate further the mechanism of action of CDDO 
derivatives as inducers of Nrf2, click tagged probes were targeted. 
The synthesis of CDDO click probes required the formation of a carboxylic acid 
group followed by the amine coupling reaction used earlier for the formation of the 
artemisinin click probes. This involved a further two steps for the formation of DDO 
click derivative and one step from CDDO as shown in Scheme 5.9. 
The synthesis of 71 required the use of 8 which was synthesised in Chapter 2 and 
the EDCI coupling reaction with propargyl amine giving 71 in 33% yield. Synthesis of 
21 was described in Chapter 3 and is used to form the carboxylic acid 72 in 64% 
yield. Lithium iodide was used to form 72 as described in Chapter 2 for the 
formation of 8. EDCI coupling reaction with propargyl amine and 72 gave 73 in 40% 
yield. Formation of 74 required the synthesis of the azide amine. This involved a 
two-step synthesis from 1,4-dibromobutane 75 where the first step involved the 
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use of sodium azide in DMF to form 1,4-diazidobutane 76 in 100%.  Reduction of 76 
using triphenylphosphine gave 4-azidobutane-1-amine 77 in 95% yield. EDCI 
coupling reaction between 77 and 72 gave 74 in 38% yield. 
 
Scheme 5.9: Reagents and conditions: (i) EDCI (3 equiv), DMAP (5 equiv), click 
amine (3 equiv), DCM, r.t. overnight; (ii) ) LiI (19 equiv), anhydrous DMF, N2 (g), 
reflux, overnight, 22%. 
 
Scheme 5.10: Reagents and conditions: (i) DMF, NaN3 (2.1 equiv) H2O, 80°C, 20 
hours, 100%; (ii) EtOAc:Et2O (1:1), PPh3 (1 equiv), HCl (1 M), 0°C to r.t., overnight, 
90% 
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The ability of 71, 73 and 74 to induce Nrf2 signalling was determined using the Nrf2 
sensitive luciferase reporter assay used in previous chapters. The data is shown in 
Table 5.1 and Graph 5.1 
Compound Structure 
Concentration that 
induces Nrf2 reporter to 
200% (EC200) 
CDDO-Me (7) 
 
0.62 nM ± 0.02 
DDO-Me (21) 
 
0.90 µM ± 0.08 
71 
 
2.76 nM ± 0.67 
73 
 
0.73 µM ± 0.05 
74 
 
1.01 µM ± 0.05 
Table 5.1: Relative potencies of CDDO-Me, DDO-Me, 71, 73 and 74 as inducers of 
an Nrf2 regulated luciferase reporter transgene in H4IIE-ARE cells. 
Similar to the potent compound CDDO-Me, 71 is a potent inducer of Nrf2. 
Furthermore, compounds 73 and 74 are comparable to DDO-Me. This data shows 
that in comparison of alkyne and azide groups into the CDDO and DDO scaffolds 
does not impact on pharmacological potency; therefore, these novel probes are 
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suitable for determining the molecular target(s) of the CDDO class and determining 
mechanisms of action. 
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5.2.3 Click reaction proof of concept. 
As described earlier in this chapter, biotin tagged probes are a useful tool for the 
investigation of biological processes. However, the use of such probes comes 
disadvantages including steric bulk, altered cell permeability and harsh conditions 
required to disrupt the biotin-streptavidin interaction during purification. This has 
resulted in the synthesis of click tagged derivatives of irreversible CDDO probes. In 
order to determine if the click probes are viable tools for in vitro and eventually in 
vivo experiments, it is necessary to demonstrate their ability to undergo the click 
reaction with a relevant counterpart. Towards this goal, a counterpart was 
synthesised for 74. This involved a one-step synthesis between propargyl bromide 
(78) and benzyl alcohol (79) with the addition of sodium hydride to form benzyl 
propargyl ether (80) in 74% yield. This is shown in Scheme 5.11.  
 
Scheme 5.11: Reagents and conditions: (i) benzyl alcohol, THF, 0°C, NaH (1 equiv), 
30 mins, (ii) propargyl bromide added dropwise, warm to r.t., stir 1 hour, 78%. 
The click reaction between 74 and 80 was performed in a dichloromethane water 
solution in the presence of sodium ascorbate and copper (II) sulphate catalyst to 
obtain 81 in 40% yield. This demonstrates that the click reaction can occur between 
the synthesised CDDO click probes and a counterpart, providing proof-of-concept 
that such probes can be used in a biological context to enable purification and 
identification of drug targets. 
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Scheme 5.12: Reagents and conditions: (i) DCM:H2O (1:1), CuSO4.5H2O (5%), 
sodium ascorbate (15%), r.t., 2 hours, 40%. 
5.3 Conclusion 
The work described here resulted in the synthesis of five novel click functionalised 
probes, two in the artemisinin series and three in the CDDO series. The artemisinin 
click probes have demonstrated acceptable antimalarial activity against P. 
falciparum 3D7 strain while the CDDO click probes demonstrated similar activity as 
inducers of the Nrf2-regulated luciferase reporter compared to their parent 
compounds. The reaction between synthesised click probe 74 and the simple click 
tag counterpart 80 has demonstrated that these novel compounds are capable of 
forming the resulting triazole, enabling their use for pull down purification and 
target identification and verification. 
Future work will include synthesising the click tagged CDDO-Epoxide and the azide 
tagged artemisinin. Lengthening the linker between the drug and click tag will aid in 
developing an SAR profile between the linker length. This SAR profile will provide 
information on drug activity vs pull-down purification. This data will enable the 
selection of the most viable probe for ABPP testing and eventually enable the full 
characterisation of the target proteins in both in vitro and ultimately, in vivo 
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context. Therefore, the click probes described here will inform the design and 
development of safe and efficacious new drugs. Specifically for CDDO-Me, the 
reversibility of a click-functionalised probe may be an issue. Photoaffinity 
functionalised probes can be produced to overcome the reversibility issue, as 
described in detail earlier in this chapter. Such a strategy will further ensure that all 
potential drug targets can be characterised and identified, thus informing the 
design and development of next-generation drug candidates. 
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5.4 Chemistry experimental 
5.4.1 General 
See sections 2.4.1 
5.4.2 Purification of solvents and reagents 
See sections 3.4.2 
5.4.2.1 Stains 
See sections 3.4.2.1 
5.4.3 Purification of products 
See sections 2.4.4 
5.4.4 Analysis 
See sections 2.4.5 
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5.4.5 Numbering 
Oleanolic acid 
 
Artemisinin 
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5.4.6 General procedure. 
General procedure 1 
Acid (8, 59, 67 or 72) was dissolved in DCM (50 mL) and N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDCI) (3 equivalents) was added to the 
reaction and left to stir at room temperature for 5 minutes. 4-
(dimethylamino)pyridine (DMAP) (5 equivalents) and amine or alcohol was added 
to the reaction and left to stir at room temperature overnight. The reaction mixture 
was diluted with ethyl aceate (50 mL) and washed with ammonium chloride 
solution, water, brine, dried over magnesium sulfate and filtered. The solvent was 
removed to give crude product and purified by flash chromatography. 
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5.4.7 Synthesis artemisinin click probes 
Preparation of dihydroartemisinin 10α-benzoate (56a)36,37 
 
Dihydroartemisinin (2.05 g, 7.21 mmol) was dissolved in anhydrous DCM (50 mL) in 
a nitrogen atmosphere and cooled to 0°C. pyridine (3.77 mL, 46.86 mmol) and 
benzoyl chloride (1.34 mL, 11.54 mmol) were added to the reaction and left to stir 
for 16 hours. Citric acid (7% w/v) was added to the reaction and the reaction 
mixture was extracted with ethyl acetate (3 X 100 mL). Combined organic layers 
were washed with citric acid (7% w/v), saturated sodium hydrogen carbonate, 
water, brine, dried over magnesium sulfate and filtered. The solution was 
concentrated under reduced pressure to give crude product in which purification by 
flash chromatography using 30% ethyl acetate in hexane to give title compound 56a 
(2.62 g, 94%) as a white solid; Rf = 0.51, 30% ethyl acetate in hexane; mp = lit
37 115-
118°C found 119-120°C;  1H NMR (400 MHz, CDCl3) δ 8.13 (dd, J = 8.2, 1.1 Hz, 2H), 
7.64 – 7.54 (m, 1H), 7.50 – 7.41 (m, 2H), 6.02 (d, J = 9.8 Hz, 1H), 5.53 (s, 1H), 2.76 
(dqd, J = 14.2, 7.1, 4.7 Hz, 1H), 2.39 (ddd, J = 14.4, 13.6, 4.0 Hz, 1H), 2.10 – 1.99 (m, 
1H), 1.96 – 1.87 (m, 1H), 1.83 (ddd, J = 13.3, 7.5, 3.5 Hz, 1H), 1.75 (ddd, J = 14.2, 6.8, 
3.6 Hz, 1H), 1.69 (dt, J = 13.7, 4.5 Hz, 1H), 1.61 – 1.44 (m, 2H), 1.43 (s, 3H), 1.42 – 
1.28 (m, 2H), 1.10 – 1.01 (m, 1H), 0.99 (d, J = 6.1 Hz, 3H) and 0.93 (d, J = 7.1 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 165.5, 133.4, 130.3, 129.8, 128.4, 104.6, 92.7, 91.7, 
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80.3, 51.8, 45.5, 37.4, 36.4, 34.3, 32.1, 26.1, 24.7, 22.2, 20.4 and 12.4; IR νmax 
(neat)/cm-1 2928 (Ar-H), 2876 (CH), 1736 (C=O) and 1018 (C-O-C); HRMS (ESI) 
calculated for C22H28O6 [M+Na]
+ 411.1784 found 411.1794; Microanalysis Calculated 
for C22H28O6 requires C 68.02%, H 7.27%, found C 67.93%, H 7.31%. 
Preparation of 10β-allyldeoxoartemisinin (57a)32 
 
56a (3.21 g, 8.26 mmol) was dissolved in anhydrous DCM (50 mL) under a nitrogen 
atmosphere. Zinc chloride (1.69 g, 12.40 mmol) and 4 Å molecular sieves (2 mg) 
were added to a dry flask and introduced anhydrous DCM under a nitrogen 
atmosphere. The reaction mixture was cooled to 0°C and allyltrimethylsilane (6.57 
mL, 41.32 mmol) was added to the zinc chloride solution. The solution of 56a was 
added slowly to the solution of allyltrimethylsilane and left to stir for 3 hours at 0°C. 
The reaction was concentrated under reduced pressure to give the crude product in 
which purification by flash chromatography using 10% ethyl acetate in hexane to 
give the title compound 57a (971.5 mg, 38%) as a white solid; Rf = 0.44; 10% ethyl 
acetate in hexane; mp = lit36 76-78°C found 76-78 °C; 1H NMR (400 MHz, CDCl3) δ 
5.93 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.33 (s, 1H), 5.09 (ddq, J = 19.9, 10.2, 1.5 Hz, 
2H), 4.30 (ddd, J = 10.0, 6.1, 3.7 Hz, 1H), 2.69 (sex, J = 7.3 Hz, 1H), 2.45 – 2.37 (m, 
1H), 2.33 (ddd, J = 14.5, 13.5, 4.0 Hz, 1H), 2.25 – 2.16 (m, 1H), 2.03 (ddd, J = 14.6, 
4.7, 3.1 Hz, 1H), 1.96 – 1.87 (m, 1H), 1.81 (ddd, J = 13.4, 7.6, 3.5 Hz, 1H), 1.70 – 1.59 
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(m, 2H), 1.42 (s, 3H), 1.53 – 1.19 (m, 5H), 0.96 (d, J = 6.0 Hz, 3H) and 0.89 (d, J = 7.6 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 136.6, 116.2, 103.3, 89.3, 81.2, 74.8, 52.5, 
44.5, 37.6, 36.8, 34.6, 34.4, 30.4, 26.2, 25.0, 24.9, 20.3 and 13.1; IR νmax (neat)/cm
-1 
2957 (C-H), 2865, 1642 (C=C), 1056 (C-O-C), 1041 and 879 (C=CH); HRMS (ESI) 
calculated for C18H28O4 [M+Na]
+ 331.1885 found 331.1882; Microanalysis Calculated 
for C18H28O4 requires C 70.1%, H 9.15%, found C 69.86%, H 9.13%. 
Side product anhydroartermisinin (61)32 
 
1H NMR (400 MHz, CDCl3) δ 6.09 (d, J = 1.4 Hz, 1H), 5.46 (s, 1H), 2.32 (ddd, J = 14.5, 
13.2, 4.0 Hz, 1H), 2.03 – 1.93 (m, 2H), 1.89 – 1.81 (m, 1H), 1.52 (d, J = 1.4 Hz, 3H), 
1.69 – 1.35 (m, 5H), 1.34 (s, 3H), 1.21 – 0.97 (m, 2H) and 0.92 (d, J = 6.0 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 134.8, 107.6, 104.1, 89.3, 78.6, 51.2, 44.2, 37.2, 36.00, 
33.9, 29.7, 25.6, 24.2, 20.1 and 16.0; HRMS (CI) calculated for C15H22O4 [M+H]
+ 
267.1591 found 267.1599. 
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Preparation of 10β-(-2-oxoethyl)deoxoartemisinin (58)32 
 
57a (2.27 g, 7.36 mmol) was dissolved in anhydrous methanol and cooled to -78°C 
in an acetone-dry ice bath. Ozone was bubbled through the solution for 1 hour until 
the solution became saturated with ozone and appeared blue. Nitrogen was 
bubbled through the reaction to purge excess ozone. Triphenylphosphine (3.86 g, 
14.72 mmol) was added to the reaction mixture at -78°C where it was allowed to 
warm to room temperature and left to stir for 18 hours. The reaction mixture was 
concentrated to give the crude product in which purification by flash 
chromatography using 10% ethyl acetate in hexane to give the title compound 58 
(1.37 g, 60%) as a white solid; Rf = 0.05; 10% ethyl acetate in hexane; 
1H NMR (400 
MHz, CDCl3) δ 9.80 (dd, J = 3.2, 1.4 Hz, 1H), 5.32 (s, 1H), 4.99 – 4.91 (m, 1H), 2.73 
(tdd, J = 13.9, 12.4, 5.3 Hz, 2H), 2.46 (ddd, J = 16.3, 3.5, 1.5 Hz, 1H), 2.33 (ddd, J = 
14.5, 13.4, 4.0 Hz, 1H), 2.04 (ddd, J = 14.7, 4.6, 3.2 Hz, 1H), 1.98 – 1.89 (m, 1H), 1.80 
(ddd, J = 13.3, 7.4, 3.5 Hz, 1H), 1.73 – 1.64 (m, 2H), 1.41 (s, 3H), 1.49 – 1.22 (m, 5H), 
0.97 (d, J = 5.9 Hz, 3H) and 0.87 (d, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
202.0, 103.3, 89.4, 81.0, 69.6, 52.2, 44.5, 44.1, 37.6, 36.6, 34.4, 29.8, 26.1, 24.8, 
24.8, 20.3 and 13.2; HRMS (ESI) calculated for C17H26O5 [M+Na]
+ 333.1678 found 
333.1664; Microanalysis Calculated for C17H26O5 requires C 65.78%, H 8.44%, found 
C 65.68%, H 8.54%.  
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Preparation of 10β-(-2-carboxyethyl)deoxoartemisinin (59)22 
 
58 (1.37 g, 4.41 mmol) was dissolved in tert-butanol (90 mL) and water (18 mL). 2-
methyl-2-butene (2.0 M in THF, 25.85 mL, 51.64 mmol), monosodium phosphate 
(137.69 mg, 1.15 mmol) and sodium chlorite (778.43 mg, 8.61 mmol) was added to 
the solution and left to stir at room temperature for 3 hours. The yellow solution 
will slowly turn to a pale yellow over time. tert-butanol was removed in vaccuo and 
crude product was dissolved in DCM (50 mL). Sodium hydroxide (1 M, 50 mL) was 
added and washed with DCM (3 x 50 mL). Aqueous layer was acidified with 
hydrochloric acid (1 M) and extracted with DCM (3 x 50 mL). Combined organic 
layers were dried over magnesium sulfate, filtered and solvent was removed under 
vaccum to yield the title compound 59 (1.44 g, 100%) as a white solid; 1H NMR (400 
MHz, CDCl3) δ 5.36 (s, 1H), 4.83 (ddd, J = 10.0, 6.2, 3.7 Hz, 1H), 2.81 – 2.62 (m, 2H), 
2.50 (dd, J = 15.6, 3.7 Hz, 1H), 2.38 – 2.27 (m, 1H), 2.07 – 1.99 (m, 1H), 1.96 – 1.88 
(m, 1H), 1.80 (ddd, J = 10.7, 7.0, 3.2 Hz, 1H), 1.72 – 1.61 (m, 2H), 1.41 (s, 3H), 1.58 – 
1.20 (m, 6H), 0.97 (d, J = 6.0 Hz, 3H) and 0.88 (d, J = 7.5 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 176.9, 103.4, 89.3, 80.9, 71.2, 52.2, 44.0, 37.5, 36.5, 35.9, 34.4, 29.8, 25.9, 
24.8, 24.7, 20.2 and 12.9; HRMS (ESI) calculated for C17H26O6 [M+Na]
+ 349.1627 
found 349.1623.  
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Preparation of N-(prop-2-yn-1-yl)-2-[(5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyl 
decahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]acetamide (63) 
 
The preparation of 63 involved the use of acid 59 (237 mg, 726 µmol), 
propargylamine (139.5 µL, 2.18 mmol), EDCI (338.2 mg, 2.18 mmol) and DMAP 
(443.6 mg, 3.63 mmol) following general procedure 1. Purification of the crude 
product by flash chromatography using 60% ethyl acetate in hexane to give title 
compound 63 (213.1 mg, 81%) as a white solid; Rf = 0.65, 60% ethyl acetate in 
hexane; mp = 129-130°C; 1H NMR (400 MHz, CDCl3) δ 5.39 (s, 1H), 4.82 (ddd, J = 
11.3, 6.2, 1.7 Hz, 1H), 4.06 (dd, J = 5.2, 2.6 Hz, 2H), 2.60 – 2.48 (m, 2H), 2.41 – 2.28 
(m, 2H), 2.19 (t, J = 2.6 Hz, 1H), 2.07 (ddd, J = 14.6, 4.4, 3.2 Hz, 1H), 2.03 – 1.94 (m, 
1H), 1.84 – 1.71 (m, 2H), 1.71 – 1.61 (m, 2H), 1.44 (s, 3H), 1.42 – 1.11 (m, 5H), 0.98 
(d, J = 5.9 Hz, 3H) and 0.87 (d, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.6, 
103.1, 90.5, 81.0, 79.9, 71.4, 69.2, 51.8, 43.4, 37.7, 37.5, 36.7, 34.3, 30.6, 29.1, 26.0, 
25.0, 25.0, 20.1 and 12.0; IR νmax (neat)/cm
-1 3359 ( ), 3286 (CONH), 2976 
(CH), 2948 (CH), 2921, 2858, 1675 (CONH), 1203 and 1044 (C-O-C); HRMS (ESI) 
calculated for C20H29NO5 [M+Na]
+ 386.1943 found 386.1942; Microanalysis 
Calculated for C20H29NO5 requires C 66.09%, H 8.04%, N 3.85%, found C 65.97%, H 
8.01%, N 3.72%.   
Chapter 5 – Design and synthesis of click functionalised derivatives of artemisinin 
and CDDO as probes for investigating chemical mechanism of action 
 
265 
 
Preparation of ethyl [(5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-
epoxy-[1,2]dioxepino[4,3-i]isochromen-10-yl]acetate (65)38 
 
The preparation of 65 involved the use of acid 59 (470 mg, 1.44 mmol), anhydrous 
ethanol (252.2 µL, 4.32 mmol), EDCI (670.7 mg, 4.32 mmol) and DMAP (879.6 mg, 
7.20 mmol) following general procedure 1. Purification of the crude product by 
flash chromatography using 10% ethyl acetate in hexane to give title compound 65 
(226.6 mg, 44%) as a colourless oil; Rf = 0.18, 10% ethyl acetate in hexane; mp = 
101-103 °C; 1H NMR (400 MHz, CDCl3) δ 5.33 (s, 1H), 4.81 (ddd, J = 10.1, 6.2, 4.0 Hz, 
1H), 4.25 – 4.10 (m, 2H), 2.82 – 2.71 (m, 1H), 2.65 (dd, J = 15.2, 9.9 Hz, 1H), 2.45 
(dd, J = 15.2, 4.0 Hz, 1H), 2.33 (ddd, J = 14.4, 13.5, 4.0 Hz, 1H), 2.03 (ddd, J = 14.6, 
4.6, 3.2 Hz, 1H), 1.96 – 1.87 (m, 1H), 1.80 (ddd, J = 13.3, 7.4, 3.5 Hz, 1H), 1.71 – 1.57 
(m, 2H), 1.42 (s, 3H), 1.51 – 1.20 (m, 4H), 1.27 (t, J = 7.1 Hz, 3H), 0.96 (d, J = 6.0 Hz, 
3H), 1.01 – 0.92 (m, 1H) and 0.87 (d, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
171.8, 103.4, 89.2, 81.0, 71.8, 60.8, 52.4, 44.3, 37.6, 36.6, 36.2, 34.6, 29.8, 26.1, 
24.8, 24.8, 20.3, 14.3 and 13.2; IR νmax (neat)/cm
-1 3212, 2973 (CH), 2956, 2949, 
2935, 2919, 2874, 2852, 1734 (C=O) and 1056 (C-O-C); HRMS (ESI) calculated for 
C19H30O6 [M+Na]
+ 377.1940 found 377.1934.  
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Preparation of ethyl [(2R,3R,3aS,6R,6aS,10aR,10bR)-3,6,9-trimethyldecahydro-
9,10b-epoxyoxepino[4,3,2-ij]isochromen-2(10aH)-yl]acetate (66) 
 
Preparation of activated zinc dust: Zinc dust (2.00 g) was activated by washing with 
hydrochloric acid (5%, v/v, 3 x 50 mL), water (3 x 50 mL) and diethyl ether (3 x 50 
mL). Zinc dust was dried under reduced atmosphere. 
65 (559.2 mg, 1.58 mmol) was dissolved in acetic acid (50 mL). Activated zinc dust 
(3 x 154.7 mg, 2.37 mmol) was added in triplicate over 72 hours at 24 hour periods 
to the reaction and left to stir at room temperature. The reaction was diluted with 
DCM and filtered through a pad of celite. NaHCO3 was used to neutralise the 
solution and the organic layer and removed. Organic layer was washed with 
NaHCO3, water, brine, dried over magnesium sulfate and filtered. The reaction was 
concentrated under reduced pressure to give the crude product in which 
purification by flash chromatography using 10% ethyl acetate in hexane to give the 
title compound 66 (203.7 mg, 38%) as a white solid; Rf = 0.29; 10% ethyl acetate in 
hexane; 1H NMR (400 MHz, CDCl3) δ 5.24 (s, 1H), 4.64 (dt, J = 8.4, 6.7 Hz, 1H), 4.34 – 
4.03 (m, 2H), 2.52 – 2.39 (m, 2H), 2.38 – 2.26 (m, 1H), 2.00 – 1.91 (m, 1H), 1.90 – 
1.82 (m, 1H), 1.81 – 1.66 (m, 3H), 1.64 – 1.53 (m, 1H), 1.56 (s, 3H), 1.27 (t, J = 7.1 Hz, 
3H), 1.36 – 1.10 (m, 4H), 1.06 – 0.79 (m, 1H), 0.89 (d, J = 5.8 Hz, 3H) and 0.86 (d, J = 
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7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.6, 107.1, 97.0, 82.4, 65.8, 60.4, 45.3, 
40.3, 37.5, 35.5, 34.5, 34.5, 29.0, 25.0, 23.6, 22.2, 18.8, 14.2 and 12.4; IR νmax 
(neat)/cm-1 2952 (CH), 2873, 1737 (C=O), 1093 (C-O-C), 1008 (C-O-C); HRMS (ESI) 
calculated for C19H30O5 [M+Na]
+ 361.1991 found 361.1997. 
Preparation of [(2R,3R,3aS,6R,6aS,10aR,10bR)-3,6,9-trimethyldecahydro-9,10b-
epoxy oxepino[4,3,2-ij]isochromen-2(10aH)-yl]acetic acid (67) 
 
66 (194 mg, 573 µmol) was dissolved in ethanol (25 mL).  Sodium hydroxide (25 mL, 
15%, w/v) was added to the reaction and left to stir for 3 hours at room 
temperature. The reaction was acidified with hydrochloric acid (1 M) and the 
ethanol was removed. Aqueous layer was extracted with DCM (3 x 50 mL). The 
combined organic layers were dried over magnesium sulfate, filtered and 
concentrated under reduced pressure to give the crude product. The crude product 
was purified by flash chromatography using 50% ethyl acetate in hexane to give the 
title compound 67 (142 mg, 80%) as a white solid; Rf = 0.26; 50% ethyl acetate in 
hexane; 1H NMR (400 MHz, CDCl3) δ 5.27 (s, 1H), 4.62 (dd, J = 14.3, 7.3 Hz, 1H), 2.59 
– 2.43 (m, 2H), 2.34 (dd, J = 15.4, 7.7 Hz, 1H), 2.03 – 1.91 (m, 1H), 1.86 (dd, J = 9.7, 
5.2 Hz, 1H), 1.82 – 1.74 (m, 1H), 1.73 – 1.66 (m, 2H), 1.62 (t, J = 5.6 Hz, 1H), 1.54 (s, 
3H), 1.33 – 1.12 (m, 5H), 0.97 (dd, J = 13.8, 10.8 Hz, 1H), 0.89 (d, J = 5.9 Hz, 3H) and 
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0.88 (d, J = 7.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 176.6, 107.6, 97.0, 82.6, 65.7, 
45.4, 40.3, 37.3, 35.7, 34.6, 34.5, 29.1, 25.2, 23.7, 22.3, 18.9 and 12.5; IR νmax 
(neat)/cm-1 3210 (br, OH), 2951 (CH), 2933, 2873, 1735 (C=O), 1710, 1094 (C-O-C), 
1009; HRMS (ESI) calculated for C17H26O5 [M+Na]
+ 333.1678 found 333.1672. 
Preparation of N-(prop-2-yn-1-yl)-2-[(2R,3R,3aS,6R,6aS,10aR,10bR)-3,6,9-trimethyl 
deca-hydro-9,10b-epoxyoxepino[4,3,2-ij]isochromen-2(10aH)-yl]acetamide (68) 
 
The preparation of 68 involved the use of acid 67 (141.5 mg, 455.9 µmol), 
propargylamine (87.6 µL, 1.37 mmol), EDCI (212.3 mg, 1.37 mmol) and DMAP 
(278.5 mg, 2.28 mmol) following general procedure 1. Purification of the crude 
product by flash chromatography using 50% ethyl acetate in hexane to give title 
compound 68 (53.7 mg, 34%) as a white solid; Rf = 0.34, 50% ethyl acetate in 
hexane; mp = 119-120 °C; 1H NMR (400 MHz, CDCl3) δ 6.98 (s, 1H), 5.32 (s, 1H), 4.54 
(ddd, J = 10.0, 6.9, 3.1 Hz, 1H), 4.13 (ddd, J = 17.5, 5.8, 2.5 Hz, 1H), 3.98 (ddd, J = 
17.5, 4.9, 2.5 Hz, 1H), 2.40 – 2.37 (m, 1H), 2.31 – 2.21 (m, 1H), 2.19 (t, J = 2.5 Hz, 
1H), 1.99 (ddd, J = 13.1, 8.7, 4.1 Hz, 1H), 1.93 – 1.86 (m, 1H), 1.85 – 1.77 (m, 1H), 
1.76 – 1.67 (m, 2H), 1.66 – 1.56 (m, 1H), 1.55 (s, 3H), 1.36 – 1.11 (m, 6H), 0.91 (d, J = 
5.9 Hz, 3H) and 0.87 (d, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.5, 107.9, 
97.3, 82.7, 80.0, 71.1, 65.2, 45.3, 39.9, 38.1, 35.7, 34.5, 29.7, 28.9, 25.4, 23.8, 22.3, 
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18.9 and 11.9; IR νmax (neat)/cm
-1 3358 ( ), 3318 (CONH), 2962 (CH), 2932, 
2875, 1683 (CONH), 1076 (C-O-C) and 1007; HRMS (ESI) calculated for C20H29NO4 
[M+Na]+ 348.2175 found 348.2177.  
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5.4.8 Synthesis of CDDO click probes 
Preparation of 2-cyano-3,12-dioxo-N-(prop-2-yn-1-yl)oleana-1,9(11)-dien-28-amide 
(71) 
 
For the synthesis of 8 see section 2.4.7. The preparation of 71 involved the use of 
acid 8 (86 mg, 174.9 µmol), propargylamine (33.6 µL, 524.8 µmol), EDCI (81.5 mg, 
524.8 µmol) and DMAP (106.9 mg, 874.6 µmol) following general procedure 1. 
Purification of the crude product by flash chromatography using 50% ethyl acetate 
in hexane to give title compound 71 (30.8 mg, 33%) as a white solid; Rf = 0.32, 50% 
ethyl acetate in hexane; mp = 256-258°C; 1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 
6.10 (t, J = 5.4 Hz, 1H), 6.00 (s, 1H), 4.07 (dd, J = 5.4, 2.5 Hz, 2H), 3.08 (d, J = 4.5 Hz, 
1H), 2.90 (dd, J = 9.8, 3.0 Hz, 1H), 2.18 (t, J = 2.5 Hz, 1H), 2.04 – 1.95 (m, 1H), 1.88 – 
1.53 (m, 10H), 1.49 (s, 3H), 1.36 (s, 3H), 1.26 (s, 3H), 1.33 – 1.19 (m, 4H), 1.17 (s, 3H), 
1.02 (s, 3H), 1.00 (s, 3H) and 0.91 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 199.2, 196.7, 
177.0, 169.0, 166.0, 124.1, 114.7, 114.5, 80.3, 71.3, 49.6, 47.8, 46.6, 46.1, 45.1, 42.7, 
42.2, 36.1, 34.6, 33.9, 33.4, 32.0, 31.8, 30.7, 29.3, 27.8, 27.1, 26.7, 25.0, 23.2, 23.1, 
21.9, 21.7 and 18.4; IR νmax (neat)/cm
-1 3306 ( ), 2926 (CH), 2865, 2360 (CN), 
2341, 1733 (C=O), 1687 (CONH) and 1659; HRMS (ESI) calculated for C34H44N2O3 
[M+Na]+ 551.3250 found 551.3249. 
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Preparation of 3,12-dioxooleana-1,9(11)-dien-28-oic acid (72)39 
 
For the synthesis of 21 see section 3.4.6. 21 (116 mg, 241 µmol) was dissolved in 
anhydrous DMF. Lithium iodide (613.7 mg, 4.59 mmol) was added to the reaction 
and left to reflux overnight. The reaction was cooled and water (50 mL) was added. 
5% HCl was added to the solution and washed with ethyl acetate (3 x 50 mL). 
Combined organic layers were washed with water (3 x 50mL), brine (3 x 50 mL) and 
dried over magnesium sulfate. The solution was filtered and the solvent was 
removed under vacuum. The crude product was purified by flash chromatography 
using 50% ethyl acetate in hexane to give the title compound 72 (100.3 mg, 89%) as 
a hygroscopic white solid; Rf = 0.35, 50% ethyl acetate in hexane; 
1H NMR (400 MHz, 
CDCl3) δ 7.33 (d, J = 10.6 Hz, 1H), 6.02 (s, 1H), 5.93 (d, J = 10.4 Hz, 1H), 3.97 (s, 1H), 
3.17 – 2.88 (m, 2H), 2.05 (s, 2H), 1.93 (s, 2H), 1.75 (s, 7H), 1.55 (dd, J = 25.5, 11.6 Hz, 
4H), 1.41 (s, 3H), 1.33 (s, 3H), 1.20 (s, 3H), 1.12 (s, 3H), 1.02 (s, 3H), 1.01 (s, 3H) and 
0.90 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 203.7, 199.6, 183.6, 171.7, 154.9, 126.0, 
123.7, 49.8, 48.4, 47.2, 45.8, 44.8, 42.1, 41.9, 35.8, 34.5, 33.3, 33.0, 32.2, 31.6, 30.8, 
28.1, 27.2, 27.0, 24.7, 23.2, 22.6, 21.8, 21.7 and 18.5; IR νmax (neat)/cm
-1 3206 (br, 
OH), 2939 (CH), 2871, 1722 (C=O), 1690 (C=O) and 1660; HRMS (ESI) calculated for 
C30H42O4 [M+Na]
+ 489.2981 found 489.2979. 
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Preparation of 3,12-dioxo-N-(prop-2-yn-1-yl)oleana-1,9(11)-dien-28-amide (73) 
 
The preparation of 73 involved the use of acid 72 (89.6 mg, 192.0 µmol), 
propargylamine (36.9 µL, 576.0 µmol), EDCI (89.4 mg, 576.0 µmol) and DMAP 
(117.3 mg, 960.0 µmol) following general procedure 1. Purification of the crude 
product by flash chromatography using 50% ethyl acetate in hexane to give title 
compound 73 (38.4 mg, 40%) as a white solid; Rf = 0.47, 50% ethyl acetate in 
hexane; mp = 136-137°C; 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 10.6 Hz, 1H), 6.10 
(t, J = 5.3 Hz, 1H), 6.01 (s, 1H), 5.93 (d, J = 10.4 Hz, 1H), 4.07 (dd, J = 5.4, 2.5 Hz, 2H), 
3.04 (d, J = 4.4 Hz, 1H), 2.89 (d, J = 13.0 Hz, 1H), 2.18 (t, J = 2.5 Hz, 1H), 2.00 (td, J = 
13.8, 3.7 Hz, 1H), 1.87 – 1.56 (m, 11H), 1.54 – 1.45 (m, 3H), 1.42 (s, 3H), 1.34 (s, 3H), 
1.19 (s, 3H), 1.12 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H) and 0.90 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 203.6, 199.8, 177.1, 172.1, 154.9, 126.0, 123.6, 80.2, 71.3, 49.5, 48.4, 
46.7, 46.0, 44.8, 42.2, 41.9, 36.2, 34.7, 34.0, 33.4, 32.2, 32.0, 30.7, 29.3, 27.9, 27.2, 
27.0, 25.0, 23.3, 23.1, 21.9, 21.8 and 18.5; IR νmax (neat)/cm
-1 3343 ( ), 3308 
(CONH), 2937 (CH), 2868, 1731 (C=C) and 1657 (CONH);  HRMS (ESI) calculated for 
C33H45NO3 [M+Na]
+ 526.3297 found 526.3292. 
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Preparation of 1,4-diazidobutane (76)40 
 
Sodium azide (632.3 mg, 9.73 mmol) in water was added to a solution of 75 (553.1 
µL, 4.63 mmol) in DMF (5 mL). the reaction was heated to 80°C and left to stir for 
20 hours. The reaction was cooled and brine was added to the reaction. The 
mixture was extracted with hexane (3 x 50 mL) and combined organic layers were 
dried over magnesium sulfate and filtered. The solvent was removed under reduced 
pressure to yield title compound 76 (649.1 mg, 100%) as a colourless oil; 1H NMR 
(400 MHz, CDCl3) δ 3.32 (t, J = 5.6 Hz, 4H) and 1.67 (dt, J = 5.4, 3.2 Hz, 4H); 
13C NMR 
(100 MHz, CDCl3) δ 50.9 and 26.1. Cannot obtain MS due to fragmentation: MS (CI) 
[C4H8N2+H]
+ m/z 85.1. 
Prepartaitoin of 4-azidobutan-1-amine (77)40,41 
 
Hydrochloric acid (20 mL, 1 M) was added to a solution of 76 (649.1 mg, 4.63 mmol) 
in ethyl acetate:diethyl ether (1:1, 20 mL). The reaction was cooled to 0°C and 
triphenylphosphine (1.21 g, 4.63 mmol) was added to the reaction in portions. The 
reaction was left to stir at room temperature overnight. The organic layer was 
removed using separating funnel and aqueous layer is washed with ethyl acetate (2 
x 50 mL). The aqueous layer was basified to pH 12 with aqueous sodium hydroxide 
solution and extracted with DCM (3 x 20 mL). The combined organic layers were 
dried over magnesium sulfate, filtered and solvent was removed under reduced 
pressure to give title compound 77 (488 mg, 92%) as a colourless oil; 1H NMR (400 
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MHz, CDCl3) δ 3.36 – 3.22 (m, 4H, diazido form), 2.73 (t, J = 6.9 Hz, 2H) and 1.72 – 
1.47 (m, 6H, 4H, diazido form); 13C NMR (100 MHz, CDCl3) δ 51.4, 41.8, 30.9 and 
26.4; HRMS (CI+) calculated for C4H10N4 [M+H]
+ 115.0978 found 115.0983. 
Preparation of N-(4-azidobutyl)-3,12-dioxooleana-1,9(11)-dien-28-amide (74) 
 
The preparation of 74 involved the use of acid 72 (89 mg, 190.7 µmol), 77 (65.31 mg, 
572.2 µmol), EDCI (88.8 mg, 572.2 µmol) and DMAP (116.5 mg, 953.6 µmol) 
following general procedure 1. Purification of the crude product by flash 
chromatography using 50% ethyl acetate in hexane to give title compound 74 (41 
mg, 38%) as a white solid; Rf = 0.35, 50% ethyl acetate in hexane; mp = 130-131°C; 
1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 10.5 Hz, 1H), 6.01 (s, 1H), 5.92 (d, J = 10.4 
Hz, 1H), 3.38 – 3.23 (m, 4H), 3.01 (d, J = 4.4 Hz, 1H), 2.86 (dt, J = 7.5, 4.0 Hz, 1H), 
1.97 (td, J = 13.6, 3.5 Hz, 1H), 1.85 – 1.14 (m, 29H), 1.42 (s, 3H), 1.32 (s, 3H), 1.19 (s, 
3H), 1.12 (s, 3H), 1.02 (s, 3H), 1.00 (s, 3H) and 0.90 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 203.6, 199.9, 177.4, 172.1, 154.8, 126.0, 123.6, 51.2, 49.6, 48.4, 46.7, 45.9, 
44.8, 42.2, 41.9, 39.1, 36.3, 34.7, 34.3, 33.4, 32.2, 32.2, 30.7, 27.9, 27.3, 27.2, 27.0, 
26.5, 24.9, 23.3, 23.1, 21.9, 21.8 and 18.5; IR νmax (neat)/cm-1 3355 (CONH), 2930 
(CH), 2865, 2162 (N3) and 1658 (C=O); HRMS (ESI) calculated for C34H50N4O3 
[M+Na]+ 585.3781 found 585.3783; Microanalysis Calculated for C34H50N4O3 
requires C 72.56%, H 8.95%, N 9.96%, found C 72.40%, H 9.26%, N 8.79%. 
Chapter 5 – Design and synthesis of click functionalised derivatives of artemisinin 
and CDDO as probes for investigating chemical mechanism of action 
 
275 
 
Preparation of benzyl propargyl ether (80)42 
 
Sodium hydride (148.0 mg, 3.70 mmol, 60%) was washed with hexane (5 mL) under 
an anhydrous nitrogen atmosphere. Anhydrous THF (30 mL) was added to the 
sodium hydride and the reaction was cooled to 0°C. Benzyl alcohol (382.8 µL, 3.70 
mmol) was added to the reaction and left to stir for 30 minutes. Proganyl bromine 
(432.6 µL, 3.88 mmol, 80%) was added dropwise and left to stir for 5 minutes prior 
to warming to room temperature. The reaction was left to stir for a further 1 hour 
at room temperature. The reaction was quenched with sodium sulphate, filtered 
through a pad of celite and washed with ethyl acetate. The solvent was removed 
under vacuum to give the crude product which was purified by flash 
chromatography using 30% ethyl acetate in hexane to give the title compound 80 
(400 mg, 74%) as a yellow oil; Rf = 0.76, 30% ethyl acetate in hexane; 
1H NMR (400 
MHz, CDCl3) δ 7.36 – 7.31 (m, 4H), 7.31 – 7.24 (m, 1H), 4.58 (s, 2H), 4.14 (d, J = 2.4 
Hz, 2H) and 2.45 (t, J = 2.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 137.3, 128.4, 128.1, 
127.9, 79.7, 74.7, 71.4 and 57.0; MS (CI) C10H10O [M+NH4]
+ m/z 164.1075. 
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Preparation of N-(4-(4-((benzyloxy)methyl)-1H-1,2,3-triazol-1-yl)butyl)-3,12-
dioxooleana-1,9(11)-dien-28-amide (81) 
 
74 (41 mg, 72.85 µmol) was dissolved in DCM:water (1:1, 4 mL). 80 (11.7 mg, 80.14 
µmol), copper(II) sulphate pentahydrate (909.5 µg, 3.64 µmol) and sodium 
ascorbate (2.16 mg, 10.93 µmol) was added to the reaction and left to stir for 2 
hours. The reaction was extracted with DCM (3 x 20 mL) and washed with water, 
brine and dried over magnesium sulfate. The solvent was removed under vacuum 
to give the crude product which was purified by flash chromatography using 40% 
ethyl acetate in hexane to give the title compound 81 (20.5 mg, 40%) as a white 
solid; Rf = 0.03, 50% ethyl acetate in hexane; 
1H NMR (400 MHz, CDCl3) δ 7.56 (s, 
1H), 7.41 – 7.28 (m, 6H), 5.99 (s, 1H), 5.93 (dd, J = 12.4, 8.2 Hz, 2H), 4.68 (s, 2H), 
4.61 (s, 2H), 4.38 (t, J = 7.0 Hz, 2H), 3.31 (dd, J = 13.2, 6.6 Hz, 2H), 2.99 (d, J = 4.3 Hz, 
1H), 2.87 (d, J = 13.2 Hz, 1H), 2.02 – 1.87 (m, 1H), 1.83 – 1.06 (m, 18H), 1.40 (s, 3H), 
1.27 (s, 3H), 1.18 (s, 3H), 1.11 (s, 3H), 1.01 (s, 3H), 0.99 (s, 3H) and 0.89 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 203.6, 199.8, 177.6, 172.0, 154.8, 145.5, 137.9, 128.6, 
128.0, 127.9, 126.0, 123.6, 122.6, 72.8, 63.9, 49.8, 49.6, 48.4, 46.7, 45.9, 44.8, 42.1, 
41.9, 38.8, 36.2, 34.7, 34.4, 33.4, 32.2, 32.1, 30.7, 27.9, 27.8, 27.2, 27.0, 27.0, 24.9, 
23.3, 23.1, 21.8, 21.8 and 18.5; HRMS (ESI) calculated for C44H60N4O4 [M+Na]
+ 
731.4512 found 731.4516. 
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5.5 Biological experimental 
5.5.1 Materials 
See section 3.5.1 
5.5.2 Cell culture 
See section 2.5.2 
5.5.3 Plating 
See section 2.5.3 
5.5.4 Treatment of cells for luciferase activity assay. 
See section 2.5.5 
5.5.5 Preparation of cells for luciferase reporter assay 
See section 2.5.6 
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6.1. Final conclusions 
The major aim of this thesis was to produce novel chemical probes for the 
investigation and identification of molecular targets in biologically-relevant contexts. 
These probes were rationally designed based on knowledge of the pharmacophore 
and appropriate sites for chemical modification (Figure 6.1). 
 
Figure 6.1: Flow diagram depicting the strategy adopted throughout this thesis for 
the successful development of chemical probes for biological target identification. 
Specifically for the CDDO series, a SAR profile was generated via the synthetic 
modification of oleanolic acid. NMR and MS analyses enabled the identification of 
the active pharmacophore and candidate sites for chemical modification. This 
information, together with literature data on the endoperoxide (tetraoxanes and 
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artemisinins) antimalarials enabled the design and synthesis of a total of fifteen 
novel probes. These include DDO-Me and CDDO-Epoxide (Figure 6.2), for which 
irreversible protein binding was demonstrated following reaction with the model 
protein GSTP1, further supporting the use of these probes to define the molecular 
targets of CDDO-Me and its derivatives in cells. 
 
Figure 6.2: Chemical structures for DDO-Me and CDDO-Epoxide included the 
highlighted pharmacophore responsible for irreversible binding. 
Eight novel phenyl amide tetraoxane probes were also successfully synthesised and 
tested for their activity to inhibit the proliferation of P. falciparum in vitro. The 
tetraoxane probe 35 (Figure 6.3) was utilised for the examination of the role of 
ferrous iron and phosphatidylcholine in the bioactivation of this compound class.  
 
Figure 6.3: Chemical structure for tetraoxane probe 35. 
This has provided a deeper understanding of the radical formation induced by 
ferrous iron, and identified a potential novel molecular mechanism via the lipid-
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peroxidation of phosphatidylcholine. Click functionalised probes (Figure 6.4) were 
also designed and synthesised.  
 
Figure 6.4: Chemical structures of click functionalised probes and their highlighted 
pharmacophores. Three in the CDDO class and two in the artemisinin class. 
These probes could be used to identify protein targets and resolve mechanisms of 
action through traditional proteomic techniques that would have previously been 
difficult to use due to the harsh conditions required to elute drug-protein 
complexes for affinity matrices. Proof-of-concept of the ability of these probes to 
undergo the click reaction with a relevant counterpart has provided evidence of 
their utility as investigational tools. A summary of the strategy used is depicted in 
Figure 6.5. 
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6.2. Future work 
The successful synthesis of irreversible probes will allow a range of previously 
unsuitable biological techniques to be used for the identification of molecular 
targets. 
6.2.1. Future work for the CDDO class 
Despite reports of a direct interaction of biotinylated CDDO derivatives with Cys-
179 of IKKβ,1 Cys-1077 of JAK1 and Cys-259 of STAT3,2 the failure to identify direct 
targets responsible for the potency of these compounds as inducer of Nrf2 has 
raised questions about the chemical and molecular mechanism for this class and 
other small molecule Nrf2 inducers. As discussed in chapter 1, CDDO-Me failed 
phase III clinical trials (BEACON trial) for the treatment of advanced chronic kidney 
disease (CKD) due to serious adverse events and mortality in patients.3,4  It is now 
thought that CDDO-Me modulates the endothelin signalling pathway,5 resulting in 
fluid retention, raised blood pressure and cardiovascular failure in CKD patients. 
The effects are similar to those observed in CKD patients with endothelin receptor 
antagonists.5 Therefore, the adverse events associated with CDDO-Me do not 
appear to be related to Nrf2 per se, and are specific to advanced CKD patients. As a 
result, Nrf2 inducers continue to hold promise as novel drug candidates. Indeed, a 
new phase I clinical trial (LARIAT) of CDDO-Me for the treatment of pulmonary 
arterial hypertension (PAH) has been launched with the aim of targeting 
inflammation in PAH patients via the induction of Nrf2.6,7 
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With a lack of clinical data, it is currently unclear whether the beneficial effects of 
CDDO-Me in CKD patients are linked to its ability to induce Nrf2. Understanding 
whether CDDO-Me specifically targets the endothelin pathway and whether other 
Nrf2 inducers have similar effects is important, as there is an urgent need for new 
therapies in CKD. Such knowledge would allow the design and development of 
more potent, specific and safe alternative inducers of Nrf2, which have potential 
applications in numerous diseases. Preliminary data indicates that CDDO-Epoxide 
modifies six cysteine residues in Keap1. However, it is unclear whether the 
modification of one or more of these targets is directly responsible for the 
induction of Nrf2 by CDDO-Epoxide and related compounds. With further work, it 
may be possible to refine the chemistry of a small molecule inducer to retain 
pharmacological efficacy and avoid undesirable interactions with off-target proteins, 
therefore minimising the risk of toxicity. For the induction of the Keap1-Nrf2 
pathway the next question is ‘is the induction of Nrf2 due to specific interaction 
with critical cysteines in Keap1?’. As there is an urgent need for new therapies in 
CKD, the CDDO-Epoxide and click probes will be useful tools to investigate the exact 
targets within the endothelin pathway, further revealing the toxicological target(s) 
and mechanism(s) responsible for the ADRs. Depending on the data obtained a 
decision can be made based on the benefits vs risk of the use of triterpenoids in 
CKD, and indeed other relevant diseases. This information is also useful for the 
chemist, who can manipulate the chemical structure to selectively target the 
beneficial pharmacological pathway and potentially eliminate the toxicological 
effects. 
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6.2.2. Future work for the endoperoxide class 
The endoperoxide class of antimalarial drugs are currently the front line treatment 
against multi-resistant strains of P. falciparum due to their broad stage specificity 
against the Plasmodium life cycle. The precise mechanism of action of these 
compounds is still highly controversial despite the identification of the 
endoperoxide as the active pharmacophore. There is strong evidence to suggest 
that the mechanism of action requires endoperoxide activation via an iron source.8 
However, an alternative non-iron mediated mechanism of bioactivation cannot be 
excluded and further additional biological support is required for both 
mechanisms.9,10 Although protein alkylation in Plasmodia is well established, the 
identity of molecular targets responsible for parasite cell death has so far evaded 
researchers. Novel probes, such as those synthesised as part of this thesis will aid 
ongoing research to resolve the chemical and molecular targets responsible for 
parasite cell death. In recent years, the emergence of artemisinin resistance in P. 
falciparum in Southeast Asia has posed a threat to efforts to control and eliminate 
malaria.11 Therefore the identification of molecular target(s) will aid the design and 
synthesis of next-generation antimalarial drugs that can delay or reverse parasite 
resistance to existing drugs. A molecular marker of artemisinin resistance within P. 
falciparum has also been recently identified.12 This marker is known as 
PF3D7_1343700 kelch propeller domain (‘K13-propeller’). It is currently unknown 
whether artemisinin directly targets the K13-propeller, however, this protein 
exhibits homology with human Keap1 (which contains a kelch propeller at its C-
terminal). Studies by Olagnier et al have demonstrated that CD36 is the major 
receptor mediating Plasmodium phagocytosis by macrophages, a process that is 
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mainly controlled by PPARγ. Therefore, promotion of CD36 expression on 
inflammatory macrophages aids the clearance of Plasmodia parasite. Nrf2 controls 
CD36 expression, independently of PPARγ. As a result, the Nrf2 pathway could be 
an alternative mechanism for clearance of Plasmodia parasites.13 The discovery of 
the K13-propeller further questions whether a similar Keap1-Nrf2 system exists 
within the P. falciparum parasite. Therefore, whilst more work is required to define 
the function of K13-propeller within the malaria parasite,                                                                                                                                                                      
this protein may become a novel molecular target via which new drugs could 
selectively target resistant strains of P. falciparum.  
Artemisinins are also known for their anticancer properties. Indeed, they are 
cytotoxic towards drug and radiation resistant cancer cells. This suggests that 
artemisinins have a different mode of action compared with traditional anticancer 
therapies.14 Similar to malaria, the exact chemical mechanism and molecular 
target(s) responsible for the anticancer effects of artemisinins is unknown, but 
identifying such targets could provide opportunities to design and develop novel 
cancer therapies.  
The discovery of the K13-propeller as a marker of artemisinin resistance in P. 
falciparum along with its similarity to Keap1 raises interesting questions. It is known 
that CDDO and related compounds possess anticancer properties. Could Keap1 also 
be a molecular target for artemisinin within cancer therapy? Such a concept 
warrants further investigation. The probes described here will facilitate the testing 
of this and other hypothesis, potentially revealing novel drug targets in important 
diseases, this informing the design and synthesis of much needed new medicines.  
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